roche annual report creating value patientskey figures roche group index sales mchf free cash flow mchf research development mchf total dividend mchf operating profit mchf number employees income taxes mchf total employee remuneration mchf net income mchf patients clinical trials core earnings per share chf ecoefficiency rate price development nonvoting equity security genussschein chf roche nonvoting equity security swiss market index rebased key figures indexed figures annual report core results full index global reporting initiative gri proposed board directors indicators used report see development phase iv wwwrochecomreportingandindices calculation ecoefficiency rate see wwwrochecomenvironmenthighlights january january february eu commission approves fda approves actemra roche annual general meeting votes herceptin treatment treatment moderately severely increase shareholder dividend positive advanced stomach cancer active rheumatoid arthritis april june july roche acquires medingo expand fda expands lucentis approval athena clinical trial demonstrates position growing insulin delivery include treatment macular edema high medical value cobas systems market following retinal vein occlusion hpv test detects highrisk genotypes screening cervical cancer women september september october fda clearance cobas roche named healthcare super encouraging new clinical data modular analyser series high sector leader dow jones sustain avastin ovarian metmab lung volume lab testing ability indexes second year running tdm breast cancer presented esmo conference october november rdge c efirsmtincblasse grri schizophrenia creating value patients means report promising phase ii results launch operational excel tpheh acosuer aiig es ttuod gyo wwihtehr ef inresetdsi narec glaresast rg braf inhibitor lence initiative maintain longterm cthoemrs phaovue nfadile rdg shows new targeted medicine innovation capabilities improvement negative symptoms advanced melanoma av oes pbaf oeii gf tslena wic tib feift viil ecv ee nea n aah yst cmge uar pi tia dn etcp oe em itee p p sfs ifh soeooscfdi ttt es eiv inse zs tiy lm l oop ct co um prs thhe strabele phnasesi r gepfn efo ef w te wec en rm ti viseae icld hteog e ntfri ifne semsacttt sons fue gb aao cttp ii ovtie nm sayllmy pctoonmtrsolled positive symptoms affecting nearly million people worldwide schizo rg glycine reuptake inhibitor gri developed phrenia severe mental disorder distorts roche may first drug treat negative way person thinks acts expresses emotions per symptoms schizophrenia representing entirely ceives reality relates others lifelong novel approach rg normalises glutamate neu disease cured average shortens rotransmission increasing synaptic levels glycine life expectancy years due higher risk thereby targeting important pathway psychiatric suicide also due cardiovascular pulmo disorders potential become firstinclass nary events negative symptoms compound type treatment schizophre usually greatest impact quality life nia addition rg combination current patients may unable live independently hold jobs treatments potential treat suboptimally con establish personal relationships manage every trolled positive symptoms little increase day social situations many drugs developed treat side effects novel mode action could also negative symptoms failed clinical trials valu able therapeutic applications psychiatric available treatments offer modest benefits disorders rochearengdiagnosticsindd pharmaceuticals pipeline targeting areas high unmet medical need phase phase ii phase iii registration project id projectproduct indication project id projectproduct indication project id projectproduct indication project id projectproduct indication oncology oncology oncology oncology rg dulanermin cancer rg pertuzumab early bc rg mabtherarituxan nhl fast infusion rg mabtherarituxan indolent nhl stline maint rg braf kinase inh metastatic melanoma rg pertuzumab mbc ndline rg mabtherarituxan nhl sc formulation rg avastin ovarian cancer stline rg mdm antag solid hematologic tumours adc rg trastuzumabdm early bc rg avastin adj breast cancer rg avastinxeloda met breast cancer stline rg antiegfr humab solid tumours rg hedgehog pathway inh advanced basal cell carcinoma rg avastinherceptin mbc stline rg tarceva nsclc egfr mutation rg cifmek dual inh solid tumours rg hedgehog pathway inh operable basal cell carcinoma rg avastin adj nsclc positive stline rg raf mek dual inh solid tumours rg antimet mab metastatic nsclc rg avastin adj breast cancer herneg rg pi kinase inh solid tumours rg anticd mab nhl cll rg avastin adj bc triple negative inflammation autoimmune disorders rg antiplgf mab solid tumours rg braf inh met melanoma ndrdline rg avastin relapsed ovarian cancer rg mabtherarituxan ancaassociated vasculitis rg antiegfl mab solid tumours rg navitoclax abt solid hematologic tumours rg avastin highrisk carcinoid rg actemraroactemra jia systemic onset rg mek inh solid tumours chu topoisomerase inh gastric cancer rg avastin gbm stline rg mek inh solid tumours rg avastin met colorectal cancer treat others rg pi kinase inh solid hematologic tumours inflammation autoimmune disorders ment multiple lines chu epogin epoch chemotherinduced anemia rg akt inh solid tumours rg lebrikizumab asthma rg avastin met breast cancer ndline rg antifgfr mab multiple myeloma rg oxl mab asthma rg herceptin bc sc formulation rg iap antag solid tumours lymphoma rg rontalizumab systemic lupus erythematosus rg herceptin adj bc yr treatment adc rg anticd hematologic malignancies rg antilt mab rheumatoid arthritis rg pertuzumab mbc stline nme rg antiangiogenic solid tumours rg xolair chronic idiopathic urticaria rg tarceva adj nsclc rg antiher mab metastatic epithelial tumours rg antim prime mab asthma rg tarceva nsclc egfr mutation rg antiglypican mab liver cancer positive stline chu alk inh nsclc virology adc rg trastuzumabdm mbc stline chu solid tumours rg hpv immunotherapy cervical neoplasia adc rg trastuzumabdm advanced mbc rg nucleoside polymerase hepatitis c rg anticd mab chronic lymphocytic leukemia inflammation autoimmune disorders inh prodrug rg anticd mab indolent nhl rg antiil mab rheumatoid arthritis rg danoprevir hepatitis c rg braf inh metastatic melanoma stline rg crth antag asthma rg anti rhumab ulcerative colitis cardiovascular metabolic diseases inflammation autoimmune disorders selected abbreviations rg antip selectin mab cardiovascular disease rg actemraroactemra ankylosing spondylitis adj adjuvant treatment hpv human papillomavirus virology rg sglt inh type diabetes rg actemraroactemra ra sc formulation adc antibodydrug conjugate inh inhibitor rg nucleoside polymerase hepatitis c rg actemraroactemra early rheumatoid arthritis amd agerelated macular jia juvenile idiopathic arthritis inh central nervous system rg actemraroactemra ra dmard inadequate antag aneg tae gn oe nra ist tion maa ib n mo tc el na cl ea n trt eib ao tmdy ent chu serine palmitoyltrans hepatitis c rg gantenerumab alzheimers disease responders headtohead bc breast cancer met metastatic cancer ferase inh rg ocrelizumab relapsingremitting ms cll chronic lymphocytic ms multiple sclerosis leukemia nhl nonhodgkins lymphoma rg nicotinic receptor alzheimers disease cardiovascular metabolic diseases dmard diseasemodifying nme new molecular entity cardiovascular metabolic diseases agonist rg aleglitazar cardiovascular risk reduction antirheumatic drug nsclc nonsmall cell lung cancer rg hsd inh metabolic diseases rg mglur antag treatmentresistant depression type diabetes g hb erm g hl eio rb la pst oo sm itia v emultiforme r sca r sh ue bu cm uta eid ua srthritis rg cat antag cardiovascular risk chronic evo nmda receptor antag treatmentresistant depression rg dalcetrapib atherosclerosis cardiovascular herneg hernegative kidney disease risk reduction rg abca inducer dyslipidemia rg antioxldl mab secondary prevention central nervous system cardiovascular events rg ocrezulimab primary progressive ms rg gipglp dual agonist type diabetes rg glycine reuptake inh schizophrenia negative symptoms legend central nervous system rg glycine reuptake inh schizophrenia suboptimally therapeutic protein biologic rg mglur antag depression controlled small molecule rg gabaa inverse cognitive disorders blue type first indication agonist ophthalmology black type additional indications rg triple reuptake inh depression rg lucentis diabetic macular edema rg antiamyloid peptide alzheimers disease rg lucentis amd high dose rgno roche andor genentech managed mab chu chugai managed evo evotec ophthalmology rg antifactor mab geographic atrophy phase initial studies healthy volunteers possibly patients phase ii efficacy tolerability dosefinding studies patients phase iii largescale studies patients statistical confirmation safety efficacy registra marketing applications filed eu us andor japan tion filed eu filed usa current january business innovation answer medical challenges research create stateoftheart diagnostics pioneering medicines help millions people around world focus personalised healthcare roche aim develop novel medicines diagnostics help patients live longer better lives constantly strive scientific excellence continue developing effective thera peutic options previously none worlds largest biopharmaceutical company number one supplier vitro diagnostics roche brought many highly effective drugs market including industrys leading portfolio cancer medicines also one first companies recognise potential personalised medicine today expertise molecular biology enabling us develop targeted medicines specific patient groups contributes better safer costeffective healthcare rochearengtable contentsindd contents key figures inside cover pharmaceuticals pipeline inside cover highlights letters shareholders letter chairman letter ceo roche group group results outlook group strategy pharmaceuticals results sales review development highlights research development diagnostics results business area highlights research development corporate governance remuneration report corporate governance remuneration report corporate responsibility stakeholder engagement patients people society responsible practices safety security health environmental protection independent assurance report gri statement rochearengtable contentsindd roche business report letter shareholders franz b humer dear shareholders wasachallengingyearforthepharmaceuticalindustrymarketconditionsas anticipatedforquitesometimebecameeventougherinthewakeofthefinancial crisishighgovernmentbudgetdeficitsaddedtopricingpressuresintheglobalhealth caresectorineuropemanygovernmentscutdrugpricessignificantlywhilehealthcare reformintheusresultedinhigherrebatesonprescriptiondrugsontheregulatory frontthehurdlesforgainingapprovalofnewmedicineswereraisedevenhigherdra maticallyincreasingthecostofdrugdevelopmentanddelayingaccesstoinnovative treatments amidthesechallengesrochepostedgoodfullyearresultshoweverwealsofeltthe effectsofthemarketchangesivejustdescribedinjulytheusfoodanddrugadmin istrationfdarejectedourapplicationforacceleratedapprovaloftdmeven thoughthisnovelcompoundisexpectedtosignificantlyimprovethetreatmentofbreast cancerthiswillincreasetheclinicaldevelopmentcostsfortdmanddelaythis rochearengletter shareholdersindd letter shareholders roche business report promisingdrugsapprovallateintheyearthefdaannounceditsintentiontowithdraw approvalofavastinincombinationwithchemotherapyforfirstlinetreatmentofmeta statichernegativebreastcancerwhileawithdrawalwillnotaffectuspatients accesstoavastininitsotherapprovedcancerindicationsitwouldadverselyimpact patientswiththisveryseriousdiseasethedaythefdamadeitsannouncement theeuropeanmedicinesagencyemaconfirmedavastinsvalueinthefightagainst breastcancerineuropewomenwithadvancedbreastcancerwillthuscontinueto haveaccesstothistreatmentoption wearecloselymonitoringdevelopmentsinhealthcarepolicyaroundtheworldprecisely becausewebelieveourhighlyinnovativeproductscontributeinimportantwaysto moreeffectivecostefficienthealthcaredeliveryweconsideritvitalforthefuturethat policymakersandhealthofficialslooknotonlyatthecostsofnewmedicinesbutalso attheinnovationtheyembodyandthebenefitstheyofferpatientsgiventhemanydis easesthatstillcannotbetreatedsatisfactorilyoratallmedicalprogressshouldbe viewedmoreasapublicgoodthatdeservesvigorouspoliticalsupport whenwediscussinnovationwemustbearinmindthatitisinherentlyriskypioneering researchanddevelopmenteffortssometimesproducebreakthroughsbuttheyalsocan sometimesnotachievethedesiredendpointstaspoglutideisacaseinpointwesus pendedalatestagedevelopmentprogrammeonthisnewtreatmentfortypediabetes ataverylatestageofdevelopmentaftercarefulassessmentoftheavailablesafetyand efficacydata ourintenseresearchanddevelopmentactivitiesalsoyieldedsomeverystrongand promisingresultslastyearwecurrentlyhavetwelvenewmolecularentitiesinlatestage developmenthalfofwhicharedesignedfortargeteduseinspecificpatientpopulations withthehelpofcompaniondiagnostictestswehavemadeenormousprogressin personalisedhealthcarehelpedbythecloseinterplaybetweenourpharmaceuticals anddiagnosticsdivisionsthesedevelopmentsrepresentmajorstridesandmakeus confidentthatwewillremainanindustryleader rocheconvincinglymetitssalesandearningstargetsforexcludingsalesofour influenzamedicinetamifluwhichasexpectedweredownsharplyfortheyeargroup salesroseinlocalcurrenciesnetincomeattributabletorocheshareholders showedastrongincreaseadvancingtobillionswissfrancsdespitethecosts associatedwiththeoperationalexcellenceprogrammeamountingtoaconsiderable billionswissfrancscoreearningspershareakeyindicatorofunderlyingbusiness performanceincreasedinlocalcurrenciesinswissfrancs inviewofthecompanyshealthycashflowandpositiveoutlooktheboardofdirectors willproposeadividendincreaseforoftoswissfrancspershareand rochearengletter shareholdersindd roche business report letter shareholders nonvotingequitysecurityupfromswissfrancsforsubjecttoyour approvalattheannualgeneralmeetingagmthiswillberochesthconsecutive annualdividendincrease lookingaheadtotheannualgeneralmeetingonmarchiwouldliketomention theupcomingchangesontheboardofdirectorswalterfreyandwolfgangruttens torferhavedecidednottostandforreelectiononbehalfoftheentireboardiwould liketothankthembothfortheirdedicatedservicetorocheduringhislongtenureon theboardmrfreywhorunsahighlysuccessfulfamilycompanyhasmadesignificant contributionstothegroupsgrowthandsuccessamongthestrengthsmrruttenstorfer broughttotheboardhisexpertiseonthegrowthmarketsineasterneuropeandthe middleeasthasbeenparticularlyvaluable weintendtousethisopportunitytostrengthentheboardfurtherbynominatingaddi tionalindependentdirectorsasannouncedindecemberpaulbulckeceonestlsa christophfranzchairmanandceodeutschelufthansaagandpeterrvoser ceoroyaldutchshellplcwillbestandingforelectionasnewmembersoftheboard attheannualgeneralmeetingwewillalsoproposethatthetermofboardmembers bereducedfromthreetotwoyearsthiswillenableshareholderstoinfluencethecom positionoftheboardatshorterintervalsinfuture aftertenyearsofexceptionalserviceonthecorporateexecutivecommitteeerich hunzikerhasdecidedtoretirefromrocheattheendofmarcherichhunzikerwas appointedchieffinancialofficerinbecomingdeputyheadofthecorporate executivecommitteeinduringhislongcareeratrocheerichhunzikerwasone ofthekeyarchitectsofthegroupssuccessfuldevelopmentiwouldliketotakethis opportunitytothankerichhunzikersincerelyforhisoutstandingcontributiontothe groupsoverallsuccess theboardofdirectorshasappointedalanhippetosucceederichhunzikeraschief financialofficeralanhippewilljoinrocheasamemberofthecorporateexecutive committeeasofaprilalanhippeservedasamemberoftheexecutiveboardof continentalagfromtosinceaprilhehasbeencfoandamember oftheexecutiveboardofthyssenkruppag ourcompanywashonouredlastyearforoutstandingachievementsinanumberof areasiamparticularlypleasedthatthedowjonessustainabilityindexesnamedusthe supersectorleaderinhealthcareforthesecondyearinarowrankingrocheasthe worldsmostsustainablehealthcarecompanywefirmlybelievethatsustainablecorpo ratepoliciesandpracticesultimatelycreatelongtermvalueandpromoteinnovation rochearengletter shareholdersindd letter shareholders roche business report oursuccessasacompanyisbuiltonscientificexcellencethatbenefitspatientsthe successfulintegrationofgenentechhasfurtherstrengthenedourinnovativecapa bilitiesastheworldslargestbiotechcompanyandtheleadingsupplierofcancermedi cinesweleadinpersonalisedhealthcarearetheworldsnumberonesupplierof vitrodiagnosticsandhaveoutstandingproductportfoliosinboththepharmaceuticals andthediagnosticsdivision ourabilitytocreatevalueforallstakeholdersiscrucialtoourfuturesuccessandwe willcontinuetovigorouslypursuethisstrategy franzbhumer chairmanoftheboard rochearengletter shareholdersindd roche business report letter shareholders severin schwan dear shareholders sandrobhadbeenrecentlydiagnosedwithmalignantmelanomashortlyafterhisth birthdaymalignantmelanomaisoneofthedeadliestmostaggressiveformsofskincancer withovernewcasesreportedworldwideeachyearitishighlylikelytometastasise ataveryearlystageandoncepatientshavedevelopedmetastasestherearealmostno treatmentoptionsavailabletothemlifeexpectancyfollowingdiagnosisistypicallyamatter ofmonthshisdoctorsgavehimfourmonthstolive sandrobmettheinclusioncriteriaforaphaseiiclinicaltrialinwhichwearetestingour novelinvestigationaldrugrginpatientswithadvancedmalignantmelanomawhose cancercellscarryaspecificgeneticmutationadiagnostictestconfirmedthathehadthis mutation beforereflectinginmoredetailsonourclinicaltrialsiwouldliketobrieflyreviewthe groupsbusinessperformanceindespitestrongpressureonpricesintheusandin europethepharmaceuticalsanddiagnosticsdivisionsbothpostedgoodresultsexcluding tamiflusaleswhichweredownbillionswissfrancsfortheyearsalesinthepharma ceuticalsdivisionadvancedabovetheoverallmarketgrowthincludingtamifludivisional salesdeclinedinlocalcurrenciestobillionswissfrancsgrowthwasdrivenbykey rochearengletter shareholdersindd letter shareholders roche business report productsforoncologyophthalmologyinflammatoryandautoimmunediseaseandanemia thankstocontinuedstrongdemandforouranticancermedicinesweexpandedourleadin thisimportantmarketsegmentinthediagnosticsdivisionsalesadvancedinlocal currenciesagainsignificantlyoutpacingthemarketandsolidifyingrochespositionasthe leadingsupplierofin vitrodiagnosticsprofessionaldiagnosticsanddiabetescarewere thedivisionsprimarygrowthdrivers thegroupscoreoperatingprofitgrewfasterthansalesrisingbyarobusttobillion swissfrancsinlocalcurrenciesprofitabilityimprovedfurtherwiththecoreoperatingmar ginsinthepharmaceuticalsanddiagnosticsdivisionsadvancingpercentagepointsto andpercentagepointstorespectivelyonceagaintheearningspower ofouroperatingbusinesseswasalsoreflectedinthegroupsoperatingfreecashflowwhich lastyearreachedastrongbillionswissfrancsthankstoourstrongcashflowby yearsendwehadalreadyrepaidathirdofthedebtincurredinconnectionwiththegenen techtransactionearlierthanoriginallyplanned succeedinginourindustryistougherthaneverpricingpressuresarerisingsharplyandthe requirementsforapprovalandreimbursementofnewmedicinesarebecomingincreasingly stringentatrocheweadditionallyexperiencedsetbackswithsomeofourlatestagedevel opmentprojectslastyearincludingthediabetesdrugtaspoglutide inresponsetothesechallengesmycolleaguesontheexecutivecommitteeandidecided totakeappropriateactionnowtoensurerocheslongtermsuccessinnovemberwe launchedthecomprehensivegroupwideoperationalexcellenceprogrammewhichis designedtostrengthenthegroupsproductivityandinnovativecapacityintheyearsahead wehaveidentifiedawiderangeofopportunitiestoimproveprocessesandraiseproductivity andefficiency implementationoftheoperationalexcellenceprogrammeisalreadyunderwayandwillcon tinuethroughasaresultofthisinitiativetheworkforceofroughlyatjune willbereducedbypositionsalmostoftheglobalworkforcethegreatest changeswillbeinthepharmaceuticalsdivisionwherewewillbeadjustingourglobalsales organisationandtakingstepstoimproveefficiencyandproductivityinproductdevelopment andoptimiseourmanufacturingnetworkinthediagnosticsdivisionthecolocationof relatedbusinessrdandoperationalfunctionsatselectedsiteswillenablethedivisionto streamlineitssitenetwork wearetakingthesemeasuresproactivelyfromapositionofstrengthrocheistheworlds biggestbiotechcompanywithproductsandproductlinesthatgenerateannualsales ofoveronebillionswissfrancseachanddespitelastyearssetbacksourresearchand developmentpipelineremainsoneofthestrongestintheindustrywithourcombined strengthsinpharmaceuticalsanddiagnosticsandprovenexpertiseinmolecularbiologywe rochearengletter shareholdersindd roche business report letter shareholders areuniquelypositionedtorealisethepromiseofpersonalisedhealthcaretomaketreatments saferandmoreeffectivetherevolutionaryadvanceswearestartingtoseeinmolecular biologygiveusastrategiccompetitiveedgeacrossanumberofareasincludingourability toraiseresearchproductivity personalisedhealthcareparadigmsincreasinglyshapeourresearchanddevelopmentpro grammeswecurrentlyhavetwelvenewmolecularentitiesinlatestagedevelopmenthalf ofwhicharetailoredtospecificpatientpopulationsourbrafinhibitorformalignant melanomametmabforlungcancertdmandpertuzumabforbreastcancerandother projectsinvirologyandinflammationallrepresentpotentialmajoradvancesforpatients similarlyourdiagnosticsdivisionisdevelopinganumberofbiomarkerstosupportthera peuticdecisionmakingtargetedtherapiesanddiagnosticteststhatcontributetobetter medicaldecisionsnotonlyimprovepatientcarebutalsohavehealtheconomicbenefitsthat makethemattractivetoregulatorsandpayers oneofthemostimpressiveexamplesofpersonalisedhealthcareisrgthedrugused totreatmalignantmelanomawhichimentionedearlierthankstoinsightsintospecific geneticchangesintumourcellshugestridesarebeingachievednowinclinicaltrialsina diseaseonceconsideredvirtuallyuntreatable tumoursgenerallydevelopfromjustonecelleverycellcontinuouslyundergoeschanges knownasmutationsthataffectcertainsignallingpathwayswithinthecellmostmutations arecorrectedspontaneouslybutsomemanagetoevadethebodysrepairmechanisms causingcellstodivideuncontrollablyandthusformtumoursscientistshavediscoveredthat inoverhalfofallmelanomapatientsthediseaseistriggeredbyahighlyspecificmutation ofthegenecodingforthebrafproteinwhichisinvolvedincellgrowthabrafve mutationtriggersuncontrolledcellgrowthandthesecancerpatientssandrobfor examplehavevirtuallynoprospectofbeingcured rganoralcancerdrugcodevelopedwithourpartnercompanyplexxikonactsvia ahighlyinnovativemechanismtoinhibitthebrafproteinimplicatedinthediseasethenew drugspecificallydestroysthosecellscarryingthevemutationanddoesnotattack healthycellswithoutthemutation wehavedevelopedadiagnosticassayforusewiththedrugwhichiscapableofdetecting thevemutationintumoursandwillthushelpidentifypatientswhoareverylikelyto respondtothenewdrugthismeansthenewdrugwillbeusedonlyinpatientslikelyto benefitfromthenewtreatment theinterimresultsofaphaseiiitrialwhichwepublishedinjanuaryarevery encouragingforthefirsttimeapersonalisedinvestigationalmedicinerghasshown asignificantsurvivalbenefitinmetastaticmelanomathisisanimportantadvance letter shareholders roche business report forpeoplewiththebrafvmutationpositiveformofthediseasewhohavehad extremelylimitedtreatmentoptionsfulldatawillbepresentedatamedicalmeetinglater thisyearrocheisworkingcloselywithglobalhealthauthoritiessothatpatientsworld widecanalreadybetreatedwiththenewdrug thepursuitoftreatmentsofferingrealbenefitstopatientsisthecoreofourcorporate strategyconsistentwiththatstrategywewillcontinuetodriveprogressonourpromising developmentportfolioweexpectresultsfromatotalofphaseiiandphaseiiitrials inandbasedonourcurrentlatestageportfolioweexpecttosubmituptoeight regulatoryfilingsforapprovalofnewmolecularentitiesbytheendofmoreover wearecurrentlyworkingonmorethanadditionalindicationsforexistingproducts goingforwardinnovationsthatbenefitpatientswillcontinuetodriveoursuccessthrough excellenceinsciencewestrivetodeveloppioneeringtreatmentsanddiagnosticteststhat prolongpatientslivesandtangiblyimprovetheirqualityoflife rocheowesitssuccesstoitsemployeesthankstotheirtremendousdedicationandhard workweonceagainachievedourgoalslastyeardespiteanincreasinglychallengingmarket environmentonbehalfoftheentireexecutivecommitteeiwouldliketothankallour employeesfortheirimportantcontributions makingsurethatrocheremainsanemployerofchoiceisanimportantpriorityformeso iamespeciallypleasedtoreportthatinourcompanywasagainvotedatopemployer inpollsinanumberofcountriesbeingatopemployerisnotjustaboutgivingasmany employeesaspossibleopportunitiestodevelopprofessionallyandmakethingshappenin thecompanyinnovationdependsonadiversityofviewsandapproachesoneoftheways werepromotingdiversityatrocheisbyfillingmoremanagerialpositionswithwomenatthe startofwesetourselvesthegoalofincreasingtheproportionofwomeninthetop leadershippositionsbyhalftooverthenextfiveyearsiamhappytoreportthat wemadeprogressonthisfrontaswelllastyear whathappenedtotheyoungmanwithmelanomalikemanyoftheothertrialparticipants sandrobhasrespondedwelltoournewdrugforskincancerheisstillaliveanddoingwell thisisexactlywhatwehaveinmindwhenwetalkabouthelpingpatientsthroughexcel lenceinscience severinschwan chiefexecutiveofficer rochearengletter shareholdersindd roche group group posted solid overall results challenging market core operating profit grew faster sales core earnings per share increased doubledigit rate steadily making progress personalised healthcare twelve new molecular entities latestage pipeline half targeted specific patient populations rochearenggroupindd roche group roche business report group results inthediagnosticsdivisionwasinlocalcurren ciesmainlyresultingfromsalesgrowthdueto outlook newproductlaunchesandtheongoingoperational efficiencyprogrammesthegroupscoreoperating profitmarginincreasedbypercentagepointsto overall results withthepharmaceuticalsdivisionimproving therochegrouppostedsolidoverallresultsin percentagepointstoandthediagnos groupsaleswerestableinlocalcurrencies ticsdivisionbypercentagepointsto atbillionswissfrancsinswissfrancs inusdollarsthegoodunderlyinggrowthof inthegroupsnetincomeincreasedbyto bothdivisionscompensatedfortheexpected billionswissfrancscomparedtonet declineintamiflusalesandtheimpactsofhealth incomeattributabletorocheshareholdersrose carereformsandausteritymeasuresexcluding tobillionswissfrancs tamiflusalesincreasedbyinlocalcurrencies thepharmaceuticalsdivisionrepresented thegroupsoperatingfreecashflowremainedstrong ofgroupsalesandthediagnosticsdivisioncon atbillionswissfrancsafreecashflowof tributed billionswissfrancswasachievedindespite higherinteresttaxanddividendpayments salesinthepharmaceuticalsdivisiondeclinedby inlocalcurrenciestobillionswissfrancs excludingtamiflulocalgrowthwasabovemar board directors ketgrowthdemandfortheoncologydrugsavastin mabtherarituxanherceptinxelodaandtarceva proposing increase continuedtogrowstronglyadditionalmajorgrowth driverswereactemraroactemrainrheumatoid dividend arthritismircerainanemiaandlucentisinophthal mologyactemrawhichisnowlaunchedinsome swiss francs per share countriesincludingtheunitedstatestheeuand japanreachedsalesofmillionswissfrancsin nonvoting equity security thesepositivefactorscompensatedformostof theexpectedstrongdeclineintamiflusalesthe approval annual general reductionincellceptsalesduetouspatentexpiry inmayandtheimpactsoftheushealthcare meeting reformseuropeanausteritymeasuresandpricecuts injapan thediagnosticsdivisionincreasedsalestobil ofthedebtraisedinearlyhadalready lionswissfrancsingrowinginlocal beenrepaidbydecemberinadditionthe currenciesinswissfrancsinusdollars groupexerciseditsoptiontocallforredemption therebystrengtheningitsleadingmarketposition aportionoftheusdollarnotesduemarch majordriverswereprofessionaldiagnosticswith ofthetotalprincipalamountofbillionusdol salesgrowthanddiabetescarewithsales larsbillionusdollarswillberedeemedinmarch growth thenetdebtpositionofthegroupis bil lionswissfrancsadecreaseofbillionswiss thegroupscoreoperatingprofitincreasedbyin francsfromdecember localcurrenciesinswissfrancsthepharma ceuticalsdivisionincreaseditscoreoperatingprofit theboardofdirectorsisproposinganincreaseof byinlocalcurrenciesdrivenprimarilybycost inthedividendfortoswissfrancs synergiesfromthegenentechintegrationandprod pershareandnonvotingequitysecurityforapproval uctivityimprovementscoreoperatingprofitgrowth attheannualgeneralmeeting rochearenggroupindd roche business report roche group thiswouldbethethconsecutiveincreaseofthe outlook dividendandcorrespondstoanincreaseinpayout ingroupandpharmaceuticalssalesexcluding ratiofromintofor tamifluareexpectedtogrowatlowsingledigit ratesinlocalcurrenciesreflectingtheimpactofus financial implications operational excellence healthcarereformandeuropeanausteritymeasures onnovemberthegroupannouncedimple pharmaceuticalssalesarethereforeexpectedto mentationplansforitsoperationalexcellencepro growinlinewiththemarket grammewhichisaimedatadaptingcoststructures toanincreasinglychallengingmarketenvironment indiagnosticssalesareagainexpectedto andachievingsignificantefficiencyandproductivity growsignificantlyaheadofthemarketdrivenbyfur gainstheinitiativeisexpectedtogeneratesavings therrolloutofnewproductsinallbusinessareas ofbillionswissfrancsinwithprojected savingsofbillionswissfrancsfromonwards inspiteofamorechallengingenvironmentandthe implementationisscheduledtobesubstantially introductionofanexcisetaxintheunitedstates completedbytheendofduringtheperiod rocheaimsforcoreearningspersharetogrowata fromthroughrocheexpectstoincur highsingledigitrateinatconstantexchange restructuringcoststotallingbillionswissfrancs rates asaconsequenceofimplementingtherespective rocheaimstoincreasethedividendinlinewith restructuringmeasuressignificantcostswere coreearningspersharegrowth alreadyincurredinthecostsinofbil lionswissfrancsmainlyrelatetoseverancepayments basedonthestrongoperatingfreecashflowroche andimpairmentsofintangibleassetsthepharma expectstoreducedebtprogressivelyandtoreturnto ceuticalsdivisionaccountsforbillionswissfrancs anetcashpositionby ofthesecostsandbillionswissfrancsrelate tothediagnosticsdivisionroughlyofthe chargesarenoncashbeingmainlyimpairmentsof propertyplantandequipmentandintangibleassets group expanded presentation core results previously core eps shown full income statement group operating results divi sions shown ifrs core basis allows transparent assessment actual results underlying performance business core results concept fully described pages finance report reconciliations ifrs core results given roche group roche business report key achievements businessfinance pharmaceuticals sales excluding tamiflu increased market growth achievements diagnostics sales growth significantly ahead market core operating profit margin significantly divisions doubledigit rise core earnings per share constant exchange rates dividend increase proposed reporting year products pipeline key drug approvals including approved new indications actemra herceptin lucentis mabtherarituxan twelve new molecular entities latestage development six personalised healthcare approach four new molecular entities moved latestage clinical development lebrikizumab asthma metmab lung cancer rg hepatitis c ocrelizumab multiple sclerosis fifty diagnostic tests instruments launched key markets patients access defined new pricing arrangements increase patient access medicines healthcare emerging markets expanded commitment file enforce patents low income coutries lic defined world bank launched educare progamme africa international atomic energy agency iaea establish online university provide oncology training doctors people genentech voted science magazines top employer eighth time roche rose th th place increased percentage women key positions published scientific articles nearly highimpact journals nature science cell society employees generated million swiss francs annual childrens walk support aids orphans malawi refurbished primary health coach phelophepa health train south africa responsible practices first year roche speakup line reporting violations code conduct demonstrated responsible use employees launched global marketing sales compliance questionnaire promote good business conduct rolled supplier code coduct suppliers received commitment introduced online procurement training completed employees roche named healthcare supersector leader dow jones sustainability indexes second year running safety security health reduced ecobalance measure total environmental impact environmental five years ahead target protection kept greenhouse gas emissions stable despite significant growth company learn roches achievements area corporate responsibility see pages rochearenggroupindd roche business report roche group group strategy changing healthcare sector dynamic healthcare markets impacted tension steadily rising demand limited financial resources growing pressure healthcare budgets means increasingly new funds available real innovations products offer patients significant added value compared conventional treatments despite current challenges pharmaceutical industry excellent prospects long term key drivers success include rising life expectancy increasing prosperity developing countries numerous diseases yet effective therapies last least rapid scientific technological advances theworldspopulationcontinuestoexpandand ashiftinthegrowthdynamicfromwesterntofar peoplearelivinglongeronaveragegreaterlife easternandlatinamericanmarketshasbeenappar expectancymeansariseinagerelateddiseases entforsometimethistrendwillbecomeeven suchascancerdiabetesrheumatoidarthritis strongerinfuturebytheemergingmarketswill parkinsonsandalzheimersthisistruenotonly accountforsomeofthegrowthintheglobal oftheindustrialisedworldbutincreasinglyof pharmaceuticalmarketandtheirshareoftheworld developingcountriesandemergingmarketstoo marketwillincreasetoaroundtheasianphar moreovertherearestillnoeffectivetherapies maceuticalmarketforexamplehasgrowntwice forsome diseasesandpatientresponseto asfastastheoverallglobalmarketinrecentyears existingdrugsisoftenunsatisfactorythereis chinawhererocheagainexpandeditspres consequentlysubstantialunmetmedicalneedand encesignificantlyinhasbecomethethird increasingdemandformoretargeteddiagnostics largestpharmaceuticalmarketaftertheunited andmoreeffectiveandbettertoleratedtherapies statesandjapanin demographicchangesandgrowingdemandson medicalcareareplacinganevergreaterburdenon healthcaresystemstherecentfinancialandeco nomiccrisisandtheresultinggovernmentdeficitsin europeandtheunitedstateshavefurtherexacer batedthesituationpoliticalpressuretocurbhealth carecostshasthereforegrownineuropeseveral countriesimposedsignificantpricereductionson pharmaceuticalproductsinhealthcarereform intheunitedstateshasledtoanincreaseindrug rebatesundergovernmenthealthinsuranceplansand anewconsumptiontaxonpharmaceuticalsalesis plannedforinadditionusandeuropeanregu latoryauthoritieshavesignificantlyraisedthebar forapprovalofnewproductsandaretakingamuch morecriticallookatthetherapeuticbenefitsand safetyofnewdrugsdecisionsaboutwhichmedi cinestoadministerarebeingmadeincreasingly bypublicagenciesandhealthinsurersratherthan byphysicians rochearengstrategyindd roche group roche business report transforming practice medicine tapping vast potential personalised healthcare modern science tailoring treatment patients inordertoremaincompetitiveinthefuturedespitea patientswiththesameclinicaldiagnosismayre tougherglobalenvironmentinthehealthcareindustry spondverydifferentlytothesamemedicineswhile rocheispursuingaclearinnovationstrategybased treatmentmaybeeffectiveandsuccessfulinsome onoutstandingscientificachievementswehavecon patientsothersmayexperienceundesirableside fidenceinmodernsciencesvastpotentialfordevel effectsorthedesiredclinicalbenefitdoesnotoccur opingtherapiesanddiagnosticteststhatwillreduce thisphenomenonisdueinmanycasestogenetic sufferingandhelppeopletolivelongerhealthier andothermoleculardifferencesbetweenindividual livesinparticularweseesignificantopportunitiesin patients thefastgrowingbodyofknowledgeaboutthemolec ularbasisofdiseasesadeeperunderstandingof treatmentstailoredtodifferentpatientpopulations diseasemechanismsandthegrowingrangeofestab havemedicalandeconomicadvantagesandarecon lishedandnewtherapeuticapproachesisenabling sequentlynotonlyimportantforpatientsandphy ustodevelopmorespecifictargetedproducts siciansbutarealsowelcomedbyregulatoryagencies andhealthinsurersinadditionearlyselectionof throughourmedicallydifferentiatedtherapieswe patientswhoarehighlylikelytorespondtoanew wanttoofferpatientsanddoctorssignificantmedical compoundincreasesthesuccessrateindrugdevel benefitintermsofeffectivenessqualityandsafety opmentwhilealsoloweringdevelopmentcosts toprovidelaboratorieswithefficiencygainsandto givepayershealtheconomicbenefitswealsostrive combiningstrengthsinpharmaceuticalsanddiag toensurepatientsaccesstotreatments nosticswithprovenexpertiseinmolecularbiology rocheisuniquelypositionedtomakeitspersonal targetedcosteffectivetherapiescanplayakeyrole isedhealthcarestrategyarealitythankstotheclose inovercomingcurrentchallengesinthehealthcare cooperationbetweenthepharmaceuticalsand sectorstateoftheartdiagnosticswillalsobecome diagnosticsdivisionsunderasingleroofonevery increasinglysignificantinarationalhealthcaresys thingfromresearchtosalesrocheiscommitted temdiagnosticscurrentlyaccountforonlyaround tothesystematicpursuitofpersonalisedhealthcare ofhealthcarespendingyetaroundofallmed thisconceptisbecomingarealityformoreand icaldecisionsdependonaccuratefastdiagnosis moreofourdevelopmentprojects heretoothereisvastpotential rochearengstrategyindd roche business report roche group pairing targeted therapies companion diagnostics roche already number products custommade specific patient populations become established standard treatments including therapies herpositive breast stomach cancer infections caused hepatitis b hepatitis c viruses latestage pipeline contains twelve new molecular entities six tailored specific patient groups companion diagnostic test include new drugs skin lung breast cancer viral infectious diseases see features encouraging results battle thesereceptorscanbeidentifiedusingmoleculartis malignant melanoma sueteststhemonoclonalantibodymetmabbinds rochesdevelopmentaldrugrgbrafinhib specificallytometreceptorsandpreventsactivation itoriscurrentlybeingtestedinpatientswith ofacancerpromotinggrowthfactorrocheisalso advancedmalignantmelanomainafinalphaseiii developingadiagnostictestfordetectingepidermal clinicaltrialdiagnosedworldwideinabout growthfactorreceptoregfrmutationsforpa peopleeachyearmalignantmelanomaisthemost tientswithnsclcpatientswithegfrmutationsre aggressiveformofskincancerthankstoinsightsinto spondespeciallywelltotheanticancerdrugtarceva specificgeneticchangesintumourcellshugestrides sodeterminingegfrmutationstatuswouldhelp arebeingachievednowinadiseaseonceconsid oncologiststopersonaliseandoptimisecancertreat eredvirtuallyuntreatabledevelopedonthebasisof mentseealsopersonalisedhealthcareforlung biomolecularfindingsrgisanoraldrugthat canceronand specificallyinhibitsthedeadlychainofeventsasso ciatedwiththedevelopmentofmelanoma progress fight stomach cancer stomachgastriccanceristhesecondleading inroughlyhalfofallmelanomapatientsthedisease causeofcancerrelateddeathsintheworldwith istriggeredbyadangerousmutationofthebraf overnewcasesdiagnosedeachyear genearocheassaydevelopedtodetectthismuta ineuropeanusandsouthkoreanregulators tionwillhelpidentifypatientsverylikelytorespond approvedherceptinforuseinherpositivemeta torginitialphaseiitrialdataareencouraging staticstomachcancer diseaseprogressionwassignificantlydelayedtu moursshrankmarkedlyinoverofpatientsand alreadyanestablishedtherapeuticoptioninbreast therewasanoticeableimprovementinpatients cancerherceptinisoneofthemostsuccessful qualityoflife examplesofpersonalisedhealthcaretodatethe herbiomarkerisdetectedinaboutof extending lives lung cancer patients gastrictumoursafastreliabletestforherstatus nonsmallcelllungcancernsclcisthemost providescriticalguidanceinbothapprovedher frequenttumourrelatedcauseofdeathintheworld ceptinindicationshelpingdoctorstoidentifythe accordingtopreliminarydatafromaphaseiitrial patientsmostlikelytorespondtothedrugher combiningthenovelmonoclonalantibodymetmab ceptinpluschemotherapyhasbeenshowntoprolong withtarcevaerlotinibnearlydoublesprogres thelivesofpatientswithstomachcancerbyupto sionfreesurvivalincertainpatientswithnonsmall celllungcancerthesepatientstumourcells carryanabnormallyhighconcentrationofacell surfaceproteinknownasthemetreceptor rochearengstrategyindd roche group roche business report mapk signalling diagnostics therapeutics moleculartestpcr activeingredientbraf identifiespatientscarrying inhibitor rgtargets amutatedbrafgene melanomacancercells inpatientswithmutated brafgene met signalling diagnostics therapeutics tissuetestidentifies antibodymetmab tumourswithhighexpression rgdocksonmet ofthemetreceptor receptorandinhibits cancertriggeringgrowth factor signalling diagnostics therapeutics tissuetestdetermines antibodydrugconjugate herreceptorsorher bindstoherreceptors geneexpression herceptinandlinked chemotherapyagentpene tratescancercelltdm rg tests developed roche diagnostics precision twopronged attack breast cancer theantibodytrastuzumabbindstoherpositive preliminaryresultsfromaphaseiistudyoftrastuzu cancercellsandblocksasignallingpathwaythat mabdmtdminherpositivemetastatic makestumoursgrowwhilethechemotherapyagent breastcancershowthatthedrugshranktumoursin dmpenetratesanddestroysthecancercells onethirdofthewomenwhohadfailedpriorther anotherpotentialnewweaponagainstbreastcancer apiesknownasanantibodydrugconjugatetdm ispertuzumabrgthefirstofanovelclass linkstrastuzumabtheactiveingredientofhercep oftargetedtherapeuticsknownasherdimerisation tinwiththepotentchemotherapeuticagentdm inhibitorsrgblocksherfrompairingwith thisrepresentsanewtargetedtwoinone otherherproteinsthuspreventingtheabnormalac approachtotreatingcancer tivationofsignalcascadesthatoccursincancercells rochearengstrategyindd roche business report roche group combining forces hepatitis c hope asthma sufferers hepatitiscvirushcvcausesacuteandchronic asthmastillrepresentsamajorunmetmedicalneed liverdiseasesthatcanleadtoliverfailurecirrhosis moreovertheunderlyingdiseasemechanismsare andcancertherearecurrentlyovermillion notthesameinallcasesourscientistshavediscov peopleinfectedwithhcvworldwidediagnostictests eredthatinaparticularsetofpatientscertain basedonpcrtechnologycannowmeasureviral genesareactivatedinthewrongplaceandatthe loadinthebloodofpatientswithchronichepatitisc wrongtimebythechemicalmessengerinterleukin infectionanddeterminewhichofthefourdifferent ilakeymediatorinasthmareactionsreduc hcvsubgroupsgenotypesispresent ingillevelscouldthusbeawayofrelieving asthmasymptomsinthispatientsubpopulation thediseasecanthenbetreatedbypegylatedinter thisapproachiscurrentlybeingtestedinaphaseii feronstailoredtotherespectivegenotypeandviral trialwithlebrikizumabrginvolvingthe loadlevelsuchastherocheproductpegasysthe measurementofakeybiomarkercalledperiostin viralloadtestisalsousedafterafewweekstocheck itmaymakeitpossibletoidentifythepatientsmost treatmentresponseinmanypatientstheviruscan likelytorespondtoanantiilantibodylike becompletelyeliminatedforchronichepatitisc rgrochediagnosticsiscurrentlydeveloping patientswhodofailtobenefitfrominterferonbased anappropriateassay therapyseveralsmallantiviralmoleculesareinclinical developmentatroche oncejustavisionpersonalisedhealthcareis increasinglybecomingarealityhelpedbypioneering thefocushereisonhepatitiscsubtypeinfection effortsatrocheforyearswehavebeenworking whichisverydifficulttotreatinitialresultsshowthat toadvancemorepersonalisedtreatmentoptions inpatientswhohavenotrespondedtointerferons acrossallourtherapeuticareasofinterestgoingfor thenewcombinedtreatmentcanachievea wardweareideallyequippedtoremainatthefore reductioninbloodviralloadwithinjusttwoweeks frontofthisgroundbreakingnewapproachtohealth careandtocontinuerealisingitstremendous potentialforallourstakeholders rochearengstrategyindd roche group roche business report signalling diagnostics therapeutics tissuetestdetermines antibodypertuzumab herreceptorsorher rginhibitspairingof geneexpression herherandher receptorsandthusprevents fatalsignallingincancer cells hepatitis c virus diagnostics therapeutics moleculartestpcrto hcvnucleosidepolymerase determinelevelsofcirculating inhibitorrgprevents hepatitiscvirus reproductionofhepatitisc viruses lebrikizumab diagnostics therapeutics immunoassaymeasures antibodylebrikizumab theserumleveloftheprotein rginhibitschemical periostinanilgene messengerinterleukin productandthusdetects thattriggersinflammationin lunginflammationdriven asthmaticreactions byil il molecule tests developed roche diagnostics rochearengstrategyindd roche business report roche group precise diagnosis personalised therapy nonsmall cell lung cancer nsclc worlds number one cause cancer related death common form adenocarcinoma illustrations show diagnostic tests provide patients suffering nsclc physicians information tumours molecular profile likelihood response drug therapy appropriate therapeutic options roche developed several immunohisto chemistry situ diagnosis lung hybridisation tests cancer complex determine exact imaging technologies type tumour present often used initial examination initial diagnosis prognosis tissuesamplesfromthepatientarefirstexamined thepathologistthencharacterisesthetumouron inthepathologylaboratorytoseewhethercancer thebasisofcelldifferentiationandothercriteria cellsarepresentifirregularitiesincellularshapeor rocheiscurrentlydevelopinganumberofmolecular structurearefoundmoreextensivetestsare biomarkersthatwillenablephysicianstopredict required thecourseofcancersasaccuratelyaspossible specific cancer diagnosis rochehasdevelopedseveralimmunohistochemistry andin situhybridisationtestsforuseonthebench markfamilyofinstrumentsthatreliablydeterminethe typeandsubtypeoflungtumourpresent rochearengstrategyindd roche group roche business report pathologist grades roche tests tumour looking market individual cells development help determining extent physicians cell differentiation stand mecha nisms driving cancer growth thus select treatments likely benefit roches avastin specific patients tarceva become pillars treat ment lung cancer roche continues develop new com pounds targeted cancer therapy tests therapy anumberofgeneshavebeenidentifiedasgrowth rochesanticancermedicinesavastinbevacizumab driversinnonsmallcelllungcancernsclcthese andtarcevaerlotinibplayacrucialroleinthe includetheegfrgenethemetreceptorsandthe treatmentoflungcancerandthecompanyiscurrently plkinase developinganumberofnewinnovativedrugsto addresscancerspecificpathwaysandofferpatients testsfromrochehelpdoctorsunderstandthemech targetedtherapiesinadditionrochediagnostics anismsdrivingtumourgrowthandthustoselect offersabloodtestenablingphysicianstomonitor drugsmostlikelytoworkbestforaparticularpatient responsestocancertreatment rochehasseveraltestsonthemarketorindevel opmentwhichusethreekeytechnologiesimmuno histochemistryihcin situhybridisationish andthepolymerasechainreactionpcr rochearengstrategyindd pharmaceuticals solid local currency growth sales strategic products core operating profit despite lower tamiflu revenues tougher market environment additional approvals key medicines progress promising projects latestage development pipeline made successful year pharmaceuticals division focused translating excellence science effective medicines patients combines cutting edge research roche genentech us chugai japan partners worldwide global scale reach clinical development manufacturing commercial operations rochearengpharmaceuticalsindd pharmaceuticals roche business report pharmaceuticals division brief sales millions chf core operating profit millions chf number employees key figures change change millions chf chf local currencies sales sales united states western europe japan international asiapacific cemai latin america canada others core operating profit operating free cash flow research development core basis cemai central eastern europe middle east africa central asia indian subcontinent pharmaceuticals management team december pascal soriot chief operating officer pharmaceuticals head pharma medicines hal barron global product development chief medical officer ian clark commercial operations north america ceo genentech tuygan gker commercial operations cemai meeta gulyani global portfolio management peter hug commercial operations western europe michael knierim human resources david loew global product strategy luke miels commercial operations asiapacific patrick mongrolle finance jrg rupp commercial operations latin america patrick yang global technical operations jeanjacques garaud pharma research early development pred osamu nagayama president ceo chugai richard scheller genentech research early development gred dan zabrowski roche partnering member corporate executive committee see corporate governance p member pharma medicines leadership team rochearengpharmaceuticalsindd roche business report pharmaceuticals pharmaceuticals division sales region solidlocalcurrencygrowthinsalesofstrategic productsandcoreoperatingprofitadditionalmar united states ketingapprovalsforstrategicproductsandprogress asiapacific witharangeofpromisingprojectsinourlatestage latin america rdpipelinemadeasuccessfulyearoverall regions forthepharmaceuticalsdivisiongrowthwasdriven cemai primarilybystrongdemandforkeymedicinesfrom thegroupsoncologyandinflammatorydiseaseport foliosfollowingtheendoftheinfluenzaahn western europe pandemicandcompletionofgovernmentstockpiling japan orderssalesoftamifludeclinedstrongly italics growth rates local currencies cemai central eastern europe middle east africa weachievedimportantproductdevelopmentsuc central asia indian subcontinent cessesinincludingexpandedmarketing approvalsforactemraroactemraforrheumatoid arthritisintheusandtheeuherceptinforstomach bursementpricesorhigherrebatesonmedicines cancereuandusmabtherarituxanforchronic understatutoryhealthinsuranceorgovernment lymphocyticleukemiausandmaintenancetreat fundedprogrammesthesedevelopmentsalready mentoffollicularlymphomaeuandlucentisfor hadanoticeableimpactonsalesinand macularedemafollowingretinalveinocclusionus weexpectthistocontinueintoandbeyond keyregulatoryfilingsincludedmarketingapplica inadditionweexperiencedseveralproductdevel tionsforactemraroactemraforjuvenileidiopathic opmentsetbacksinthemostseriousof arthritisintheeuandusherceptinforstomach thesewerethedecisiontosuspendphaseiiitesting cancerinjapanandavastinforadvancedovarian oftaspoglutidefortypediabetesandregulatory cancerintheeu developmentsintheusandeuconcerningavastin asatreatmentforadvancedbreastcancer duringtheyearwemadedecisionstomoveseveral projectsintolatestagedevelopmentincluding indecembertheeuropeanandushealthauthorities ocrelizumabformultiplesclerosisrgforhep announceddecisionsthatarepivotalindetermining atitisclebrikizumabforasthmaandrg whetheravastinremainsavailableasatreatment metmabforlungcancerpositiveresultsfromclin formetastaticbreastcancerwebelievestronglythat icaltrialswithotherlatestagecompoundssuch patientsshouldhavethisoptionandarepleased asrgbrafinhibitorformelanomarg thattheeuropeanauthoritiescontinuetosupportthe gafornonhodgkinslymphomaandchronic useofavastininthisindicationitisdisappointing lymphocyticleukemiaandtdmandpertuzumab thattheusfoodanddrugadministrationfdahas forherpositivebreastcancerwerepublishedor cometoadifferentconclusionafterreviewingthe presentedatmajormedicalconferencesduring samesetofdatawebelievethatwomenwithher thesetargetedcompoundsaredesignedtomove negativemetastaticbreastcancerlivingintheus thestandardofcareforthesediseasesandimprove shouldalsohaveavastinasatreatmentoptionand patientsurvivalrochespharmaceuticalpipeline wehaverequestedahearingwiththefdaaccord currentlyincludesnewmolecularentitiesinlate inglyseep stagedevelopment respondingtothetougheroperatingenvironment atthesametimewasayearofsignificant andsetbacksoutlinedabovewecontinuedto challengespressureonhealthcarebudgetsinmany strengthenourpharmaceuticalsorganisationto countriesandhealthcarereformsintheunited statestheworldslargestmarketforpharmaceuti calstranslatedintomandatoryreductionsinreim unless otherwise stated growth rates local currencies rochearengpharmaceuticalsindd pharmaceuticals roche business report increaseefficiencyandmaintainitsfocusoninno vationwebelievethatthemeasuresnowbeing excluding tamiflu pharma implementedthroughthegroupsoperationalexcel lenceprogrammewillenhancerochesabilityto ceuticals division sales grew deliverbreakthroughmedicinesforpatientsallowing ustoexpandfurtherinhighgrowthemergingecon global market omieswhilestrengtheningourpresenceinestab lishedmarkets healthcarereformsintheunitedstatesandausterity results main measuresineuropehadanegativeimpactontotal salesofapproximatelymillionswissfrancsor business developments percentagepointsexcludingtamiflusalesinthe usandwesterneuropeincreasedand salesbythepharmaceuticalsdivisionin respectivelycomparedwithmarketgrowthof declinedinlocalcurrenciesinswissfrancs andadeclineinsalesofinjapanreflects inusdollarscomparedwithto bil bothsignificantlylowerdemandfortamifluand lionswissfrancsexcludingtamifluthedivisions theimpactofrevisednationalhealthinsurancereim localcurrencysalesgrewabovetheglobal bursementpricesthatcameintoeffectinapril marketinadditiontothegroupsfivemaincancer excludingtamiflujapanesesalesgrewinavir medicinestheprimarysalesdriverswerelucentis tuallyflatmarket actemraroactemraandmirceragrowthfromthese andotherpharmaceuticalslargelycompensated coreoperatingprofitgrewinlocalcurrencies forlowersalesoftamiflucellceptandneorecor andwasstableinswissfrancsatbillionswiss monepogintogetherthetopsixsalesdrivers francsthecorrespondingmarginincreased avastinmabtherarituxanherceptinlucentis percentagepointstodrivenbysynergiesfrom actemraroactemraandxelodacontributedover themergerwithgenentechandproductivityimprove billionswissfrancsinadditionalsalesin mentsthiswasachieveddespitetheexpectedsharp duetothepassingoftheinfluenzaahnpan declineintamiflusalesandtheimpactofhealth demicarelativelymildinfluenzaseasonandthe carereformsandausteritymeasuresareductionof completionofmostgovernmentstockpilingorders inmarketingexpenseswasachievedthrough salesoftamifludeclinedstronglyto million tightcostmanagementwhichmorethancovered swissfrancs billionfrancslowerthanin anincreaseinallowancesforbaddebtsinsouthern europeresearchanddevelopmentexpenses salesexpandedfastestintheinternationalregion declinedversusthankstoresourcepriori orexcludingtamifludrivenbydemandfor tisationwhilesecuringlongtermgrowththrough mabtheraherceptinavastinandotherkeymedi therichrdpipelineinadditiontoinvestmentsin cinesinemergingmarketsparticularlystronggrowth phaseiiiinitiationsthemetabolismfranchiseand wasrecordedinlatinamericaledbybrazil theearlierstageneurologyportfolioresearchand andvenezuelasolidgrowthintheasiapacific developmentexpensesincludedcostsassociated regionwasledbychinaandtaiwanaslight withthediscontinuationoftheocrelizumabrheuma decreaseintheunitedstatesreflectssig toidarthritisprogrammeseepbelowand nificantlylowersalesoftamifluandcellceptaswell projectterminationcostsassociatedwiththeopera ashealthcarereformimpactsaffectingallmajor tionalexcellenceprogramme productsadeclineinsalesinwesterneurope wasdueprimarilytomarkedlylowersalesoftamiflu andneorecormonandtheeffectsofgovernment austeritymeasuresintroducedinanumberofcoun pharmaceutical market growth according ims end september triesincludinggreeceandspaininthesecond unless otherwise stated results core basis quarterandgermanyinthethirdquartertogether see p p finance report rochearengpharmaceuticalsindd roche business report pharmaceuticals germanyandswitzerlandinadditionexpansion ofthekentuckydistributioncenterwascompleted core operating profit inthefacilitynowservesastheprimary distributioncentreforallproductsmarketedinthe margin increased percentage unitedstates points inallglobaltechnicaloperationsfacilitiespassed morethanhealthauthorityinspectionsin ourbiotechproductionfacilityinsingaporereceived thedivisionsfullyearoperatingfreecashflow itsfirstapprovalsbytheusfoodanddrugadmin remainedstrongatbillionswissfrancsthe istrationfdatomanufacturelucentisandavastin decreaseofcomparedwithprimarily biologicbulkdrugsubstanceforcommercialuse reflectsthepaymentinofcertainlarge intheusapprovalbytheeuauthoritiesistargeted yearendaccrualsincludingemployeeretention forourkaiseraugstswitzerlandfacility andseverancepaymentsandhighroyaltypayments successfullylaunchedactemraproductforcommer relatingtostrongtamiflusalesinthesecondhalf cialisationintheunitedstatesdaysafterfda ofthepharmaceuticalsdivisionisontrackto approvalourbulkdrugmanufacturingfacilitiesin achieveitsgoalofpretaxannualsynergiesfrom southsanfranciscovacavilleandoceanside thegenentechmergerofapproximatelybillion californiausareceivedclassacertificationan swissfrancsbysynergiesofovermillion internationalbusinessawardrecognisingsystem swissfrancswereachievedinformore aticprocessimprovements informationonthedivisionsoperatingresults seethefinancereportpartofthisannual aspartofthecontinuousevaluationofourglobal report manufacturingnetworkwearealwaysreviewingand analysingourstructuresorganisationsprocesses intheyearunderreviewthepharmaceuticals andoperationsinwesoldfacilitieslocatedin divisionincurredsignificantnoncorecostsassoci isandosouthafricaandkarachipakistanin atedwithrestructuringmeasuresimplemented additionplantsinmontevideouruguayandnutley undertheoperationalexcellenceprogrammemost newjerseyusawereclosedandwecontinue ofthesecostsrelatetoseverancepaymentsfol toplanfortheclosureofcertainoperationsinmann lowingreductionsinpositionsinsalesandmarket heimgermanyandbaselswitzerland ingglobalmanufacturingglobaldevelopment andresearchandearlydevelopmentaswellas followingadetailedanalysisoforganisational impairmentsofintangibleassets structuresandprocessesaspartofthegroupwide operationalexcellenceprogrammeglobaltechnical operationswillfurtherrefineitsorganisational manufacturing infrastructure structuretoimproveoperationalefficienciesopti misemanufacturingassetsandconsolidatethe integrationoftherocheandgenentechmanufactur technicaldevelopmentandclinicalsupplynetwork ingandsupplynetworkscontinuedinas someactivitieswillbereorganisedincalifornia initiativeswereimplementedtoensurethatglobal mannheimandothersitesbytheendofresult demandforcommercialandclinicalsuppliesof inginareductionofapproximatelypositions ourmedicinescanbemetandthatnecessaryadap inadditionrocheintendstoseekbuyersforitsus tationstoourgrowingpipelinearemadeintime sitesinflorencesouthcarolinaandboulder coloradopotentiallyaffectinganadditionaljobs anumberofimportantmilestoneswereachieved togetherwithactivitiesinitiatedinthelasttwo ininaprilhillsborooperationsoregonusa yearsthesechangeswillreducethenumberof wasofficiallyinauguratedbyhillsborowill manufacturinglocationsfromtobythe betheuscommercialfillingandpackagingfacility endof forourmedicinessupplementingfacilitiesin rochearengpharmaceuticalsindd pharmaceuticals roche business report sales therapeutic area oncology inflammatory autoimmune diseases transplantation central nervous system respiratory metabolic diseases bone diseases infectious diseases cardiovascular diseases virology others renal anemia ophthalmology italics growth rates local currencies partnering activities networkeinprojectwhichisdesignedtocreate anddeepenrelationswithleadingacademicinsti collaborationwithexternalpartnershaslongbeen tutionsworldwideunderaneweinpartnershipwith acornerstoneofrochesrdstrategyaccess harvarduniversityrocheprovidesstrategicques toexternalinnovationthroughlicensingandtargeted tionsandknowhowtoharvardwithharvardprovid acquisitionsisasignificantmeansofstrengthening inginnovativesolutions therdportfolioandexpandingthegroupstech nologycapabilitiesinrochepartneringsigned genentechpartneringcompletedfourproducttrans atotalofnewagreementsincludingoneprod actionsandresearchandtechnologycollabo ucttransactionandresearchandtechnologycol rationsinsupportingthecuttingedgework laborationsinadditiontenproductoutlicensing ofgenentechresearchandearlydevelopment agreementsweresigned amongtheseisanexpansionoftheantibodydrug conjugatecollaborationwithseattlegeneticsin amongrochepartneringsmaintransactionsin oncologynewcollaborationsinimmunology wereanagreementwithbelgiancompanyremynd includedanexclusivelicensingagreementwith todevelopnoveltherapeuticsthatcouldslowdown swissbasedantibodyspecialistnovimmunecover neurodegenerationinparkinsonsandalzheimers inganantiilantibodythathasthepotential patientsanewcollaborationwasagreedwithaileron tobenefitpatientsacrossarangeofautoimmunedis therapeuticstodiscoverdevelopandcommercial easesanovelresearchprogrammewasagreed iseanovelclassofdrugscalledstapledpeptidether withuscompanyadimabwhichwilluseitspropri apeuticsapotentiallytransformativetechnology etarydiscoveryplatformtoidentifyfullyhumananti tocreatedrugsforimportantdiseasetargetsthatare bodiesagainsttwotargetsselectedbygenentech intractabletocurrentlyavailablemodalitiesin undertheagreementgenentechhasrightsto decemberrocheacquiredmarcadiabiotechapri commercialiseantibodiesgeneratedfromthecollab vatelyowneduscompanyfocusingonthedevel oration opmentofinnovativetherapeuticsformetabolic diseasesmarcadiasresearchanddevelopmentpro grammesonnewpeptidetherapiesforthetreatment sales review oftypediabetesandobesitywillbeintegrated selected key products intorochesrdportfoliotheseincludenextgener ationpeptidessuchasmarcurrentlyinphasei developmentfortypediabetesseveralpartners thepharmaceuticalsdivisionsbroadbasedportfolio wereaddedtorochesexpandingtheinnovation ofmarketedproductsincludestenmedicinesfrom rochearengpharmaceuticalsindd roche business report pharmaceuticals topselling pharmaceuticals roche group millions chf avastin mabtherarituxan herceptin pegasys lucentis active substance active substance active substance active substance active substance bevacizumab rituximab trastuzumab peginterferon alfaa ranibizumab indications indications indications indications indications colorectal cancer nonhodgkins lymphoma herpositive breast hepatitis b c wet agerelated macular breast cancer nonsmall chronic lymphocytic cer advanced herposi degeneration macular cell lung cancer kidney leukemia rheumatoid tive stomach cancer edema following retinal cancer glioblastoma arthritis vein occlusion rochearengpharmaceuticalsindd pharmaceuticals roche business report thanks pharmaceuticals divisions broadbased portfolio roche one worlds leading providers clinically differentiated medicines cancer viral inflammatory diseases metabolic disorders xeloda tarceva cellcept neorecormon epogin bonvivaboniva active substance active substance active substance active substance active substance capecitabine erlotinib mycophenolate mofetil epoetin beta ibandronate indications indications indications indications indications colorectal cancer breast advanced nonsmall cell transplantation anemia osteoporosis cancer stomach cancer lung cancer advanced pancreatic cancer images show molecular diagrams representing active substance medicine therapeutic protein small molecule yearonyear sales growth local currencies us sales lucentis marketed outside united states novartis rochearengpharmaceuticalsindd roche business report pharmaceuticals sixtherapeuticareasthatgeneratedsalesofover latinamericainthethirdquarteravastin billionswissfrancseachinofthesethetop waslaunchedinchinainitsfirstindicationfirstline threerecordedsalesofwelloverbillionswiss treatmentofmetastaticcolorectalcancerinitial francseachcombinedsalesofthegroupstop uptakehasbeenveryencouraging pharmaceuticalsamountedtobillionswiss francsorofdivisionalsales fullyearsalesoncologyandautoimmunediseases ofmabtherarituxanrituximabfornonhodgkins salesofthedivisionsoncologyportfolioroseto lymphomanhlchroniclymphocyticleukemia billionswissfrancsinledbykeyproducts cllandrheumatoidarthritisratotalled bil avastinmabtherarituxanherceptinxelodaand lionswissfrancsinanincreaseofversus tarcevatogetherthesefivemedicinesaccountedfor sustainedgrowthintheoncologysegmentwas overhalfoftotalpharmaceuticalsalessalesof drivenbyuptakeincllandcontinuedstronguse antiviralmedicinesdeclinedforafullyeartotal innhlinwesterneuropeandtheussoliddouble ofbillionswissfrancsduemainlytothesharp digitgrowthintheinternationalregionincluding declineinsalesoftamifluoverallsalesoftherenal stronggainsinkeyemergingmarketsreflectsuptake anemiaportfoliodeclinedbytobillionfrancs ofthemedicineinitsnhlindicationstheeuropean withstrongdemandformirceraoutweighedby rolloutofmabtherainanewindicationfirstline decreasingsalesofneorecormonepoginsalesin maintenancetreatmentofpatientswithfollicularlym thecombinedinflammationautoimmunetransplan phomacommencedinthefourthquarterestimated tationportfoliorosetobillionfrancsgrowing salesofmabtherarituxanintherasegment demandformabtherarituxanforrheumatoid reachedthebillionswissfrancmarkin arthritisandstronguptakeofactemraroactemra oftheproductstotalsaleshigherthanin offsetcontinuedgenericerosionofcellceptinthe growthisbeingdrivenbyincreasedusein unitedstates patientswithaninadequateresponsetooneormore tumournecrosisfactorinhibitorsandbygrowing oncology acceptanceofsixmonthrepeattreatmentintervals globalsalesofavastinbevacizumabforadvanced colorectalbreastlungandkidneycancerandfor globalsalesofherceptintrastuzumabforher relapsedglioblastomaatypeofbraintumourrose positivebreastcancerandherpositivemetastatic tobillionswissfrancsreflectingcontinued stomachcancerrosetobillionswissfrancs positiveuptakeoftheproductoverallsalesgrowth onsustainedsolidsingledigitgrowthintheunited inwesterneuropewasdrivenprimarilyby statesandwesterneuropeanddoubledigitgains continueduptakeforbreastcancerandimproved intheinternationalregionherceptinmaintained uptakeforcolorectalandlungcancerausterity itshighmarketpenetrationinbreastcancerwith measuresintroducedduringtheyearingreece salesalsobenefittingfrominitialuptakeforstomach spaingermanyandothermarketsresultedinapro cancerineucountriesandothermarketsinaddi gressiveflatteningofgrowthintheregionasa tionimprovementsinthequalityofhertesting wholethatwasparticularlynoticeableinthefourth areexpandingthepopulationofpatientseligiblefor quartersalesintheuswereflatfortheyearreflect treatmentwithherceptininjapanwhereherceptin ingreserveadjustmentsduetothehealthcare hasamarketshareofapproximatelyinits reformsenactedinandregulatoryandreim breastcancerindicationsastablesalesvolumeand bursementuncertaintyregardingthemetastatic revisedreimbursementpricesfromaprilresulted breastcancerindicationseeptogetherthese inasignificantdeclineinsalesrevenuecompared factorsledtoadeclineinsalesinthesecond halfyearespeciallythefourthquarteravastinmain taineditshighusmarketshareinitsmetastatic xelodacapecitabineforcolorectalstomach colorectalandlungcancerindicationsverystrong andbreastcancergeneratedtotalsalesofbillion salesgrowthinjapanwasdrivenbycontinued swissfrancsanincreaseofcomparedwith gooduptakeincolorectalandnonsmallcelllung growthwasdrivenprimarilybystronggainsin cancerverystronggrowthwasalsorecordedin theunitedstatesjapanandchinatheproducts pharmaceuticals roche business report threelargestmarketsglobalsalesofxelodaare swissfrancsinbillionfrancslower benefittingfromanumberofnewindications thaninwithgovernmentstockpilingorders includingstomachcancerinchinaanexpanded largelycompletedbyearlyandtheinfluenzaa metastaticcolorectalcancerindicationinjapan hnpandemicpassingitspeaksalesfellsharply andadjuvantcoloncancerineuropeaswellas inthelastthreequarterssaleswerealsoaffected increasedpatientshareinmetastaticbreast byrelativelymildinfluenzaseasonsinbothhemi cancerintheusandeu spheresduringrocheremainsreadytoaddress potentialthreatsposedbyinfluenzaandismain salesoftarcevaerlotinibforadvancedlung tainingproductioncapacityincooperationwith andpancreaticcancerincreasedtobillion externalmanufacturingpartnerstoenablearapid swissfrancsdrivenmainlybyincreasedusein responsetofuturesignificantoutbreaksorgovern thesecondlinenonsmallcelllungcancersetting mentstockpilingorders themaincontributionstogrowthcamefromthe internationalregionjapanandtheusmidsingle ophthalmology digitgrowthintheusreflectssteadydemandin ussalesoflucentisranibizumabforwetage thelungandpancreaticcancerindicationsandthe relatedmaculardegenerationandmacularedema impactofgovernmenthealthcarereformsagainst followingretinalveinocclusionroseto abackgroundofstabledemandsalesinwestern billionswissfrancsstronggrowththroughout europedeclinedslightlymainlyasaresultofgovern wasdrivenprimarilybyincreasesinthe mentmandatedpricereductionsandrebatesin totalnumberofpatientsreceivinglucentisandthe severalmajormarketssustainedstrongsalesgrowth timepatientsareontreatmenttheuslaunchof injapanreflectscontinuedmarketpene lucentisforthetreatmentofmacularedemaswell trationandoncologistsincreasingconfidenceinthe ingintheretinafollowingretinalveinocclusion benefitsoftreatmentwithtarceva beganinlatejuneandinitialuptakeisencouraging lucentiswasdiscoveredbygenentechwhich virology retainscommercialrightsintheunitedstates worldwidesalesofpegasyspeginterferonalfaa novartishasexclusivecommercialrightsforthe forhepatitisbandcincreasedtobillion restoftheworld swissfrancsinflatsalesintheunitedstates andsalesdecreasesinwesterneuropejapan inflammation autoimmune disorders andcertainothermaturemarketswereoffsetby astheglobalrolloutofthenovelrheumatoid growthintheinternationalregionespecially arthritismedicineactemratocilizumabknownas asiapacificandcemaicountriestheproducts roactemraintheeucontinuedsalesin marketsharecontinuedtoexpandinthemain totalled millionswissfrancsariseofover europeanmarketstheusandjapanglobalsales uptakeofactemraroactemraintheeu continuedtobenefitfromclinicaldatareinforcing theunitedstatesandotherlaunchmarketsremains thesuperiorityofpegasysoverothertreatment veryencouragingaroundofusrheumatol optionsandincreaseduseinhepatitisbthehepatitis ogistshavealreadyprescribedthemedicinecontin cmarketispoisedformajorexpansionwiththe uedstrongsalesgrowthinjapanreflectsincreas introductionofanewgenerationofdirectacting inguseofactemraasafirstlinebiologicchugai antiviralagentsexpectedfromonwards announcedinaugustthatthejapanesehealth becausepegasystheleadingpegylatedinterferon authoritieshadremovedtheapprovalconditionsfor isusedinmosthepatitistreatmentdevelopment actemrafortherheumatoidarthritisandpolyartic programmestodayitisexpectedtobecomethe ularcoursejuvenileidiopathicarthritisindications backboneoffuturecombinationtherapieswiththe newantiviralsseealsopbelow followingexceptionaldemandinduetothe adjuvant treatment given surgical removal tumour lower risk relapse influenzaahnpandemicsalesoftamifluosel cemai central eastern europe middle east africa tamivirforinfluenzaaandbtotalledmillion central asia indian subcontinent rochearengpharmaceuticalsindd clinical development long process continues even market launch creating value patients means investing skill resources long uncertain journey molecules investment molecules volunteers patients preclinical development phase years years preclinical testing evaluates drugs safety profile pharma phase trials test safety cological effects laboratory every promising new compound various doses new drug dur must pass rigourous preclinical testing studied ing phase trials researchers humans new drugs usually undergo vitro test tubes cell looking drug absorbed cultures isolated organs vivo animal testing computer distributed changed metabo models playing increasingly important role preclinical devel lised body eliminated opment data preclinical tests essential determining long processes take whether drug safe enough administered people clinical whether unwanted trials effects trials involve small number people usually healthy volunteers cases people whose disease advanced cancer example may also participate rochearengpharmaceuticalsindd patients patients patients molecules molecules molecule phase ii phase iii phase iv years years market entry phase ii trials test new drug new drug moves phase iii phase iv trials conducted people disease clinical trials phase drug approved regu designed treat number phase ii trial results suggest latory agencies launched patients phase ii trials limited might benefit patients signfi market also known postmar usually larger phase cant ways phase iii trials compare keting trials designed studies addition safety new drug current treatments gather broader realworld experience testing trials identify appropri trials placebo new drug routine medical ate dose ranges test whether many phase iii trials last long time practice phase iv trials generate addi drug demonstrates clinical effi typically year may tional data safety efficacy cacy proof concept many new involve several thousand patients large numbers patients par drugs fail phase ii testing several countries ticular patient subgroups also provide information phase iii trials must include large drug works comparison number patients investiga combination treatments tors evaluate differences types treatment regula even large phase iii trials iden tory agencies normally require results tify potential side effects phase iii trials approving another area phase iv trials pro new drug vide essential additional information roche maintains system risk assessment programmes identify evaluate side effects appear phase iiii trials patients per trial trials rochearengpharmaceuticalsindd roche business report pharmaceuticals development highlights major approvals key marketed products actemraroactemra herceptin inthepharmaceuticalsdivisionfiledmajor mabtherarituxan newmarketingapplicationsandgainedmajor regulatoryapprovalsseetablesppandthe lucentis followingsummariespresentapprovalsfilingsand majorclinicaltrialresultsforkeymarketedproducts byindication thedecisiongivesmorepatientsaccesstoactemra actemraroactemra andfollowspositiveresultsfromaroutinepost approvals injanuarytheusfoodanddrug marketingsurveillanceprogrammeactemra administrationfdaapprovedactemrafor roactemraisnowavailableinsomecountries thetreatmentofadultpatientswithmoderatelyto worldwide severelyactiverheumatoidarthritisrawho havehadaninadequateresponsetooneormore anemia transplantation tumournecrosisfactortnfinhibitorsactemra salesoftherenalanemiamedicationmircerame thefirstinterleukinreceptorinhibitingmonoclonal thoxypolyethyleneglycolepoetinbetaroseto antibodyapprovedtotreatramaybeusedalone millionswissfrancsdemandformircerawhich orincombinationwithmethotrexateorotherdisease isnowavailableinovercountriesworldwide modifyingantirheumaticdrugsinjunetheeuro iscomingmainlyfromthepredialysissegmentand peancommissionextendedtheproductsexisting newpatientcommencementscombinedsalesof marketingapprovaltoincludetreatmentwith thegroupsestablishedanemiamedicinesroches roactemraplusmethotrexatetoreducetherateof neorecormonandchugaisepoginepoetinbeta progressionofjointdamageandimprovephysical declinedtobillionswissfrancsroche functioninpatientswithrheumatoidarthritisthe pharmaceuticalsoverallshareoftheeuropeanane newindicationwhichisbasedontwoyeardatafrom miamarketremainedstabledespiteincreasing aglobalphaseiiistudylithecamejustovera biosimilarcompetitionduemainlytothestrongper yearafterthemedicinesinitialeuapprovalfurther formanceofmircerainthemajoreucountries reinforcingitsvalueasaneffectivetreatmentfor andarobustmarketsharebyvolumeforneorecor rainjanuarythefdaapprovedactemrafor monintherenalindicationadeclineinsales asimilarindicationinhibitionandslowingof ofepogininjapanwasduemainlytocompetitionin structuraljointdamageimprovementofphysical thedialysismarketandalowernationalhealth functionandachievementofmajorclinicalresponse insurancereimbursementpricefactorswhichout inadultswithmoderatelytoseverelyactivera weighedincreaseddemandforthemedicinein basedonasupplementalbiologicslicenseappli thepredialysissegment cationsblasubmittedbygenentechinmarch atbillionswissfrancsforthefullyearsales revenuefromcellceptmycophenolatemofetilfor filings inoctobergenentechsubmittedasecond thepreventionofsolidorgantransplantrejection sblatothefdaandrochesubmittedanaccel remainedsignificantthesalesdecreaseofwas eratedassessmentapplicationtotheeuropean dueprimarilytothelossofpatentexclusivityin medicinesagencyemaseekingtoextendthe theunitedstatesintheresultinglossesto approvedindicationsofactemraroactemrato competitionfromgenericversionswerepartlyoffset includetreatmentofsystemicjuvenileidiopathic bysalesgrowthinjapanandtheinternational arthritissjiabothapplicationsarebasedonposi region tivedatafromtheglobalphaseiiitenderstudy therearecurrentlynoapprovedtherapiesintheeu orusforsjiaadebilitatinganddifficulttotreat rochearengpharmaceuticalsindd pharmaceuticals roche business report diseasethataffectsthewholebodyandrepresents thefdasnoticeofopportunityforhearingwe anareaofhighunmetmedicalneed believethiswouldprovideanopportunitytopresent ourviewsthatthedataareclinicallymeaningful avastin andmeettheapplicablelegalandregulatorystan sinceitsinitialapprovalinintheunitedstates dardsforcontinuedapprovaluntiltheconclusion foradvancedcolorectalcanceravastinhasmade oftheseproceedingsavastinremainsfdaapproved antiangiogenictherapyafundamentalpillarofcancer foruseincombinationwithpaclitaxelformetastatic treatmentavastinisapprovedinmanycountries hernegativebreastcanceratthesametimethe forthetreatmentofadvancedstagesofcolorectal fdaissuedcompleteresponsesforallotherpending breastnonsmallcelllungandkidneycanceritis applicationsconcerningavastininmetastaticbreast alsoavailableintheusandothercountriesforthe cancersayingthattheapplicationsfailedtosupport treatmentofpatientswithglioblastomaatypeof theextensionoftheproposedindicationsforfirst braincancernearlyamillionpatientshavebeen linetreatmentincombinationwithdocetaxelbased treatedwithavastinsofarmorethanongoing onavadoandincombinationwithstandardchemo rochesponsoredorsupportedorindependently therapybasedonribbonandforsecond conductedclinicaltrialsareinvestigatingtheuseof linetreatmentincombinationwithstandardchemo avastininovertumourtypesincludingcolorec therapybasedonribbonthesedecisionsdo talbreastnonsmallcelllungbraingastricovarian notaffecttheavailabilityofavastinforitsapproved andothersanddifferentsettingsadvancedor usesinothertypesofcancerintheunitedstates earlystagedisease approvals infebruarythechinesehealthauthor breast cancer indecemberfollowingareview itiesapprovedavastinforthetreatmentofmetastatic ofallrelevantdatatheeuropeancommitteefor colorectalcanceritsfirstindicationinthisimportant medicinalproductsforhumanusechmpsup market portedthecontinuedfirstlineuseofavastinin combinationwithpaclitaxelchemotherapydescrib filings indecemberrochefiledanapplication ingitasavaluabletreatmentoptionforpatients withtheeuauthoritiesforapprovalofavastin sufferingfrommetastaticbreastcancerpaclitaxelis asfrontlinetreatmentforovariancancerbasedon thechemotherapymostfrequentlyusedandalso theresultsofthephaseiiigogandicon mostfrequentlypartneredwithavastintocontrolthe trialsseebelowclinical milestones diseasethecommitteealsoconsideredcombina tionsofavastinwithtwoothertypesofchemother clinical milestones twolargephaseiiitrials apybasedondatafromtheavadoandribbon involvingsomepatientshavedemonstratedthe trialsthechmprecommendedthatthecombination potentialofavastininovariancancerresultsfrom withdocetaxelberemovedfromtheavastinlabel gogwerepresentedattheannualmeetingofthe andthatthecombinationwithcapecitabinexeloda americansocietyofclinicaloncologyascoin notbeapprovedadecisionbytheeuropeancom junethetrialmetitsprimaryendpointofextending missionontheserecommendationsisexpectedearly progressionfreesurvivaltheperiodapatient inthechmpopiniondoesnotaffectthe liveswithoutthediseasegettingworseinwomen otherapprovedusesofavastinintheeuropeanunion withpreviouslyuntreatedadvancedovariancancer foradvancedcolorectalkidneyandlungcancer iconafurthertrialwithavastininovariancancer reportedpositiveresultsinearlyjulythedata alsoindecemberthefdaannouncedanumber werepresentedattheeuropeansocietyformedical ofregulatorydecisionsconcerningtheuseofavastin oncologyesmoconferenceinoctoberinaddition formetastaticbreastcancerintheusthemost totheeufilingindecemberrocheplanstouse importantoftheseistheagencysdecisiontoinitiate theresultsofbothtrialstosupportaregulatoryappli theprocesstowithdrawthecurrentconditional cationforthisadditionalindicationintheusin acceleratedapprovalforavastinforfirstline treatmentofmetastaticbreastcancerrocheand clinicaltrialresultsledtoanumberofadjustments genentechhaverequestedahearingpursuantto intheavastindevelopmentprogrammeinas rochearengpharmaceuticalsindd roche business report pharmaceuticals major regulatory filings clinical data supporting product filing indication andor dosage form country actemra lithe year data rheumatoid arthritis reduction inhibition progression usa roactemra joint damage improvement physical function ml rheumatoid arthritis signs symptoms china refiled progressive joint damage tender systemic onset juvenile idiopathic arthritis eu usa avastin ribbon metastatic breast cancer secondline treatment usa icon gog metastatic ovarian cancer eu herceptin toga advanced herpositive gastric cancer usa china herceptin toga advanced herpositive gastric cancer japan xeloda mabthera prima advanced follicular lymphoma firstline maintenance eu usa rituxan following induction treatment mabtherarituxan switzerland plus chemotherapy rave ancaassociated vasculitis usa mircera ml renal anemia china cordatus correction symptomatic anemia adults chronic eu switzerland nh kidney disease yet need dialysis oncemonthly administration tarceva emerging data metastatic nonsmall cell lung cancer egfr eu clinical trials activating mutations firstline treatment ongoing clinical experience xeloda xeloxa adjuvant colon cancer combination oxaliplatin switzerland data public advanced refractory gastric cancer patients japan domain candidates curative surgery xelox metastatic colorectal cancer combination oxaliplatin china refiled includes supplemental indications phaseiiitrialswithavastininstomachavagast meaningfulprogressionfreeandoverallsurvival andprostatecalgbcancerdidnotmeet benefitinbothfirstandsecondlinetreatment theirprimaryendpointsofextendingoverallsurvival avastinhasshownapositivebenefitriskratioin rochehasdecidednottopursueregulatoryfilings theseandallotherapprovedmetastaticcancer fortheseindicationsaphaseiiiprogrammeinves indications tigatingtheadditionofavastintostandardtreat mentwithmabtherarituxanpluschemotherapy herceptin fordiffuselargebcelllymphomaanaggressive approvals theeuropeancommissionapproved formofnonhodgkinslymphomawasdiscontinued herceptinincombinationwithchemotherapyforuse afterasafetyandefficacyanalysisshowedanunfa inpatientswithmetastaticstomachgastriccancer vourablebenefitriskassessmentfollowingeval exhibitinghighlevelsofherinjanuary uationofphaseiiidataavantrochehasdiscon approvalsforthesameindicationwerereceivedin tinueddevelopmentofavastininadjuvantcolorectal switzerlandinmayandtheusinoctoberfollowing cancertheresultsanddecisiononadjuvantcolo priorityreviewbythefda rectalcancerdonotaffecttheuseofavastinin themetastaticadvancedcolorectalcancersetting filings injunethejapanesehealthauthorities wherethemedicinehasdemonstratedaclinically gavepriorityreviewstatustoanapplicationsub rochearengpharmaceuticalsindd pharmaceuticals roche business report major regulatory approvals clinical data supporting product filing indication andor dosage form country actemra option toward rheumatoid arthritis signs symptoms usa roactemra radiate ambition lithe month data lithe year data rheumatoid arthritis reduction inhibition progression eu switzerland joint damage improvement physical function usa avastin avf e metastatic colorectal cancer china global artist china herceptin toga advanced herpositive gastric cancer eu usa switzerland lucentis cruise bravo macular edema following retinal vein occlusion usa mabthera cll firstline chronic lymphocytic leukemia usa rituxan reach relapsed refractory chronic lymphocytic leukemia usa prima advanced follicular lymphoma firstline maintenance eu switzerland following induction treatment mabtherarituxan plus chemotherapy reflex rheumatoid arthritis inhibition progression joint eu damage improvement physical function mircera cordatus correction symptomatic anemia adults eu switzerland nh chronic kidney disease yet need dialysis oncemonthly administration tarceva saturn nonsmall cell lung cancer firstline maintenance usa eu chemotherapy xeloda xeloxa adjuvant colon cancer combination oxaliplatin eu includes supplemental indications january mittedinmarchbychugaiforapprovalofherceptin lucentis foradvancedherpositivestomachcancerin approvals injunetheusfoodanddrugadmin junerochesubmittedanapplicationforapproval istrationfdaapprovedlucentisforthetreatment ofthesameindicationinchina ofpatientswithmacularedemaswellinginthe retinafollowingretinalveinocclusionrvothe clinical milestones indecemberpatientenrol approvalfollowedasixmonthpriorityreviewby mentwascompletedforaphaseiiistudywithanew thefdarvooccurswhenbloodflowthrougharet subcutaneousformulationofherceptininwomen inalveinbecomesblockedcausingswellingmacu withherpositivebreastcancerherceptiniscur laredemaandhemorrhagesintheretinawhichmay rentlygivenintravenouslyovertominutes resultinblurringorvisionlossinallorpartofone theinnovativesubcutaneousformulationwhichis eye basedonhalozymesenhanzetechnologysee pisexpectedtotakelessthanfiveminutes mabtherarituxan oncology toadministerandmayallowpatientswithher approvals infebruarythefdaapprovedrituxan positivebreastcancertoreceivetreatmentintheir combinedwithfludarabineandcyclophosphamide physiciansofficeorathomewithouthavingto chemotherapyforpeoplewitheitherpreviously gotoahospital untreatedfirstlineorpreviouslytreatedrelapsed rochearengpharmaceuticalsindd disease area oncology indication secondline herpositive metastatic breast cancer trials emilia tdmg bo patients recruited december study sites countries jone f participant emilia study tdm houston rochearengpharmaceuticalsindd work wayne c tdm medical director genentech south san francisco rochearengpharmaceuticalsindd tdm antibodydrug conjugate creating value patients means building good treatments make even better future nonspecific chemo herceptin trastuzumab adc targets chemo therapy agents new standard therapy specifically care herpositive tumour cells metastatic breast cancer points attack cancer cell chemotherapy trastuzumab chemo tdm healthy cell attacks healthy monoclonal antibody attacks cancer cells cancerous cells trastuzumab specifically conventional targets herpositive chemotherapy burden tumour cells first therapeutic antibody targeting specific cancerrelated biomarker receive fda approval herceptin trastuzumab launched revolution treatment breast cancer continue build breakthrough tras tuzumabdm tdm novel antibodydrug conjugate adc developed tdm treat herpositive breast cancer tdm combines two powerful anticancer approaches one medicine trastuzumab antibody component trastuzumab blocks signals make herpositive cancer cells aggressive sends message patients immune system destroy cancer cells also delivers dm potent chemo dm therapy agent directly tumour cells induce cell death tdm may offer patients herpositive breast cancer effective treatment stable linker spares burden side effects conventional chemotherapy emilia phase iii registration trial comparing singleagent tdm treatment combined lapatinib another hertargeted drug plus capecitabine xeloda chemotherapy women advanced herpositive breast cancer trials testing tdm combination roches pertuzumab another nextgeneration hertargeting antibody therapy rochearengpharmaceuticalsindd pharmaceuticals roche business report orrefractorycdpositivechroniclymphocytic mabtherarituxan inflammation leukemiabasedontheresultsoftheclland approvals rochereceivedregulatoryapproval reachtrialsfollowingregulatoryapplicationsby inoctoberfortwoadditionstotheexistingeu rocheandgenentechinthefirstquarterinocto marketingauthorisationformabtherainrheumatoid bertheeuropeanmedicinesagencyema arthritisbasedprimarilyondatafromthereflex approvedmabtheraasmaintenancetreatmentfor studytheindicationswereexpandedtoinclude peoplewithfollicularlymphomawhohavere inhibitionofprogressionofjointdamageandim spondedtoinductiontherapythefdaiscurrently provementofphysicalfunctionandinformation reviewinggenentechssblaforthesameindica onenhancedtreatmentresponsesinseropositive tionandhassetanactiondateinlatejanuary rapatientsseebelowclinical milestones bothsubmissionswerebasedontheresultsof wasaddedtotheproductsprescribinginformation theprimastudywhichshowedthatcontinuing mabtherarituxanfortwoyearsmaintenance filings inoctoberbasedondatafromthephase therapyinpatientswhorespondedtoinitialtreat iiiiiravestudygenentechandbiogenidec mentwithmabtherarituxanpluschemotherapy submittedasupplementalbiologicslicenseappli nearlydoubledprogressionfreesurvivalcompared cationtothefdaforapprovalofrituxanforanca withthosewhodidnotreceivemaintenance associatedvasculitisagroupofrareseverelife treatment threateningautoimmunediseasescharacterisedby inflammationofbloodvesselsleadingtoorgan clinical milestones basedonpositiveresults damagetherearecurrentlynoapprovedtherapies fromaphaseibstudyinpatientswithfollicularlym fortheconditionandtreatmentassociatedtoxicities phomainjulyrochedecidedtoadvanceanew arecommonwiththeunapprovedstandardofcare subcutaneousformulationofmabtheraalsobased cyclophosphamide onhalozymesenhanzetechnologyintophase iiidevelopmentsubcutaneousadministrationhas clinical milestones ananalysisofsamplesfrom thepotentialtosignificantlysimplifytreatment patientswithrawhoparticipatedintwophaseiii byshorteningadministrationtimetolessthanten trialswaspresentedattheeuropeanleagueagainst minutesandimprovingpatientcomfortaphase rheumatismeularannualcongressinjuneit iiitrialisexpectedtostartinthefirstquarterof showedthattestingforspecificbloodmarkersatthe positivedatafromaphaseiiistudyofmabthera timeofdiagnosiscouldhaveasignificantimpact rituxaninpatientswithadvancedfollicularlym ontreatmentdecisionsandleadtoimprovedpatient phomawhodidnothavesymptomsasymptomatic qualityoflifeapproximatelyofrapatients diseasewerepresentedattheannualmeeting haveatleastoneoftwocharacteristicbiomarkers oftheamericansocietyofhematologyindecember producedbyautoreactivebcellsrheumatoid thestudyshowedthatimmediateadministration factorrfandanticycliccitrullinatedpeptideanti ofsingleagentmabtherarituxanasinductionther ccpintheirbloodsuchpatientsarereferred apyfollowedbycontinuedmaintenancetreatment toasseropositivedatafromapooledcohortofthe withmabtherarituxandelayedtheneedforchemo twostudiesshowedthatwhilebothseropositive orradiotherapyandextendedprogressionfree andseronegativepatientsbenefittedfromtreatment survivalcomparedwithwatchfulwaitingtheseare withmabtherarituxantheresponsewasenhanced thefirstphaseiiidatatoshowthatinitialuse intheseropositivepopulationadditionalbiomarker ofmabtherarituxanmonotherapyasinductionfol analysesfromotherphaseiiistudiesarepending lowedbymaintenancecanprovideclinicalbenefit mabtherarituxanisthefirstandonlyselectivebcell forpatientswithasymptomaticfollicularlymphoma targetedtherapyavailableforra adiseasethatiscommonlytreatedonlywhen symptomsappearanapproachknownaswatchful tarceva waiting approvals inapriltheusfoodanddrugadminis trationfdaapprovedtarcevaasamaintenance treatmentforpatientswithlocallyadvancedormeta staticnonsmallcelllungcancernsclcwhose rochearengpharmaceuticalsindd roche business report pharmaceuticals egfractivatingmutationswouldcontinuetobenefit fromtreatmentwithtarcevainlaterlinesoftherapy roche innovative new clinical milestones resultsfromarandomised molecular entities latestage phaseiiistudyoptimalpresentedatthe europeansocietyformedicaloncologyesmo development including six congressinoctoberdemonstratedthatfirstline potential personalised healthcare treatmentwithtarcevaextendedprogression freesurvivalinpatientswithadvancednsclcwith medicines planned egfractivatingmutationstomorethanoneyear almostthreetimeslongerthanpatientswhoreceived companion diagnostic tests conventionalchemotherapyinterimresultsfrom asecondtrialinvestigatingtarcevainthisindication eurtacareexpectedinthefirstquarterof asmanyasofasianpatientswithlungcancer diseasehasnotprogressedafterfourcyclesof andanestimatedoflungcancerpatientsin platinumbasedfirstlinechemotherapyinaprilthe westerncountrieshavethisdistinctformofnsclc europeancommissionapprovedtarcevaasmono therapyformaintenancetreatmentinpatientswith xeloda advancednonsmallcelllungcancernsclc approvals inmarchtheeuauthoritiesapproved whosediseaseremainslargelyunchangedknown xelodaincombinationwithoxaliplatinacom asstablediseaseafterplatinumbasedinitial binationknownasxeloxfortheadjuvantpost chemotherapybothapprovalsarebasedondata surgicaltreatmentofpatientswithearlycolon fromthephaseiiisaturnstudywhichshowed cancertheapprovalwasbasedonresultsfrom thatcomparedwithplacebotarcevasignificantly thenoxeloxastudyoneofthelargest improvedoverallsurvivalinpatientswithstable studiesofpatientswithstageiiiearlycoloncancer diseasepatientswithadvancednsclcandstable whichshowedthatpatientstakingxeloximme diseaseafterinitialchemotherapyhavetumours diatelyaftersurgeryliveddiseasefreeforlonger thatprogressfasteraremoreresistanttofurther comparedwiththosetreatedwithachemotherapy linesofchemotherapyandhaveapoorerprognosis regimenconsistingoffluorouracilplusleucovorin comparedwithpatientswhohaveacompleteor partialresponsetoinitialchemotherapy filings injapanchugaifiledmarketingapplica tionswiththeministryforhealthlabourand filings injunerochesubmittedanapplicationto welfareinmarchforapprovalofxelodacombined theeuropeanmedicinesagencyematoextend withherceptinforthetreatmentofadvanced thecurrentmarketingapprovalfortarcevatoinclude herpositivestomachcancerandinseptember firstlinetreatmentofpatientswithadvancednsclc forxelodainadvancedorrefractorygastric withegfractivatingmutationstheapplication stomachcancerinpatientswhoarenotcandi issupportedbyemergingdatafromclinicaltrialsand datesforcurativesurgery ongoingclinicalexperienceincludingnewdata fromtheoptimaltrialpresentedatesmosee clinical milestones adataanalysiscompleted belowtarcevaistheonlyepidermalgrowthfactor injuneshowedthatnoaphaseiiitrialinves receptoregfrinhibitorapprovedforusein tigatingxelodaincombinationwithdocetaxelfor maintenanceandsecondlinetreatmentsettings theadjuvantpostsurgicaltreatmentofwomenwith inpatientswithadvancedormetastaticnsclc earlybreastcancerdidnotmeetitsprimaryend irrespectiveofthepresenceofegfractivating pointofextendingdiseasefreesurvivalbutdidmeet mutationsalicencefortarcevaforuseinthefirst thesecondaryendpointofextendingoverallsur linesettingwouldallowphysicianstopersonalise vivalrochehasdecidednottopursueregulatory earlytreatmentaccordingtoegfractivatingmuta filingsforthisindication tionstatuswhilepeoplewithnsclcwithout rochearengpharmaceuticalsindd pharmaceuticals roche business report research development lationsrochesresearchonantibodydrugconju gatesasameansoftreatingcancerisanother rochespharmaceuticalsdivisioniscommitted exampleofahighlytargetedapproachwiththe todiscoveringandcommercialisinginnovativemedi potentialofimprovingoutcomeswhilereducing cinesthatrepresenttruemedicalvalueinareas thesideeffectsoftreatmenttdmforher ofhighunmetneedtoensureastrongflowofsuit positivebreastcanceristhemostadvanced ablecandidatemoleculesintoitsdevelopmentpipe oftheseprojectsformoreinformationseebelow linerochehasbuiltauniqueinnovationnetworkof oncologyandalsoppandofthisreport independentresearchanddevelopmentcentresin additiontorocheandgenentechitincludeschugai aspartofthegroupsoperationalexcellencepro injapanandallianceswithmorethanpartner grammethepharmaceuticalsdivisionisprioritising organisationsworldwidethispromotesadiversity itsrdinvestmentsinordertodedicateresources ofresearchapproachesandenablesaccesstonew toprojectswiththehighestpotentialfollowing technologiesandpromisingdrugcandidates acomprehensiveportfolioreviewrochedecidedto discontinuerdactivitiesinrnainterference closecooperationbetweenthepharmaceuticals consolidateinternalfunctionalresourcesandreduce divisionandrochediagnosticsisakeystrategic thenumberofpharmaresearchandearlydevel advantageforourcompanyitensuresthatdiagnos opmentsitesfromtoseventherebyreducing ticsexpertiseisseamlesslyintegratedintoallparts fixedcostsandmakingfundsavailableforadditional ofthepharmaceuticalrdprocessthisiscentral externalresearchpartnershipsandpromisingnew torochesgoalofadvancingpersonalisedhealthcare programmesenteringphaseiiclinicaldevelopment phcanapproachthatseekstotailortreatments tospecificpatientsubpopulationsbasedongrowing atthebeginningofthedivisionsrdpipe scientificunderstandingofbiologyanddiseaseat lineincludedprojectsinclinicaldevelopment themolecularlevel phaseitoiiiandfiledforregulatoryreviewof theseinvolvednewmolecularentitiesnmes tworecentexamplesoftheprogressthatrocheis andinvolvedadditionalindicationstwelve makingtowardsphcinthedevelopmentoftherapies nmesareinlatestagedevelopmentseetable fordifficulttotreatdiseasesarergmetmab ptwentytwoprojectsinvestigatingadditional forlungcancerandrgbrafinhibitorfor indicationsforexistingproductsareinphaseiii malignantmelanomarochediagnosticsisdevelop thepharmaceuticalspipelineisshowninthefoldout ingdiagnostictestsdesignedtoguideappropriate insidethefrontcoverofthisreportfurtherdetails useofbothcompoundsintheirtargetpatientpopu areavailableatwwwrochecom roche genentech projects roche genentech projects research early development phase iii marketing applications discovery phases ii january filed january inflammation oncology metabolic metabolic others cns ophthalmology virology ophthalmology inflammation cns oncology rochearengpharmaceuticalsindd roche business report pharmaceuticals targetherpositivetumoursseepdatafrom arandomisedphaseiitrialtdmgwithtdm four additional nmes advance inpreviouslyuntreatedherpositivemetastatic breastcancerpresentedattheesmoconferencein latestage development octobershowedefficacycomparabletoherceptin pluschemotherapythestandardofcarealongwith metmab lung cancer lebriki asignificantlyreducedsideeffectburdenfinal zumab asthma rg resultsfromthisstudyareexpectedin hepatitis c ocrelizumab ms twophaseiiiregistrationstudiesinmetastatic herpositivebreastcancerareongoingandwe plantosubmitglobalmarketingapplicationsin emiliainvestigatingtdminpretreated oncology patientsisexpectedtoyielddataonprogression rochesclinicaldevelopmentpipelineinoncology freesurvivalinandoverallsurvivalin includesnewmolecularentitiesthepharma marianneacomparativetrialoffirstlinetreat ceuticalsdivisionisfurtherstrengtheningitsoncol mentwitheithertdmaloneortdmplus ogyportfoliothroughnewtargetedtherapeutic pertuzumabversusherceptinpluschemotherapy optionsandexpandingintonewindicationssix beganinjulybothtrialsareinvestigatingtherapeu oncologynmesarenowinlatestageclinicaltesting ticoptionsthattargetherpositivetumours whilesparingpatientstheburdenandsideeffects pertuzumabrgisaherdimerisationinhib ofconventionalchemotherapy itorthatisbeingstudiedwiththecurrentstandard ofcareherceptinpluschemotherapyinher rgplxcollaborationwithplexxikon positivebreastcancerdatafromaphaseiitrial isafirstinclassmoleculedesignedtoselectively neosphereinvestigatingpertuzumaband inhibitacancercausingmutatedformofthebraf herceptinplusdocetaxelchemotherapyinher proteinfoundinapproximatelyhalfofmetastatic positiveearlybreastcancerwerepresentedat melanomatumourspromisingresultsfromaphase thesanantoniobreastcancersymposiuminde iiclinicaltrialbrimwerepresentedinnovember cembertheresultsshowedthatthetwoantibodies attheinternationalmelanomaresearchcongress plusdocetaxelgivenintheneoadjuvantsetting thedatashowedthatrgshranktumours beforesurgeryimprovedtherateofcomplete inoverhalfofpatientswithpreviouslytreatedbraf tumourdisappearanceinthebreastbymorethan vemutationpositivemetastaticmelanoma halfcomparedwithherceptinplusdocetaxelchemo medianprogressionfreesurvivalinthestudywas therapybasedontheencouragingefficacyresults monthstypicallyprogressionfreesurvivalfor fromneospherepertuzumabwillalsobestudied thesepatientsisapproximatelytwomonthsaphase asadjuvantpostsurgicaltherapyinherpositive iiitrialbriminpreviouslyuntreatedbraf earlybreastcancerthephaseiiiclinicalprogramme mutationpositivemetastaticmelanomapatientsmet inthissettingisscheduledtostartinlate itsprimaryendpointsinjanuarywithan resultsandrelatedregulatoryfilingsareexpected interimanalysisshowingsignificantlyimprovedover infromaphaseiiistudycleopatraeval allandprogressionfreesurvivalinpatientswho uatingtheadditionofpertuzumabtoherceptinand receivedrgcomparedwiththosetreatedwith chemotherapyinthefirstlinetreatmentofpatients dacarbazinethecurrentstandardofcareroche withadvancedmetastaticdisease moleculardiagnosticsisdevelopingacompanion diagnosticcobasbrafvmutation trastuzumabdmtdmrgisanovel testseepptoidentifypatientswhose antibodydrugconjugatethatcombinesthethera tumourscarrytheabnormalbrafgeneandare peuticeffectoftrastuzumabtheactivesubstance thereforeappropriatefortreatmentwithrg ofherceptinwithintracellulardeliveryofdm ahighlypotentchemotherapyagenttospecifically rochearengpharmaceuticalsindd pharmaceuticals roche business report twelve new molecular entities ongoing planned latestage studies compound indication status expected first filing pertuzumab herpositive metastatic phase iii started breast cancer first line trastuzumabdm herpositive metastatic phase iii started first quarter breast cancer first second line rg braf metastatic melanoma phase iii trial firstline treatment met primary inhibitor endpoints january rg hedgehog advanced basal cell pivotal phase ii started first quarter pathway inhibitor carcinoma rg ga chronic lymphocytic phase iii started fourth quarter leukemia nonhodgkins chronic lymphocytic leukemia lymphoma rg metmab solid tumours lip decision made preparing phase iii post lebrikizumab asthma lip decision made preparing phase iii post aleglitazar cardiovascular risk reduc phase iii initiated first quarter post tion type diabetes dalcetrapib dyslipidemia cardio phase iii enrolment completed second quarter vascular high risk rg hcv po hepatitis c lip decision made preparing phase iii lymerase inhibitor rg glycine negative symptoms phase iii started november reuptake inhibitor schizophrenia subopti mally controlled positive symptoms schizophrenia ocrelizumab multiple sclerosis phase iii planned start first quarter ppms post rrms ppms second quarter rrms lifecycle investment point decision commence latestage development leading submission marketing applications rggdccollaborationwithcurisis cellsbyactivatingotherimmunecellstoattack anovelcompoundtargetingthehedgehogsignalling thecancercellsandbyinducingdirectcelldeath pathwaywhichisthoughttobeimplicatedin intwophaseiistudiespresentedattheamerican severalcancersapivotalphaseiistudywithreg societyofhematologyannualmeetingindecem istrationpotentialiscurrentlyinvestigatingrg bertreatmentwithrgproducedpromising asapotentialtreatmentforadvancedbasalcell responseratesinverydifficulttotreatpatientswith carcinomabccrgisalsobeingevaluated eitherindolentoraggressivenhlwhohadnot inaphaseiistudyasatherapyforoperablebcc respondedtomultiplepriortreatmentsincluding inthefourthquarterrochedecidedtodiscontinue mabtherarituxanfurtherclinicaldataforrg developmentofthecompoundinovarianandcolo innhlandcllareexpectedinphaseiii rectalcancerduetolackofbenefitinphaseiitrials studiesofrgversusmabtherarituxanin aggressiveandindolentnhlarescheduledtostart rggaisthefirsttypeiiglycoengineered anticdmonoclonalantibodybeinginvestigated inlatestageclinicaltrialsasapotentialtreatmentfor rgmetmabisauniquemonoclonalantibody nonhodgkinslymphomanhlandchroniclym thatbindsspecificallytothecmetproteinreceptor phocyticleukemiacllithasbeenspecifically themetpathwaycanbeinappropriatelyactivated designedtoenhancethedestructionofcancerousb incancerandleadtoinvasivegrowthnewphaseii rochearengpharmaceuticalsindd disease area metabolic cardiovascular diseases indication cv risk reduction patients type diabetes trials alecardio patients study sites countries ragnar b participant alecardio aleglitazar trial stockholm rochearengpharmaceuticalsindd implications anita mw operations program leader roche basel rochearengpharmaceuticalsindd aleglitazar creating value patients means focusing unsolved issues patients type diabetes td blood glucose aleglitazar dual ppar coagonist developed control longer biggest concern roche may become first compound patients diabetes die heart disease potential reduce cardiovascular morbidity stroke inability control blood glucose mortality specifically highrisk patients td patients experience acute coronary aleglitazar excellent example translational syndrome acs event heart attack die within medicine biochemical parameters animal data one year currently drugs market biomarkers efficacy safety consistently specifically effectively control high risk supported hypotheses later proven cardiovascular disease clinical settings increased risk heart attack stroke alecardio innovative global randomised associated td controlled phase iii clinical trial patients testing hypothesis alegli healthy people tazar reduce cardiovascular morbidity mortality patients td suffered people heart attack stroke recent acs event people td people td heart attack stroke risk demonstrating multiple effects aleglitazar years conventional trial people td reduction blood glucose levels years trial aleglitazar td highrisk subpopulation blood glucose blood fats hypertension focused reducing cardiovascular risk people type diabetes saving lives rochearengpharmaceuticalsindd pharmaceuticals roche business report datapresentedattheannualeuropeansocietyfor metabolic cardiovascular diseases medicaloncologyesmoconferenceinoctober rochehasninenewcompoundsindevelopmentfor showedasignificantincreaseinprogressionfree metabolicandcardiovasculardiseasesdalcetrapib survivalforpatientswithhighmetexpressingnon rgjttlicensedfromjapantobaccois smallcelllungcancernsclcwhoweretreated anovelcholesterylestertransferproteincetp withmetmabplustarcevabasedonthisdatain modulatorbeingtestedforitsabilitytoreducecardio septemberrocheadvancedthecompoundintolate vasculareventsinpatientswithstablecoronary stagedevelopmentforthesecondandthirdline heartdiseasefollowingarecentacutecoronarysyn treatmentofnsclcaphaseiiistudyinpatients dromeeventthephaseiiidalheartprogramme withhighmetexpressingnsclcisexpectedto isontrackrecruitmentforthephaseiiidalout startinrochetissuediagnosticsisdeveloping comestrialhasbeencompletedwithover acompaniondiagnostictesttoidentifypatients participantsenrolledresultsfromtwophaseiib withhighmetexpressingnsclcwhoaremostlikely studiesdalvesselanddalplaqueareexpected torespondtotreatmentwithrgseepp inandrecruitmentforafurtherphaseiiistudy aphaseiistudytoinvestigatetheaddition dalplaqueisongoingthesesupportingstudies ofmetmabtochemotherapywithorwithoutavastin areinvestigatingthepotentialimpactofdalcetrapib forthetreatmentoftriplenegativemetastaticbreast treatmentonatheroscleroticplaqueburdenusing cancerisexpectedtoenrolitsfirstpatientinthe imagingtechniquesandfunctionaltests firstquarterof aleglitazarrgisaninnovativeinvestigational inflammation autoimmune disorders treatmentdesignedtoreducetheincidenceand rochehaseightnewcompoundsindevelopment impactofcardiovascularmortalitynonfatalheart forchronicandprogressiveautoimmuneandinflam attackandstrokeinpatientswitharecentacutecor matorydiseasessuchasrheumatoidarthritisra onarysyndromeandtypediabetesaglobalphase andasthmafiveofwhichareinphaseiiclinicaltest iiiprogrammealecardiobeganrecruitment inglebrikizumabisahumanisedmonoclonalanti earlyinaleglitazarhasthepotentialtobethe bodydesignedtobindspecificallytointerleukin firsttherapytospecificallyreducecardiovascular aproteinthoughttoplayakeyroleintheairway riskinpeoplewithtypediabetes inflammationhyperresponsivenessandobstruction experiencedbyasthmapatientsthecompound taspoglutidergbimlicensedfrom isbeingdevelopedforthetreatmentofmoderateto ipsenisaonceweeklyhumanglucagonlikepep severepersistentasthmapatientrecruitmentfor tideglphormoneanalogueindevelopment twokeyphaseiitrialsmollyandmillyhasbeen forthetreatmentoftypediabetesinseptember completedbasedonpromisingphaseiiresultswith rochecommunicateditsdecisiontostopadminister lebrikizumabinpatientswhosesymptomsremained ingtaspoglutidetopatientsinglobalphaseiii uncontrolledoninhaledcorticosteroidswithor clinicaltrialsbasedonhigherthanexpectedpatient withoutasecondcontrollerrochehasdecidedto discontinuationratesobservedinanalysesofdata advancethemoleculeintolatestageclinicaltesting fromthetemergeprogrammeandalsodueto inmayrocheandbiogenidecannouncedtheir theantibodymonitoringplanimplementedtoaddress decisiontodiscontinuedevelopmentofocrelizumab serioushypersensitivityreactionsaftercareful rgforrheumatoidarthritisrafollowing assessmentoftherelevanceofthetemergesafety adetailedanalysisoftheefficacyandsafetyresults andefficacydatatosupportfutureregulatory fromtheraprogrammethecompaniesconcluded approvalintypediabetesincludingconsideration thattheoverallbenefitriskprofileofocrelizumab ofthecurrentportfolioevaluationinitiative wasnotfavourableinratakingintoaccount rochehasdecidedtodiscontinuethetaspoglutide currentlyavailabletreatmentoptionsincluding temergedevelopmentprogramme mabtherarituxandevelopmentofocrelizumab asatherapyformultiplesclerosisiscontinuing seep rochearengpharmaceuticalsindd roche business report pharmaceuticals therearecurrentlynoapprovedtreatmentsthe firstofsixplannedtrialsbeganinnovember first new class asthefirstinanewclassofmedicinesrg hasthepotentialtoredefinethetherapeutic medicines rg approachtoarangeofpsychiatricdisordersand deliverclinicalbenefitsbeyondthoseachievable potential redefine thera withcurrenttreatmentoptions peutic approach range inoctoberrocheandbiogenidecreportedposi psychiatric disorders tiveresultsfromaphaseiitrialwiththehumanised anticdmonoclonalantibodyocrelizumab rginpatientswithrelapsingremittingmul tiplesclerosisrrmsoneoftheleadingcauses virology ofneurologicaldisabilityinyoungadultsdatapre rochecurrentlyhastwodirectactingantiviralagents sentedattheannualmeetingoftheeuropean inlatestagedevelopmentforhepatitiscthenucle committeefortreatmentandresearchinmultiple osidepolymeraseinhibitorrgpartneredwith sclerosisectrimsshowedthatcomparedwith pharmassetandtheproteaseinhibitordanoprevir placeboocrelizumabsignificantlyreducedsignsof rgbothoftheseoralagentsarebeinginves diseaseactivityasmeasuredbybrainlesionsand tigatedincombinationwithpegasysandribavirin annualisedrelapseratewithnoopportunisticinfec andincombinationwitheachotherinaninterferon tionsreportedtwophaseiiistudieswillbegininthe freeregimenrginterimphaseiibresults secondquarteroftoexplorethedrugsefficacy showedgoodefficacyandtolerabilitywithnoevi inrrmscomparedwithinterferonthecurrent denceofviralresistanceafterthreemonthstherapy standardofcareaphaseiiistudyinvestigatingthe incombinationwithpegasysandribavirinaphasei potentialofocrelizumabinpatientswithprimary trialinformofrganddanoprevirasan progressivemultiplesclerosisppmsisplannedto interferonfreecombinationshowedsignificantviral startinthefirstquarterofinoctobergenen suppressionaphaseiiiprogrammewithrg techandbiogenidecamendedtheircollaborationon isexpectedtobeginininoctoberroche antibodiestargetingcdandagreedthatgenen acquiredtheglobalrightstodanoprevirtoincrease techwillhaveresponsibilityforthefurtherdevelop thestrategicflexibilityofthegroupshepatitisc mentofocrelizumabinmultiplesclerosisintheus portfolio central nervous system therocheportfoliohasnovelcompoundsin developmentfordisordersofthecentralnervoussys temincludingschizophreniamultiplesclerosisand otherseriousconditionsoneofthesecompoundsis rganovelglycinereuptakeinhibitorbeing developedforthetreatmentofschizophreniaanarea ofhighunmetmedicalneedpromisingdatafrom aphaseiiproofofconceptstudywithrgin patientswithnegativesymptomsofschizophrenia werepresentedattheannualmeetingoftheamer icancollegeofneuropsychopharmacologyin decemberaglobalphaseiiiprogrammehasbeen initiatedtoinvestigatergincombination withantipsychoticsinpatientswitheithernegative symptomsorsuboptimallycontrolledpositive symptomsofschizophreniaindicationsforwhich rochearengpharmaceuticalsindd pharmaceuticals roche business report focus unmet medical breast cancer themostcommoncanceramong womenworldwideovermillionwomenarenewly needs diagnosedandoverdiefromthedisease eachyearasthereareseveraldifferenttypesof cancer accordingtothelatestinternational breastcancerknowledgeoftumourcharacteristics agencyforresearchoncanceriarcestimatein isimportantfortreatmentdecisionssome overmillionpeopleworldwidewerediag ofwomenwithbreastcancerhavetumourswith nosedwithcancerandsomemilliondiedofthe abnormallyhighlevelsofaproteinknownasher diseasetheiarcanticipatedthenthatcancer herpositivetumoursareparticularlyaggressive wouldsurpassheartdiseaseastheleadingcause fastgrowingandlikelytorecur ofdeathworldwideintheagencyalsofore caststhatbytherewillbeovermillionnew lung cancer themostcommonformofcancer casesandmilliondeathsperyearfromcancer worldwideandtheleadingcauseofcancerdeaths ineuropealoneoneinthreepeoplecanexpectto thereareanestimatedmillionnewcasesannually developcancerintheirlifetimecancerisnotone nonsmallcelllungcanceristhemostcommon diseasebutagroupofmorethandistinctdisor formaccountingforapproximatelyofallcases derseachwithitsownmedicalchallenges malignant melanoma thedeadliestandmost nonhodgkins lymphoma agroupofover aggressiveformofskincancerthelifeexpectancy cancersthataffectthelymphaticsystemthisclass ofpeoplewithadvancedmelanomaisusually ofcancercurrentlyaffectsovermillionpeople shortwithlessthanoneinfourexpectedtobe worldwideandsomenewdiagnoses aliveoneyearafterdiagnosiseveryyearan aremadeeachyearfollicularlymphomaaccounts estimatedpeopleworldwidediefromthe foraboutoneinfourofallcasesofnonhodgkins diseasethenumberofnewcasesindeveloped lymphomaitcanoccuratanytimeduringadulthood countriesisexpectedtodoubletoperyear thoughpeoplearetypicallydiagnosedduringtheir byapproximatelyofmelanomascarry sixtiesanditaffectsasmanymenasitdoeswomen activatingmutationsinthebrafproteinakeycom ponentoftherasrafsignallingpathwayinvolved chronic lymphocytic leukemia themostcommon innormalcellgrowthandsurvivalthesemutations typeofleukemiainadultsaccountingfor causethepathwaytobeoveractivewhichmay ofallformsofleukemiatheincidenceofcllin leadtoexcessivegrowthandcanceritisestimated westerncountriesisapproximatelyper thatapproximatelyofallsolidtumourscarry anditistwiceascommoninmenasinwomen brafvmutations colorectal cancer cancerofthelargeintestine pancreatic cancer aparticularlyaggressivedis orrectumwhichaccountsforovermillionnew easethatisextremelydifficulttotreatitkillsahigher casesaroundofallnewlydiagnosedcancers proportionofpatientsinthefirstyearafterdiagnosis worldwideeachyearitisthesecondmostcommon thananyothercancerthefifthleadingcauseof causeofcancerdeathsineuropeandthethird cancerdeathsinthedevelopedworldpancreatic mostcommonworldwide cancerclaimsnearlyliveseveryyear kidney cancer thistypeofcancerisnewlydiag nosedinaroundpeopleandcauses deathsworldwideeveryyearratesthatareexpected toincreaserenalcellcarcinomaaccountsfor ofallkidneycancers excluding nonmelanoma skin cancers easily treated lifethreatening rochearengpharmaceuticalsindd roche business report pharmaceuticals gastric stomach cancer stomachcanceristhe hepatitis b c thehepatitisbandcviruses secondmostcommoncauseofcancerrelated hbvhcvwhicharecommonlytransmitted deathsintheworldandthefourthmostcommonly throughbloodtobloodcontactcauseacuteand diagnosedcanceritaccountsforovermillion chronicliverdiseasepotentiallyleadingtoliver newcasesandsomedeathseachyearthe failurecirrhosislivercanceranddeathworldwide vastmajorityofcasesoccurinasiawherewith millionpeoplearethoughttobechronically lungcanceritistheleadingmalignancyadvanced infectedwithhbvahighlyinfectiousvirusthatis metastaticstomachcancerisassociatedwitha responsibleforanestimatedonemilliondeaths poorprognosisthemediansurvivaltimeafterdiag annuallymorethanmillionpeoplearoundthe nosisismonthswithcurrentlyavailablether worldareinfectedwithhcvandthreetofour apiesearlydiagnosisofthisdiseaseischallenging millionnewcasesoccureachyearhepatitiscis becausemostpatientswithearlystagediseasedo themainreasonforlivertransplantationarecent notshowsymptoms studyonthehcvrelatedburdenofdiseasein europeancountriesestimatedthatbetweenseven agerelated macular degeneration amd andninemillionpeopleoroverofthepopula majorcauseofgradualorsuddenpainlesscentral tionareinfectedwithhcv visuallossintheelderlyandaleadingcauseof visionlossinpeopleagedandolderthereare autoimmune disorders occurasaresultofamis twoformsofamdwetanddryallcasesbegin takenimmuneresponsetothebodysowntissues asthedryformbutprogresstothewet thecausesareunknownrheumatoidarthritismul formwhichcanresultinsuddenandseverecentral tiplesclerosisandlupuserythematosusareamong visionlossinwetamdnewbloodvesselsgrow themostcommonautoimmunedisorderswhichaffect undertheretinaandleakbloodandfluidcausing millionsofpeopleworldwide deteriorationofthemaculatheportionofthe eyeresponsibleforfinedetailedcentralvisionmore rheumatoid arthritis ra anautoimmunedis thanmillionamericanshavetheadvancedform easecharacterisedbyinflammationthatleadstostiff ofthiscondition swollenandpainfuljointsultimatelyresultingin irreversiblejointdamageanddisabilitymorethan anemia occurswhenthenumberofredblood millionpeopleworldwideandtwiceasmany cellsorthehemoglobinmoleculestheycontain womenasmensufferfromrainadditiontoinflam fallsbelownormalresultingininsufficientoxygen mationofthejointssuchasthehandsfeetand reachingorgansandtissuesitisseeninupto wristsracancausefatigueheartdiseaseand ofpatientswithchronickidneyrenaldisease increasethelikelihoodofdevelopingothercomplica whichaffectsmorethanmillionpeopleworld tionssuchasosteoporosisanemiaandproblems wideinadditionanemiaaffectsthreeoutoffour withthelungsandeyesitcanshortenlifeexpec cancerpatientsundergoingchemotherapypatients tancybyyearsbcellsatypeofimmunecell withuntreatedanemiamayneedbloodtransfusions areknowntoplayakeyroleintheinflammation thepotentiallongtermeffectsofanemiainclude associatedwithraseveralkeycytokinesorproteins cardiovasculardiseaseinrenalpatientswhilein arealsoinvolvedincludinginterleukiniltnf patientswithcanceritisassociatedwithdiminished alfaandinterleukinililhasbeenidentified qualityoflife ashavingapivotalroleintheinflammationprocess rochearengpharmaceuticalsindd pharmaceuticals roche business report multiple sclerosis ms anoftendebilitating glossary autoimmunediseaseinwhichnerveimpulsespassing throughthecentralnervoussystemaredisrupted adjuvant treatment treatmentgivenaftersurgical duetodamagetothebrainandspinalchordthis removalofatumourtolowertheriskofrelapse leadstounpredictableandhighlyvariablesymptoms rangingfromabnormalsensationsandreducedcoor diseasefree survival thelengthoftimeafter dinationtopainparalysisvisualimpairmentanda treatmentforaspecificdiseaseduringwhich declineincognitiveandotherfunctionsaccording apatientsurviveswithnosignofthedisease towhoestimatesapproximatelymillionpeople worldwidearelivingwiththedisorderwhichis firstline treatment theinitialtreatmentgiven usuallydiagnosedinadultsagedbetweenand afterdiagnosisincludingthefirsttreatment yearsrelapsingremittingmultiplesclerosis givenaftermetastaticcancerhasbeendiagnosed rrmsthemostcommonformischaracterisedby acuteexacerbationswithfullorpartialrecovery maintenance treatment treatmentgiventopre betweenattacksprimaryprogressivemultiplescle ventadiseasegettingworseortopreventacancer rosisppmsischaracterisedbyneurological fromrecurringwhenithasdisappearedfollowing disabilityfromonsetwithsymptomsgraduallywors initialtherapy eningovertime metastatic disease cancerthathasspread diabetes recognisedasaglobalepidemicby fromtheoriginalsiteofatumourtootherpartsof theworldhealthorganizationtheinternational thebodyalsoreferredtoasadvanceddisease diabetesfederationestimatesthatsomemillion peopleworldwidewillhavediabetesby neoadjuvant treatment treatmentgivento accordingtothewhotypeadultonsetdiabetes reducethesizeofatumourbeforesurgicalremoval accountsforaroundofallcasesuncontrolled isattempted typediabetescanleadtoseverecomplications suchascardiovasculardiseasestrokeblindness overall survival thetimefromthestartof amputationsandkidneyfailureresultinginsignifi treatmentuntilthepatientdies canthealthcareburdenstosociety progressionfree survival thelengthoftime schizophrenia aseverementaldisorderthat duringandaftertreatmentduringwhichapatient distortsthewayapersonthinksactsexpresses liveswithoutthediseasegettingworse emotionsperceivesrealityandrelatestoothers accordingtowhoestimatesschizophreniaaffects secondline treatment treatmentgivenifthe approximatelymillionpeopleworldwideandis initialorfirstlinetreatmentdoesnotworkorif usuallydiagnosedinadultsagedbetweenand thecancerstopsrespondingtoit yearsthesymptomsofschizophreniaarebroadly categorisedaspositivenegativeandcognitiveposi tivesymptomsarepsychoticbehaviourssuchas hallucinationsanddelusionsnegativesymptoms includeapathysocialwithdrawallackofdrive andreducedabilitytofeelpleasureineverydaylife cognitivedeficitsincludedifficultyconcentrating orfollowinginstructionsdifficultycompletingtasks memoryproblemsanddisorganisedthinking persistentnegativesymptomsareamajorcauseof burdenforpatientsandcaregivers rochearengpharmaceuticalsindd diagnostics sales grew well ahead market market share gains key segments immunoassays tissue diagnostics efforts enhance operational efficiency continue throughout division contributed higher operating profit business areas launched new products help drive market growth rochearengdiagnosticsindd diagnostics roche business report diagnostics division brief sales millions chf core operating profit millions chf number employees key figures change change millions chf chf local currencies sales sales professional diagnostics diabetes care molecular diagnostics applied science tissue diagnostics core operating profit operating free cash flow research development core basis diagnostics leadership team december daniel oday chief operating officer roche diagnostics manfred baier applied science colin brown dirk h ehlers professional diagnostics paul brown molecular diagnostics roland diggelmann asiapacific peter finckh platforms support christian hebich finance services michael heuer emea europe middle east africa latin america david lapr operations annette luther communications kent kost quality regulatory hany massarany tissue diagnostics wataru ogawa japan jack phillips north america burkhard g piper diabetes care clausjoerg ruetsch legal cris wilbur human resources robert yates business development june december rochearengdiagnosticsindd roche business report diagnostics diagnostics division sales region rochesdiagnosticsdivisionistheworldsleading supplierofin vitrodiagnosticsivdsperformedin europemiddle alaboratoryoratthepointofcareonbloodtissue eastafrica andothersamplesfrompatientsivdtestsareacrit japan icalsourceofobjectiveinformationhelpingdoctors asiapacific detectdiseasesselectappropriatetreatmentsand monitorpatientsresponsestocareinadditionsci latin america entistsusethedivisionsresearchproductstogain abetterunderstandingofthecausesofdiseaseand north america todiscovernewtreatmentsinovercountries italics growth rates local currencies rochediagnosticsservescustomersspanningthe entirehealthcarespectrumfromhospitalsand commercialmedicallabstophysicianstopatients withconditionsrequiringthemtoselftestthe nologiesandsimplifyprocessesmeetingthe divisionoffersawiderangeoftechnologiesallowing requirementsofallcustomersregardlessoflab thedetectionandanalysisofdnarnaand sizelocationortestingexperience proteinsonalargebaseofinstrumentsinstalled demonstrating medical valueisbecoming worldwidealreadyamongthebroadestinthe themaindriverofdifferentiationinthediagnostics industryrochesivdtestmenuissteadilyexpand marketcontributingtotherevaluationofivds inganddrawingonthelatestscientificadvances despitetheirfundamentalimpactonthemajority inrochehadapproximatelyashareofthe ofclinicaldecisionsivdscurrentlyaccountfor globalivdmarketwhichisvaluedatanestimated lessthanofmedicalspendingandareclearly billionusdollarsinannualsales undervaluedtherearetwomaincategoriesof diagnosticsthatcontributetobetterhealthcare decisionsstandalone diagnosticsoffervalue strategic priorities byenablingthepreciseandtimelydiagnosis ofdiseasesandfacilitatingearlyscreeningfordis scientificprogressnewtechnologiesandchanging easepredispositionandprognosisexamples demographicsareamongthetrendsexpanding includethemolecularhumanpapillomavirushpv thehealthcaremarketontheotherhandthereis testinscreeningforcervicalcancerthemrsa mountingpressureonhealthcarebudgetsand testtodiagnoseinfectionwithmethicillinresistant costsworldwidediagnosticscancapitaliseonall staphylococcus aureusandthepigfandsflt thesetrendsbytranslatingscientificinsightsinto immunoassaysintestingforpreeclampsia productsthatbringpatientsrealmedicalbenefitand companion diagnosticsareteststhatenable atthesametimecontributetosignificantcost doctorstoidentifythepatientsmostlikelyto savingsenablingpreciseandtimelydiseasediagno benefitfromaparticulartreatmentortomonitor sisandtreatmentstobetargetedatthepatients responsestoitrochealreadymarketscom mostlikelytobenefitisofgreatvaluebothforthe paniondiagnosticsforanumberofindications wellbeingofthepatientandinallocatingmedical withmoreinlatestagedevelopmentseelist resourceswheretheywillbemosteffective deploying diagnostic tests drug develop thediagnosticsdivisionsstrategicpriorities mentiscrucialtohelpincreaserdproductivity improving testing efficiency isonepillarofthe anddevelopmoretargetedmedicinesroche divisionsstrategyrochesautomateddiagnostic diagnosticsiscollaboratingcloselywiththe systemsembodydecadesofengineeringinno pharmaceuticalsdivisionandexternalpharma vationtestingcomponentsvisualisationandana lysisunitsandworkflowmanagementsystems havecontinuouslyimprovedtoincludenewtech market size based company independent reports rochearengdiagnosticsindd diagnostics roche business report roche companion diagnostics market late development disease area disease drug diagnostic test technology application virology cmv valcyte cmv viral load pcr monitoring hbv pegasys hbv viral load pcr monitoring antivirals hbv pegasys peginterferon hbsag levels immunoassay monitoring alphab mercksp hcv pegasys peginterferon hcv viral load pcr monitoring alphab mercksp hcv polymerase inhibitor r hcv viral load pcr monitoring hcv protease inhibitor r hcv viral load pcr monitoring hiv antivirals hiv viral load pcr monitoring hiv abacavir hlab pcr screening glaxosmithkline genotype oncology breast cancer herceptin lapatinib expression ihc ish selection glaxosmithkline gene amplification breast cancer tamoxifen erpgr expression ihc selection hormonal therapies breast cancer pertuzumab rg expression ihc ish selection gene amplification breast cancer tdm rg expression ihc ish selection gene amplification cancer compound merck p mutations microarray selection colon cancer cetuximab merck kras mutations pcr selection panitumumab amgen therascreen colon cancer cetuximab merck kras mutations pcr selection panitumumab amgen gastric cancer herceptin expression ihc ish selection gene amplification melanoma braf inhibitor braf mutation pcr selection rg nsclc gefitinib astrazeneca egfr mutations pcr selection tarceva therascreen nsclc tarceva egfr mutations pcr selection gefitinib astrazeneca nsclc metmab rg met expression ihc selection nsclc tg transgene muc expression ihc selection pancreatic cp hent expression ihc selection cancer clovis oncology inflammation asthma lebrikizumab rg serum periostin levels immunoassay selection cea ige rheumatoid mabtherarituxan rf anticcp ab immunoassay selection arthritis sle rontalizumab rg ifninduced genes pcr selection others osteoporosis bonvivaboniva bcrosslaps immunoassay monitoring bisphosphonates pnp levels transplantation cellcept mpa levels immunoassay monitoring black type market grey type development available markets monitoring monitoring patients response particular treatment screening screening patients particular genetic variation hlaassociated hypersensitivity abacavir selection selection patients eligible particular treatment selection patients eligible earlier treatment anticcp antibodies cyclic citrullinated peptide braf bisoform rapidly growing fibrosarcoma oncogene cea carcinoembryonic antigen cmv cytomegalovirus hbv hepatitis b hbsag hbv surface antigen hcv hepatitis c human epidermal growth factor receptor hiv human immunodeficiency virus hent human equilibrative nucleoside transporter egfr epithelial growth factor receptor er estrogene receptor ihc immunohistochemistry ish situ hybridisation ifn interferon kras member ras family oncogenes mpa mycophenolic acid nsclc nonsmall cell lung cancer pcr polymerase chain reaction pnp procollagen type nterminal propeptide pgr progesterone receptor rf rheumatoid factor sle systemic lupus erythematosus sp schering plough rochearengdiagnosticsindd roche business report diagnostics roches topselling diagnostics sales millions chf accuchekavivanano cobase cobasc cobastaqman ventanaihcreagents accuchek cobas e modules cobas c modules cobas ampliprep immunohistochemistry monitoring systems modular analytics modular analytics cobas taqman situ hybridisation elecsys cobas integra market segment market segment market segment market segment market segment blood glucose monitoring immunoassays clinical chemistry virology hepatitis c advanced tissue staining hepatitis b hiv business unit business area business area business area business area diabetes care professional diagnostics professional diagnostics molecular diagnostics tissue diagnostics rochearengdiagnosticsindd diagnostics roche business report industryleading portfolio diagnostic tests instruments clinical testing life science research coaguchekxs cobastaqscreendpxtest cobasbpoc accuchekcombo magnapurelc coaguchek cobas ampliscreen cobas systems blood accuchek insulin magna pure cobas taqscreen gases hospital blood delivery systems lightcycler glucose systems market segment market segment market segment market segment market segment coagulation monitoring blood screening intensive care insulin delivery systems dna purification gene expression business area business area business area business unit business area professional diagnostics molecular diagnostics professional diagnostics diabetes care applied science images scale yearonyear sales growth local currencies rochearengdiagnosticsindd roche business report diagnostics partnersonnewmedicinesandtheirusein bothmatureandemergingemeaeconomies personalisedsettingsseealsother section helpedbystrongperformancesbyprofessional diagnosticsanddiabetescareprofessionaldiag tofurtheraccelerate growth emerging seven nosticsandtissuediagnosticsweretheprimary e countries thedivisionisexpandingits growthdriversinnorthamericainjapan localorganisationsandinvestinginprogrammes overalldivisionalsalesgrewfasterthanthemarket tobringproductstolocalmarketsmorequickly withprofessionaldiagnosticsstrongperformanceoff thedivisionintendstofurtherimprove prof settingcontinuingchallengesindiabetescare itabilitythroughacombinationofstrongsales increasedinvestmentandstrongdemandforimmu growthandefficiencyinitiativestargetingvirtually noassaysandotherleadingedgerocheproducts everyareaofoperationsthisreportcontains contributedtorobustabovemarketgrowthinthee informationontheprogressmadein emergingmarketswhichinaccounted foralmostoftotaldivisionalrevenues results main business onaswissfrancbasisthedivisionscoreoperating profitforincreasedinlocalcur developments renciestomillionswissfrancswhilethecore operatingprofitmarginadvancedpercentage inthediagnosticsdivisionrecordedsalesof pointstotheseincreaseslargelyreflectthe billionswissfrancsanincreaseofinlocal strongperformanceofrocheskeydiagnostic currenciesoverinswissfrancsin productsaswellasongoinginitiativestoimprove u dollarsthiswassignificantlyabovetheestimat operationalexcellenceformoreinformationonthe edivdmarketgrowthrate divisionsoperatingresultsseethefinancereport thedivisionlaunchedatotaloftestswhichex pandedtheimmunoassaymenuininfectiousdis diagnostics sales increase easesextendedthemoleculartestpanelinvirology significantly ahead market andfurtherstrengthenedthetissueassayport folioinoncologyinadditioninstrumentswere launchedinkeymarketsfacilitatingmaximum efficiencyinstateofthearttestinginclinicallabo allfivedivisionalbusinessareascontributedtosales ratoriesresearchcentresandpointofcareunits growthledbyprofessionaldiagnosticsanddiabetes seetableofproductlaunchesonin careimmunoassaysandbloodglucosemonitoring thedivisionplanstolaunchkeyproductsinclud systemsremainedthesebusinessesprimarygrowth ingtheusintroductionofaccuchekcombofor driversstrongdemandforadvancedtissuestain themanagementofbloodglucoseindiabetesthe ingproductscontinuedtofuelabovemarketgrowth cobashpvtestforcervicalcancerscreen intissuediagnosticsvirologywasthemaincon ingandthecobasbrafmutationtestinmela tributortosustainedsalesgrowthinmoleculardiag nomaseetableofproductlauncheson nosticsstrongsalesofcellanalysisandgenomics systemswereappliedsciencesmaingrowthdrivers datafromthreeclinicalstudieswerepresentedat instrumentplacementswereagainupsignificantly majorscientificcongressesathenaalargeregis forthedivisionasawholeandwereamajorgrowth trationtrialinvestigatingthebenefitsofhpvtesting driverinallsegments salesagainoutpacedthemarketinallregions e countries brazil russia india china south korea growthwasverystronginasiapacific mexico turkey particularlyinchinaandsouthkoreadriven unless otherwise stated growth rates local currencies market growth based company independent reports mainlybyprofessionaldiagnosticsdespitepricing end september challengessalesoutperformedthemarketin emea europe middle east africa rochearengdiagnosticsindd diagnostics roche business report inscreeningforcervicalcancerprotectaran zerlandandthediabetescarerdactivitieson domisedtrialstudyingthentprobnpbiomarker insulindeliverysystemsfromburgdorfswitzerland guidedapproachintreatmentofheartfailure tomannheimgermanythedivisionbelieves andthesteptrialaimingatimprovementofdiabetes thatthesemeasureswhicharepartofthegroup managementthroughstructuredtestingallthree wideoperationalexcellenceprogrammwillenable trialsdemonstratedthehighmedicalvalueofroche ittoenhancesystemintegrationleverageexist diagnosticproductsseer sectionon ingcapacitiesandreduceinfrastructurecostswhile maintainingthefocusoncustomersandinnovation operations thedivisionregularlyassessesthemixofinsourcing andoutsourcinginitsmanufacturingandsupply rochediagnosticsbusinessareasbasareinno chainoperationsingeneralactivitieswhichinvolve vationenginestranslatingourgrowingunderstand proprietarytechnologyorenablerochetoleverage ingofdiseasesintonewproductsandapplications internalexpertiseareinsourcedoperationsare thebaheadquartersitesinrotkreuzswitzerland outsourcedwhenthisofferseconomiesofscaleor professionaldiagnosticsmannheimgermanydia otheradvantageswhileensuringthecontinuedinteg betescarepleasantonusamoleculardiagnos rityofrochesproductsandservicesinrecentyears ticspenzberggermanyappliedscienceand thelevelofoutsourcinghasgrowninlinewithsales tucsonusatissuediagnosticsarethedivisions mainrdsiteswithadditionalcentresofexcel lencelocatedinbranfordusalifesciences business development madisonusanimblegenandindianapolisusa diabetescareinseptemberrocheopenedanew collaborationswithacademiaresearchinstitutesand diagnosticsoperationscomplexforrdandpro otherprivateandcommercialorganisationsgive ductioninpenzberganewimmunoassayproduction rochediagnosticsrapidaccesstorelevantmedical unitinmannheimwasinauguratedinoctober scientificandtechnologicaladvancesintellectual propertyipexchangeisastrategiccomponentof inalifecyclemanagementapproachwasin rochesabilitytooffercustomersthemostextensive troducedtoestablishastrongerconnectionbetween portfoliooftestsandtechnologiesyearafteryear eachbaanditsmarketslifecycleteamsareac inlicensingisanimportantopportunityforrocheto countableforthedevelopmentfilingapprovaland accessmarkersandtechnologieswhereasout launchofnewproductstomaximisetheirvalue licensingofipcanhelpestablishnovelmarkersand fromlaunchtoobsolescenceinadditiontwonew technologiesfromrochemorerapidlyinthemarket globalcrossbafunctionshavebeencreatedto placebyinvolvingmoreplayerstodevelopand helpmaintainthefocusonproductprofitabilityand educatethemarketitisthusvitalforrochediagnos processefficiencyglobaloperationswilldrive ticstohaveexcellentinternalprocessestoidentify operationalexcellenceinmanufacturingsupply iprapidlyandtomaintainclosecontactwithpartner chainanddirectprocurementwhileglobalquality companiesforbothinandoutlicensingagreements regulatorywillensuresubmissionqualityandreduce timetoapprovaltheestablishedglobalplatforms inrochecompletedmajoracquisitionsin andsupportfunctionwillcontinuetoplayakeyrole diabetescaremedingoltdandtissuediagnos ininstrumentandsoftwaredevelopmentandcus ticsbioimageneincandenteredintoanumber tomerservice ofresearchandtechnologycollaborationsindiabetes carewithintercomponentwaremoleculardiag asannouncedinnovemberoverthenexttwoto nosticswiththegermancancerresearchcentre threeyearsrochediagnosticsintendstotransfer andappliedsciencewithibmanddnaelectron theproductionofchemicalrawmaterialsand icsmoreoverthedivisionsignedoverlicensing analyticsservicesfrommannheimtopenzbergboth agreementsapproximatelyhalfoftheminlicensing ingermanybloodgasandelectrolytesmonitor iptobroadenrochesinnovationbaseseebusiness ingactivitiesfromgrazaustriatorotkreuzswit area highlightsformoredetails rochearengdiagnosticsindd find disease area virology oncology indication hpv risk factor cervical cancer trial registration trial athena participants study sites countries usa chantal h potential participant athena trial basel rochearengdiagnosticsindd sooner rita head assay development roche pleasanton rochearengdiagnosticsindd cobas hpv test creating value patients means proving medical value diagnostic test rigorous clinical trial biomarker identification clinical validation collaborations research groups academia industry development education diagnostic test healthcare professionals regulatory approval show sensitivity specificity reimbursement health successful economics diagnostic test market demonstrate medical value roche athena trial enrolled persistent infection highrisk human papilloma women screening participants virus hpv leading cause cervical cancer cervical cell changes using pap smear cobas hpv implicated cases screening dna test highrisk hpv geno enables early identification removal precancer types results revealed one ous lesions dramatically reducing incidence ten women aged years older tested positive hpv ge mortality cervical cancer worldwide however many notypes found cer studies shown pap smear sam vical precancer despite normal pap smear tests cobas hpv test ples cells cervix currently com enables physicians identify women mon test used detect cervical cancer cervical precancer missed using adequate sensitivity pre cytology alone cancerous lesions missed single pap smear thousands women ultimately diagnosed cervical cancer normal pap smear results rochearengdiagnosticsindd diagnostics roche business report business area highlights andcobasuasemiautomatedurineteststrip analysertherolloutofthenewcobasbpoc professional diagnostics bloodgasanalysercommencedineuropeandseveral professionaldiagnosticsisaleadingsupplierof marketsinlatinamericaandasiapacifictarget instrumentstestssoftwareandservicesforclinical ingspecificallyatthepocsegmentandcapableof laboratoriesanddecentralisedtestingproductsto deliveringmanyvitalresultsintimecriticalsitua supportclinicaldecisionmakingatthepointofcare tionsthisinstrumentisanimportantadvancein pocinithadashareofagrowing bloodgasanalysistheleadingsegmentinhospital globalmarketworthbillionusdollars poctestingtheuslaunchofcobasbpoc isexpectedin professionaldiagnosticsfullyearsalesgrew abouttwiceasfastastheglobalmarketrising stronggrowthincoagulationmonitoringreinforced millionswissfrancsandoutpacingmarket rochesleadingpositioninthissegmentcontinued growthinallregionsimmunoassayswereakey strongdemandforportabletestingsystemssuchas growthdriverwithsalesupinfora thetopsellingcoaguchekxssystemandexpanded decadethissegmenthasconsistentlygrownatdou medicarecoverageforhomecoagulationtesting bledigitratesthankstoastronginstalledbase intheuswerekeyfactorscontributingtogrowth andaneverexpandingtestmenusalesofclinical studieshaverepeatedlyshownthatselftestinghelps chemistryandcoagulationmonitoringproducts patientsonanticoagulantstokeeptheirmedica grewandrespectively tionwithinthetherapeuticrangeandcanminimise theriskofcomplications inprofessionaldiagnosticslaunchedeightnew ornextgenerationimmunoassaysintheusor deliveringonthepromiseofpersonalisedhealth marketsrecognisingthecemarkincludingsixtests caretheprotecttrialpresentedattheamerican todiagnoseormonitorinfectiousdiseaseshepa heartassociationmeetinginnovemberdemon titisaandchivherpessimplexvirushsvand stratedasignificantreductionintotalcardiovascular hsvandrubellaseetableofproductlaunches eventswhenheartfailuretherapywasguidedby onthreenewornextgenerationclinical concentrationsofthecardiacbiomarkerntprobnp chemistryproductswerealsointroducedince becauseofthisstrongclinicalbenefitthetrialwas successful marketsinprofessionaldiagnosticswillexpand stoppedearlytoallowallpatientsaccesstothisnew diagnostic test market itsimmunoassaymenufurtherwithnewassays treatmentstrategyseer sectionon coveringarangeofdiseaseareasincludinginfec tofurtherstrengthenitscardiologyportfolioroche tiousdiseasesandoncology signedacrosslicenseagreementwithalereinc givingeachpartysemiexclusiveworldwiderightsfor demandforthecobasmodularanalyserseries natriureticpeptidebiomarkersprovenfortheirdiag remainedstronginfirstlaunchedinthis nosticusefulnessinavarietyofcardiovascular platformforhighthroughputtestingisnowavailable diseasesincollaborationwiththeamericancollege inallkeymarketsincludingtheusfollowingthe ofcardiologyprofessionaldiagnosticsisdeveloping introductionofthecobaseimmunoassaymodule awebportalforbiomarkersallowingphysiciansto highvolumelaboratoriesarenowabletofullycon accessthelatestinformationoncardiacbiomarkers solidatetheirserumworkareasrocheoffersacom andencouragingitsapplicationinclinicalpractice prehensiveportfolioofstandardisedintegratedsys temsforclinicallaboratoriesofalltypesandsizes diabetes care fromthestandalonelowvolumecobasandthe diabetescaredevelopsandcommercialisesblood mediumvolumecobastothecobas glucosebgmonitoringandinsulindeliverysystems modularanalyserseriesforhighvolumelaboratories thatenablepeoplewithdiabetestomanagetheir conditionmoreeffectivelythegoalofdiabetesther intheusprofessionaldiagnosticsalsolaunchedthe apyistomaintainthebglevelsinanearnormal cobaspandppostanalyticalunitswhich rangeandthusavoiddiabetesrelatedcomplications automatethestorageandretrievalofsampletubes diabetescarenotonlyoffersindividualproduct rochearengdiagnosticsindd roche business report diagnostics innovationsbutcombinesthesetoformintegrated acquiredmicropumpspecialistmedingoenhancing solutionsthatencompassallareasofdiabetesman itsportfoliowithaninnovativemicropumpthis agementitistheindustryleaderwithashare acquisitionwillenablerochetobringintegrated ofaglobalbgmonitoringmarketworthover billion insulindeliverysystemstoabroaderrangeofpeople usdollars withdiabetesandofferusersawiderrangeof optionstosuittheirneeds indiabetescaressalesroseto mil lionswissfrancsthiswaswellabovetheglobal diabetescareremainscommittedtoexploringand marketgrowthrateinanenvironmentthatremains developingnewdiabetesmanagementconcepts challengingduetotheuncertaineconomicrecov asdemonstratedbythestructuredtestingprotocol eryandgeneralpricepressuresalesofbgmonitor stepclinicalstudyintypediabeticpatients ingsystemsweredrivenbyaccuchekaviva notusinginsulinpresentedattheannualmeeting andaccuchekperformawhichshowedstrongdou oftheeuropeanassociationforthestudyofdia bledigitgrowthsupportedbystrongmarketup beteseasdinseptemberthestepstudyshows takeofthesleekversionsaccuchekavivananoand thatglycemiccontrolcanbesignificantlyimproved accuchekperformananoespeciallydesignedfor whentherapyisadjustedonthebasisofstructured younghighfrequencytestersbytheendof bgmonitoringandpatternanalysisseer sec thesedeviceswereavailableincountriesacross tionon europelatinamericaandasiapacifictheaccu chekmobilealsopostedsignificantsalesgrowth thevisualisationandassessmentofbgandin thisbgmonitoringsystemsstripfreetechnologyis sulindataarepivotaltoeffectivediabetesmanage particularlyappreciatedbyinsulindependentpa mentyetsharingthedatacontinuestoposesig tientswhomeasuretheirbloodglucosefrequently nificantchallengesforpeoplewithdiabetesand andthusbenefitmostfromenhancedtestingcon healthcareprofessionalsaliketoaddressthisissue venienceintroducedintheaccuchekmobile diabetescareispartneringwithehealthspecialist isnowavailableincountriesineuropeand intercomponentwaretodevelopawebbaseddiabe asiapacificintheeumaltoseindependentstrip tesmanagementsolutionthatimprovestheinter chemistriesfortheaccuchekavivaaccuchek actionbetweenpatientsandtheircaregiversbased performaaccuchekcompactandaccuchek onsecurelysharedwellstructuredinformation mobileproductlinesreceivedregulatoryapproval injuneandwereimmediatelyrolledout molecular diagnostics moleculardiagnosticsdevelopsandcommercial diabetescarepostedstronggrowthineuropelatin isesadvanceddiagnosticandbloodscreening americaandasiapacificwithsignificantcontri platformsandtestsbasedonrochesproprietary butionsfromemergingmarketsintheussalesde realtimepolymerasechainreactionpcrtech creasedslightlyunderperformingthemarket nologywithamarketsharerocheistheleader whichremainednegativelyimpactedbythemacro inthehighlycompetitivemoleculardiagnostics economicenvironmentresultinginpricepressures marketvaluedatbillionusdollarsandgrowing andslowvolumegrowthusandjapaneseregu thisyearmarksthethanniversaryofpcrs latoryapprovalsforthemaltosefreestripchemistries debuttothescientificcommunitypcrsunique expectedinwillenablethelatestadditions abilitytoexponentiallyamplifysmallamountsoftarget totheaccuchekportfoliotobelaunchedintheus dnahasresultedinnumerousdiagnostictech andjapanandareanticipatedtoboostsalesin niqueswhichwouldotherwisebetootimeconsum thesekeymarkets ingorimpossibletoperform insulindeliverysystemsposteddoubledigitsales moleculardiagnosticscontinueditssteadyper growthdrivenmainlybycontinuedstronguptakeof formanceinwithsalesadvancingto thenewinteractiveinsulinpumpsystemaccuchek millionswissfrancsgrowthwasledbyvirol combonowavailableincountriesineurope ogywhichcurrentlyaccountsforabouthalf latinamericaandasiapacificinmaydiabetescare ofthebusinessareassalesdemandforthecobas rochearengdiagnosticsindd diagnostics roche business report systemlaunchedinlatewasstrongwith ofhumanpapillomavirushpvdnatestinginclud thesystemnowinstalledincountriesineurope inggenotypingoverconventionalcytologic asiapacificlatinamericaandcanadacobas paptestingseer sectiononsupported offersfullautomationformidtohighthroughput bytheathenaresultsrochefiledthehpvtestin testingthemenucurrentlyincludesdualtargettests theusinjunewithapprovalexpectedinthesecond forchlamydia trachomatisandneisseria gonorrhoeae halfofthistestreceivedcemarkcertification andascreeningandgenotypingtestforhuman inlateandexperiencedastrongmarketuptake papillomavirushpvregionallynorthamericasales incemarketsthroughouttofurtherexpand showedgoodgrowthwhilesalesheldsteadyin itstestingpotentialincervicalcancerrocheentered theeulatinamericaandasiapacificpostedexcel intoaresearchcollaborationwiththegermancancer lentdoubledigitgrowthstrongcontributionfrom researchcenterdkfzrecentfindingsbythe theemarketswasledbyrussiaandmexico dkfzindicatethattherelativeamountsofspecific rnamarkersinhpvinfectedcellsenablehighly inmoleculardiagnosticsaddedfournewor accuratediscriminationofcervicalcancerandhigh nextgenerationteststoitsportfolioinvirologyand gradefromlowgradelesionsandthusfacilitate infectiousdiseasesthankstothefirstofitskind morespecificpredictionofwomensriskfordevel dualpcrtargethivviralloadtestwhichgreatlyim opingcervicalcancer provestheabilityofphysicianstomakeinformed treatmentdecisionsmoleculardiagnosticswon moleculardiagnosticsisbuildingabestinclass amajorcontractinsouthafricaforoverhalfamil oncologyportfoliobysecuringrelevantintellectual liontestsperyearrochesnextgenerationhbv propertydevelopingrobustassaysandproviding testwhichreceivedthecemarkinisnowalso completein vitro diagnosticssolutionscoveringsam availableintheusthistestenablesbroadergeno plepreparationthroughtoresultsanalysesand typedetectionandincreasedworkflowflexibilityin reportinginrocheobtainedaworldwideco themanagementofhbvinthebloodscreeningseg exclusivelicencefromjohnshopkinsuniversity mentthefirstduplexassayforsimultaneousde andqiagenforthedevelopmentofdiagnosticassays tectionofparvovirusbandthehepatitisavirus forthebiomarkerphosphoinositidekinasepik wassuccessfullylaunchedintheeuandother thepikpathwayplaysamajorroleinseveral marketsrecognisingthecemarkcontributingtoim cancersincludingcolorectalgastricbreastand provedsafetyofhumanplasmaproductsfdaap endometrialandiscurrentlyacentralfocusof provalofthistestisexpectedinthelightcycler cancerdrugdevelopmentrochehasalsoobtained mrsaadvancedtestrochesflagshipproductin alicensefromgenzymecorporationtodevelopa thehospitalacquiredinfectionsmarketwasapproved testforepidermalgrowthfactorreceptoregfr andlaunchedintheusinjulystudiesindicatethat mutationsasacompaniondiagnosticfortarcevain thetestsspeeditidentifiesmethicillinresistant recentstudiespatientswithnonsmallcelllung staphylococcus aureusmrsacarriersinlessthan cancernsclccarryingmutationsintheegfrgene twohoursversusonetothreedaysusingconven showedenhancedresponsetoandmaybenefit tionalculturebasedmethodscanhelpsignificantly mostfromtreatmentwithtarcevatheegfrmutation reducethespreadofthispotentiallydeadlymicrobe testalongwithfurtheroncologytestsforthebraf inhospitalsscreeningformrsaisoneofthefast vmutationandkrasmutationsarescheduled estgrowingsegmentsinthenorthamericanmolec forlaunchoncobasin ulardiagnosticsmarketthetestwaslaunchedinthe euandothermarketswhichrecognisethecemark applied science inseetableofproductlauncheson appliedsciencesuppliesscientistsinacademiaand thebiotechandpharmaceuticalindustrieswith datafromathenaarochesponsoredusregistra instrumentsreagentsandtestkitsforabroadrange tiontrialassessingtheutilityofthecobashpv ofresearchapplicationsthegloballifescience testinscreeningforcervicalcancerwerepresented researchmarketvaluedatbillionusdollarsgrew attheinternationalpapillomavirusconferencein approximatelyinappliedsciencehas montrealthedataconfirmtheincreasedaccuracy roughlyshareofthismarket rochearengdiagnosticsindd chosen disease area central nervous system indication schizophrenia trials phase iii trials patients study sites countries kenneth b participant clinical trial rg new york rochearengdiagnosticsindd wisely daniela research project leader central nervous system cns roche basel rochearengdiagnosticsindd rg firstinclass gri schizophrenia creating value patients means courage go needs great others failed available therapies rg effective positive symptoms effective negative symptoms significant side effects potential treat suboptimally controlled positive symptoms positive symptoms often still occur stable phases fewer side effects acute episodes new mechanism action affecting nearly million people worldwide schizo rg glycine reuptake inhibitor gri developed phrenia severe mental disorder distorts roche may first drug treat negative way person thinks acts expresses emotions per symptoms schizophrenia representing entirely ceives reality relates others lifelong novel approach rg normalises glutamate neu disease cured average shortens rotransmission increasing synaptic levels glycine life expectancy years due higher risk thereby targeting important pathway psychiatric suicide also due cardiovascular pulmo disorders potential become firstinclass nary events negative symptoms compound type treatment schizophre usually greatest impact quality life nia addition rg combination current patients may unable live independently hold jobs treatments potential treat suboptimally con establish personal relationships manage every trolled positive symptoms little increase day social situations many drugs developed treat side effects novel mode action could also negative symptoms failed clinical trials valu able therapeutic applications psychiatric available treatments offer modest benefits disorders rochearengdiagnosticsindd diagnostics roche business report appliedsciencepostedgrowthonsalestotalling quencingisalreadyonthehorizonandpromisesthe millionswissfrancsgrowthdriverswerethe nextleapinperformanceinjunerocheandibm cellanalysissegmentthankstoincreaseddemand signedanagreementtodevelopananoporebased forsolutionsinoncologyandstemcellresearch singlemoleculesequencertodirectlyreadand genomicsformerlyreportedassequencingandmi decodehumandnabasedonibmsdnatransistor croarraybusinessesandcustombiotechdueto technologythisapproachpromisesgainsincost recoveryoftheglobaleconomysalesofthemagna efficiencythroughputscalabilityandspeedcom pureandlightcyclerproductlinesforsamplepre paredwithothersequencingtechnologiescurrently parationandquantitativepcranalysisdeclineddue availableorindevelopment todramaticallylowerdemandforinfluenzaahn virustestingallregionsshowedsalesincreases nimblegencomplementeditsofferingonthecyto exceptlatinamericawherethenegativeeffectof geneticsmicroarrayworkflowsystemincluding decreasedhntestingwasparticularlypronounced arraysforsimultaneousanalysisofmultiplesamples salesinasiapacificwereexceptionallystrong instrumentsreagentsaswellasanalysisandvi ledbychinaandindia sualisationsoftwarenowprovidingacomprehensive solutionforhighresolutioncytogeneticanalyses salesforcellanalysissystemsremainedrobust ofchromosomalabnormalities fuelledbyfullintegrationoftheinnovatisproduct portfolioandsteadilyincreasingdemandfor appliedsciencetookfurtherstepstowardstransition xcelligenceautomatedrealtimecellanalysers ofitsproductsfrompureresearchuseintoroutine rtcainseptemberappliedscienceexpanded diagnostictoolsivdsapreinvestigationaldevice thisproductlinebylaunchingthertcahtin exemptionpreidesubmissionfornimblegens strumentforhighthroughputanalysisandthe microarrayplatformhasbeenfiledwiththefdaits rtcacardioinstrumentforlabelfreecardiotoxic approvalistheprerequisiteforobtainingfda itytesting clearanceforrochescytogeneticmicroarrays foruseasivdsthesemicroarrayswhichdetect doubledigitincreasesinsequencingreagentand chromosomalabnormalitiescouldspearheada microarrayssalesfuelledgrowthingenomics producttransitionintoivdsandarecurrentlyunder helpedbystrongworldwidedemandforthe developmenttodemonstratetheirmedicalvalue gsjuniordnasequencerlaunchedinmaythis anddiagnosticutility mediumthroughputbenchtopversionofthegenome sequencerflxsystembridgesthegapbetweenlow tissue diagnostics andhighthroughputsequencingandofferssolutions tissuediagnosticsventanamedicalsystemsin innearlyeveryfieldofbiologicalresearchthanks northamericaistheworldsleadingsupplier toitssizeefficiencyandcompetitivepriceitputs oftissuebasedcancerdiagnosticsitsinstruments nextgenerationsequencingtechnologywithinthe andreagentsystemsareusedinhistologycytol reachofthousandsofresearchersaroundtheworld ogyanddrugdiscoverylaboratoriesworldwidein theunithadashareofthetissuediag inresponsetotheworldwidesurgeinresearch nosticsmarketwhichisvaluedatoverbillionus projectsinvolvingresequencingofthehumangenome dollarsandgrewapproximately tostudydiseasesinlargepopulationsapplied scienceismakingadditionalinvestmentstodevelop tissuediagnosticssignificantlyoutpacedthe systemstargetingthisapplicationinnovember marketinrecordingsalesofmillionswiss appliedscienceenteredintoanexclusivepartnership francsanincreaseofcomparedtotheyear withdnaelectronicsforthedevelopmentofa earlierperiodadvancedtissuestainingimmuno lowcosthighthroughputdnasequencerthesys histochemistryihcandin situhybridisation temwillcombinelifescienceslongread ishwasthemaingrowthdriverreflect sequencingtechnologywithdnaelectronicsinex ingstrongreagentsalesandrobustuptakeof pensivehighlyscalablemethodforelectrochemical thefullyautomatedbenchmarkultrasystemfor detectionmoreoverthethirdgenerationofse simultaneousihcandishtestingonasingle rochearengdiagnosticsindd roche business report diagnostics platformthissystemwhichisnowavailablein hasbeenverystrongparticularlyindeveloping countriesworldwidesetsnewstandardsintermsof marketsvantageanadvancedworkflowmanage randomslideaccessuserfriendlinessandhigh mentsystemforimprovedproductivityandpatient qualityresultsthebusinessareaperformedstrongly safetylaunchedincontinuedtogain worldwidegrowingtwotofourtimesasfastas momentumwithsalesmorethandoublingcompared themarketineuropelatinamericaandasiapacific totheyearearlierperiod salesintheseregionsbenefitedfromintensified commercialisationeffortsoutsidetheussynergies tissuediagnosticscompletedtwoacquisitions withrochepharmaceuticalsinhertestingin bioimageneincaleaderindigitalpathologyanaly breastandgastriccancerandtheintroductionof sisandworkflowwithproductsenablinggeneration benchmarkgxataneconomicpriceinemerg ofhighresolutionwholeslidedigitalimagesfrom ingmarkets glassmicroscopeslidesaswellassoftwaretoview analyseandmanagetissueimagescomplementing intissuediagnosticslaunchednewanti andstrengtheningtheofferinginimageanalysis bodiesforihctestingtosupportthediagnosisof andinformationmanagementandmariposabio variouscancertypesseetableofproductlaunches scienceaninnovatorinthefieldofantibodyproduc onsixdnaprobesforishtestingwere tiontosupportrochesproductionofbestin addedtothemolecularassaymenuintheeuand classantibodies othermarketsrecognisingthecemarkincludingtwo newmoleculardnatestsforthehumanepidermal growthfactorreceptorhergeneenabling research development accuratetimelyassessmentofthelikelihoodofre sponsetotreatmentwithherceptininbreastand inresearchanddevelopmentrdcostscore gastriccanceradnaprobetargetingtheinsulin basisinthediagnosticsdivisiontotalled mil likegrowthfactorreceptorigfrgenewas lionswissfrancsadeclineofinlocalcurrencies addedtotissuediagnosticsnonsmallcelllung comparedtordcostsasapercentageof cancerbiomarkerpanelwhichalsoincludesassays salesdecreasedtoinlinewithoveralldivisional foregfrandmetstrengtheningitspositionin strategythefocuswasondevelopingnextgene prostatecancertestingtissuediagnosticssecured rationplatformstoimprovetestingefficiencyandon theexclusiverightsfromasymmetrxincforuse developingnewtestsanddemonstratingtheirmed ofthepbiomarkerandlaunchedtwodnaprobes icalvaluewithrobustclinicaldataclinicalvalidation enablingthedeterminationoferggenomicrear isrelativelynewintheivdindustrybesidessignif rangementsonasingleslidewhilethepbiomark icantinvestmentitrequiresexpertiseinclinicaldevel eristhegoldstandardforthedifferentialdiagno opmentandincreasedinteractionwithnontradi sisofprostatecancererggenomicrearrangements tionalcustomerssuchaspayersandhealthcare havebeenshowntobeareliableprognosticmarker professionalsseefeatureonbeingableto ofprostatecancerspecificmortalityincertain drawonrochepharmaceuticalslongstandingex patientgroups pertiseinclinicalvalidationgivesrochediagnostics anadvantageovermostotherivdcompanies theadvancedstaininginstrumentportfoliowas bolsteredworldwidewithtwonewadditionsdis inthreemajorclinicaltrialsdemonstratingthe coveryultraanautomatedihcandishplatform significantmedicalvalueofrocheproductswere designedforuseintheresearchsettingandoffering presentedatscientificcongresses improvementsineaseofuseworkflowandsystem flexibilityandbenchmarkgxalowvolumeauto datafromtheathenatrialwerepresentedatthe matedtissuestaininginstrumentdesignedforcancer internationalpapillomavirusconferenceinmontreal diagnosticsprofessionalswhowanttoexpand injulythisrochesponsoredusregistrationtrial theirtestmenuandadoptautomationwithreduced thelargesteverperformedinthisindicationaimedto investmentwithplacementsinovercountries assesstheutilityofthecobashpvtestin bytheendofacceptanceofbenchmarkgx screeningforcervicalcancerthedataclearlycon rochearengdiagnosticsindd diagnostics roche business report firmedtheincreasedaccuracyofhumanpapilloma therapyadjustmentscontributessignificantlytoa virushpvdnatestingoverconventionalcytologic reductionofhbacvaluesimprovesglycemic paptestingoutofwomenenrolledinthis controlandhelpstoreducediabetesspecificpsy trialoneintenofthoseagedyearsorolderwho chologicaldistressanddepressionwhilesmbg testedpositiveforhpvgenotypesorwere iswidelyacceptedasacorecomponentofeffective foundtohavecervicalprecancerdespitenormalpap diabetesmanagementinpeopleoninsulintherapy teststhecobashpvtestdetectshigh thevalueofsmbghassofarremainedcontroversial riskgenotypesofhpvtwelveasapooledresultand forinsulinnaivepeoplerepresentingalargepart genotypesandindividuallyasdemonstrated ofallpeoplewithtypediabetes byathenathistesthelpsphysicianstorecognise andtreatprecursorsofcervicalcancerearlierpossi inadditiontothemedicalvalueofivdtestsapplied blybeforeitspreadsinthebodyeachyeararound intheclinicdiagnosticstodayplayanumberof halfamillionwomenworldwidearediagnosedwith criticalrolesindrugdevelopmentfromidentifying cervicalcancerandmorethansuccumb newtherapeutictargetsandscreeningoutun tothedisease promisingdrugcandidatestoselectingappropriate patientpopulationsforclinicaltrialssomemay finalresultsofprotectprobnpoutpatienttai alsobecomecompaniondiagnosticsforpatientselec loredchronicheartfailuretherapyaprospective tionresponsepredictionortherapeuticmonitor randomisedclinicaltrialinpatientswerepre ingeverydrugunderdevelopmentatrochehasits sentedattheamericanheartassociationcongress ownassociatedbiomarkerprogrammeanddiag inchicagoinnovemberbythemainstudyinves nosticsexpertiseandadvicearemadeavailablefor tigatorsfromharvarduniversityandmassachusetts eachoftheseprogrammesinthediagnostics generalhospitalpromotinganewparadigmin andpharmaceuticalsdivisionsincludingpred themanagementofheartfailuretheresultsdemon gredpharmamedicinesandchugaicollaborated stratedthatntprobnpguidedheartfailurecare onmorethan projectsacrossalldiseaseareas wasassociatedwithasignificantreductionin ofinterestatrochemorethanhalfoftheseprojects totalcardiovasculareventssuchasworsening wereinoncologyfollowedbyinflammationcns heartfailureheartfailurehospitalisationandcardio virologyandmetabolicdiseasesinadditionthe vasculardeathascomparedwithstandardtreatment diagnosticsdivisioncollaboratedwithseveral asheartfailureranksamongthemostcostlychronic otherpharmaceuticalcompaniestodevelopcom conditionsindevelopedcountriesreducingthe paniondiagnosticsforkeybiomarkersparticularly riskofcardiovasculareventsnotonlycontributesto inoncology betterpatientoutcomesbutisalsolikelytoreduce healthcarecoststherochentprobnptestis availableatthepointofcareandinlaboratories worldwidewhereitrunsonthecobasplatformsitis estimatedthatasmanyasmillionpeopleworld widehaveheartfailurewithnewcasesdiag nosedeachyearintheusaloneandamortality ratethatexceedsthatofmanycancers thestepstructuredtestingprotocolstudya prospectivemonthclinicaltrialinnoninsulin treatedpeoplewithtypediabeteswaspresent edattheannualmeetingoftheeuropeanassociation forthestudyofdiabeteseasdinstockholmin septemberthestudydemonstratedthattheuseof thisnewdiabetesmanagementapproachincluding structuredselfmonitoringofbloodglucosesmbg datavisualisationpatternanalysisandderived rochearengdiagnosticsindd roche business report diagnostics product launches diagnostics division major product launches business area product name product description market timelines professional six immunoassays hiv combi min improved combined testing eu apac q diagnostics virology infectious hivantigen hivantibodies enabling reliable latam diseases early detection hiv infection hsv igg hsv igg quantitative detection eu apac q igg antibodies hsv latam rubella igm diagnose rubella infection women us q antihcv presumptive diagnosis hcv infection us q anti hav diagnose hav us q two immunoassays free hcg pappa evaluate risk trisomy eu apac q disease areas pregnancy latam stat ntprobnp evaluate risk heart failure us q three clinical chemistry nextgeneration tests hbac ferritin new eu apac q products multicontrol clinchem latam cobas e module immunoassay module immunoassays eu q cobas modular throughput testshour high volume laboratories analyser series cobas b poc system multiparameter blood gas analyser use eu apac q point care laboratories latam cobas c clinical chemistry immunoassay modules high us q cobas c cobas e volume laboratories modules cobas modular analyser series cobas u semiautomated urine test strip analyser us q cobas p cobas p postanalytical units automated storage retrieval us q barcoded primary secondary sample tubes diabetes care maltoseindependent accuchek aviva accuchek performa eu apac q strip chemistries accuchek mobile accuchek compact latam molecular four molecular tests cobas ampliprepcobas taqman dual target hiv test us q diagnostics virology infectious v simultaneous detection two regions diseases hiv genome lightcycler mrsa advanced test automated realtime us q pcrbased test mrsa cobas taqscreen dpx test simultaneous quantitative eu q detection parvovirus b qualitative result hav cobas ampliprepcobas taqman hbv test v us q newgeneration hbv viralload test enables broader genotype detection improved workflow flexibility applied science nimblegen cgx highresolution analysis chromosomal abnormalities ww q multiplex array capable analysing six samples simultaneously gs junior economic benchtop nextgeneration sequencing system ww q smaller laboratories nimblegen cytogenetic complete solution highresolution cytogenetic analysis ww q workflow system including instruments arrays analysis visualisation software rtca cardio instrument realtime cell analysis functional monitoring ww q cardiotoxicity arrhythmic effects rtca ht instrument realtime highthroughput labelfree impedancebased ww q cell analysis rochearengdiagnosticsindd diagnostics roche business report major product launches business area product name product description market timelines tissue diagnostics fifteen antibodies antiecadherin antip basal cell cocktail antip us eu q ihc testing cancer antikeratin antip catenin anticyclin anticd antick anticam anticd anticd antick antihent antimoc antigpc antick one antibody ihc antihelicobacter pylori eu q testing infectious diseases six dna probes ish ddish probe sish probe igfr probe eu q testing cancer topa probe perg probe perg probe benchmark gx economical lowvolume automated advanced tissue eu apac q staining discovery ultra automated advanced tissue staining research setting us eu q black type new productfirst market launch grey type new productlaunch additional markets apac asiapacific eu european union latam latin america us united states ww worldwide ddish dual colour dual hapten ish hav hepatitis hbac hemoglobin ac hbv hepatitis b hcg human chorionic gonadotropin hcv hepatitis c hiv human immunodeficiency virus hpv human papillomavirus hsv herpes simplex virus ihc immunohistochemistry ish situ hybridisation mrsa methicillinresistant staphylococcus aureus ntprobnp nterminal fragment btype natriuretic peptide pappa pregnancyassociated plasma protein rtca realtime cell analyser sish silver ish stat short turnaround time tests used emergency rochearengdiagnosticsindd roche business report diagnostics key product launches planned business area product name product description market timelines professional two immunoassays total vitamin measure vitamin eu h diagnostics greater precision aid detecting ovarian cancer eu h cobas c module clinical chemistry module throughput testshour us eu h cobas modular highvolume laboratories analyser series cobas b poc system multiparameter blood gas analyzer use us h point care laboratories diabetes care accuchek mobile lcm nextgeneration stripfree blood glucose monitoring system eu h integrated lancing device significantly smaller current version enhanced functionality accuchek nano sleek version highfrequency users us h accuchek combo interactive insulin delivery system combining insulin pump us h blood glucose monitoring system broad data management capabilities molecular four molecular tests cobas braf v mutation test identification eu us h diagnostics oncology infectious v mutation braf gene diseases cobas kras mutation test identification eu h mutations kras gene cobas egfr mutation test identification eu h mutations egfr gene cobas hpv test detects hpv hpv individu us h ally highrisk genotypes pooled result applied science gs g type hla primer hla genotyping gs junior system gs flx ww h sets system gs flx titanumxl new sequencing chemistry enables extended read lengths ww h gs flx system sequencing kit cgh ultrahigh resolution arrays cgh validation combined ww h cghsnp arrays cghsnp validation million million features discovery variations gene copy numbers single nucleotides tissue diagnostics erpr antibody ihc support diagnosis breast cancer us h testing benchmark ultra dual colour ish support diagnosis breast cancer us h probe ish testing futureview nextgeneration detection system benchmark platforms us eu h delivers greater specificity flexible detection options improved turnaround time black type new productfirst market launch grey type new productlaunch additional markets eu european union us united states ww worldwide braf bisoform rapidly growing fibrosarcoma oncogene cgh comparative genomic hybridisation egfr epithelial growth factor receptor erpr estrogene receptorprogesterone receptor human epididymis protein human epidermal growth factor receptor hla human leukocyte antigen hpv human papillomavirus ihc immunohistochemistry ish situ hybridisation kras member ras family oncogenes snp single nucleotide polymorphism rochearengdiagnosticsindd diagnostics roche business report glossary situ hybridisation ish amethodofstaining biologicaltissuesamplestoidentifythepresence biomarker acharacteristicthatcanbemeasured andcopynumberofspecificgenesorgeneticmuta andevaluatedasanindicatorofanormalbiological tionsincellsusedinthediagnosisofcancerand processadiseaseprocessoraresponsetoathera otherdiseases peuticinterventionelevatedlevelsoftheprotein herincancerforexampleareabiomarkerfora micropump insulin delivery anextgeneration highprobabilityofresponsetoherceptin insulinpumpsmalllightweightdiscretetowear thatdeliversinsulinwithouttubingitcombineskey cell analysis methodsofmeasuringtheproperties featuresofdurableinsulinpumpswiththebest ofcellsincludingtheirsizeandshapecellular attributesoftubefreepatchpumpsprovidingflex parameterssuchasthepresenceofspecificproteins ibilityandfreedomforabroaderrangeofinsulin andcellularprocessessuchasproliferationand dependentpeoplewithdiabetes growthcellanalysistechnologiesplayanimportant roleindrugdevelopmentandproduction microarray adevicefordetermininggenetic changesthatmaycontributetohumandiseaseor ce mark certification certificationthatanin vitro influencetreatmentresponsehighdensitymicro diagnosticivdproductcomplieswithallsafety arraysevaluatethousandsofdnaandrna healthandenvironmentalrequirementsforuseinthe sequencesatonce europeanunioncertifieddiagnosticsarereferred toasceivds pointofcare poc testing diagnostictesting performedatornearthesiteofpatientcareusing clinical chemistry abranchofdiagnosticscom transportableoftenhandheldinstrumentsandtest prisingteststhatdetectandmeasurechangesin kitsresultsareavailableimmediatelyhelpingto thechemicalcompositionofbodyfluidsandtissues speedclinicaldecisionmaking todiagnoseorpredictthecourseofadisease polymerase chain reaction pcr alaboratory dna sequencing methodsofdeterminingthe methodwidelyusedinresearchandindustrytomake orderofnucleotidesmolecularbuildingblocksin millionsofcopiesofadnasequenceofinterest geneticmaterialknowinganindividualsdna veryquicklyrealtimepcrsimultaneouslyamplifies sequencecanprovideinsightsintogeneticchanges copiesandquantifiesthetargeteddnamolecule whichcontributetohumandiseaseorinfluence treatmentresponsehighthroughputtechnologies virology inmoleculardiagnosticstestingtodetect readthousandsofsequencesatonce certainseriousandprevalentviralinfectionseg hivandhepatitiscortomonitortheirtreatment immunoassay alaboratorytestthatdetectsor measuresatargetsubstanceinasampleusingan immunochemicalreactioninwhichanantibody bindstoaspecificantigenthetargetcanbeadrug aproteinoravirusforexample immunohistochemistry ihc amethodofstain ingbiologicaltissuesamplestodeterminethepres encelevelandlocationofspecificproteinsincells usedinthediagnosisofcancerandotherdiseases rochearengdiagnosticsindd corporate governance roches commitment stakeholders reflected operating businesses focus value creation management culture conforms modern standards corporate governance groups policy communicating transparently remuneration report roches success depends abilities dedication people recognition forms basis remuneration policy system rochearengcorporate governanceindd corporate governance roche business report corporate governance rochecomplieswithallrelevantcorporategover attheagmonmarchtheboardofdirectors nancerequirementsinparticularwithallapplicable willproposeshorteningthetermofofficeofnewor lawstheswissstockexchangesixswiss directorsforreelectionfromthreetotwoyearsand exchangedirectivesincludingthecommentaries theboardwillnominatepiusbascherabrunogehrig theretoandtheswisscodeofbestpracticefor lodewijkjrdevinkandandreasoeriforreelec corporategovernancepromulgatedbytheswiss tiontotheboardandpaulbulckepeterrvoserand businessfederationeconomiesuissethecompanys christophfranzforelectionasnewmembersofthe internalgovernanceframeworkparticularlyitsarti board clesofincorporationandbylawsembodiesallthe principlesneededtoensurethatthecompanysbusi walterfreyhasdecidedtoretireasmemberofthe nessesaremanagedandsupervisedinamanner boardofdirectorsaftertenyearsofdistinguished consistentwithgoodcorporategovernanceinclud servicetheboardofdirectorsthankswalterfrey ingthenecessarychecksandbalances forhislongstandingengagementandhismanycon tributionstorochewhichstartedalreadywithhis ourprintedannualreportcontainsselectedlinksto activitiesasamemberoftheboardofrochepharma therochewebsitewwwrochecomreadersare agingermanyfromtobeforebecoming thusprovidednotonlywithasnapshotofourcom aboardmemberofrocheholdingltdin panyatthereportingdatebutarealsodirectedto sourceswhichtheycanconsultatanytimeforup wolfgangruttenstorferdecidedtoresignasamem todateinformationaboutcorporategovernance beroftheboardofdirectorsofrocheholdingltd atrochewhereaseachannualreportcoversasin afterfouryearsofservicetheboardofdirectors glefinancialyearendingdecemberourwebsite thankswolfgangruttenstorferforhisvaluablework containsinformationofamorepermanentnatureas andcontributiontoroche wellasthelatestrochenewsthecompanysarti clesofincorporationbylawsandthecurriculavitae ofthemembersoftheboardofdirectorsandthe corporate executive corporateexecutivecommitteearepublishedonour committee website startingonjanuarypascalsoriotmemberof board directors thecorporateexecutivecommitteesinceapril anddanielodaywereappointedascoodivision atthendannualgeneralmeetingagmof rochepharmaceuticalsandcoodivisionroche rocheholdingltdonmarchshareholders diagnosticsandasanewmemberofthecorporate reelecteddeannejuliusandbeatricewederdi executivecommitteerespectively mauroasmembersoftheboardofdirectorsfora termofthreeyearsasprovidedbythearticles erichhunzikerchieffinancialofficerchiefinfor ofincorporationpeterbrabeckletmatheandhorst mationofficeranddeputyheadofthecorporate teltschikhavedecidedtoretireasmembersofthe executivecommitteehasdecidedtoretirefrom boardofdirectorsaftermanyyearsofdistinguished rocheattheendofmarchandplanstofocus servicearthurdlevinsonandwilliammburns onanumberofboardmembershipstheboardof wereelectedasnewmembersoftheboardfora directorsofrocheholdingltdthankserichhunziker termofthreeyearsasprovidedbythearticlesof forhismanyyearsofexceptionalserviceandout incorporationatitsorganisingmeetingimmediately standingcontributionstothegroupssuccess followingtheagmtheboardofdirectors hasapproveditscommitteesstructureanditscom theboardofdirectorshasappointedalanhippeto mitteesmembershipsasshownon succeederichhunzikeraschieffinancialofficer httpwwwrochecomaboutrochecorporategovernancehtm rochearengcorporate governanceindd roche business report corporate governance board directors per december left dr franz b humer prof bruno gehrig andr hoffmann dr andreas oeri prof pius baschera prof sir john irving bell william burns lodewijk j r de vink dr deanne julius walter frey dr arthur levinson dr wolfgang ruttenstorfer prof beatrice weder di mauro rochearengcorporate governanceindd corporate governance roche business report board directors name year birth term ends first elected board directors dr franz b humer e chairman prof bruno gehrig c e vicechairman andr hoffmann c e vicechairman prof pius baschera e prof sir john irving bell c e william burns b e lodewijk j r de vink c e walter frey b e dr deanne julius b e dr arthur levinson c e dr andreas oeri e dr wolfgang ruttenstorfer b e prof beatrice weder di mauro b e new proposed members board directors nominated paul bulcke election peter r voser annual general meeting march dr christoph franz secretary board directors dr gottlieb keller honorary chairman board directors dr fritz gerber corporate governance sustainability committee b audit committee c remuneration committee presidiumnomination committee e nonexecutive director committee chairperson january rochearengcorporate governanceindd roche business report corporate governance corporate executive committee per december left dr severin schwan dr pascal soriot daniel oday dr erich hunziker silvia ayyoubi dr gottlieb keller dr richard scheller dr jeanjacques garaud dr dan zabrowski osamu nagayama dr stephan feldhaus perolof attinger rochearengcorporate governanceindd corporate governance roche business report corporate executive committee name year birth position corporate executive committee dr severin schwan ceo roche group dr erich hunziker chief financial officer deputy head corporate executive committee dr pascal soriot coo division roche pharmaceuticals daniel oday coo division roche diagnostics dr gottlieb keller general counsel silvia ayyoubi head human resources april dr alan hippe chief financial officer enlarged corporate executive osamu nagayama president ceo chugai committee dr richard scheller head genentech research early development gred dr jeanjacques garaud head roche pharma research early development pred dr dan zabrowski head roche partnering dr stephan feldhaus head group communications secretary corporate executive committee perolof attinger kpmg klynveld peat marwick goerdeler sa reporting years statutory auditors kpmg ag since roche holding ltd auditor charge john morris since chief compliance officer dr urs jaisli alanhippewilljoinrocheasamemberofthe effectiveauguststephanfeldhauswas corporateexecutivecommitteeasofapril appointedheadgroupcommunicationsandmember oftheenlargedcorporateexecutivecommittee asofjanuaryjeanjacquesgaraudwas reportingtoseverinschwanandreplacingperolof appointedasheadofrochepharmaresearchand attingerwhotookoveranewlycreatedposition earlydevelopmentpredandtogetherwithdan asheadceoofficeandsecretarytothecorporate zabrowskiasheadofrochepartneringbothwere executivecommitteereportingtoseverinschwan appointedasnewmembersoftheenlargedcorpo rateexecutivecommittee rochearengcorporate governanceindd roche business report corporate governance information relating capital structure informationonrochescapitalstructureispro corporate governance videdinthefinancereportnotestothefinancial statementsofrocheholdingltdpages group structure shareholders andadditionaldetailsarecontainedinthe rochesoperatingbusinessesareorganisedinto articlesofincorporationofrocheholdingltd twodivisionspharmaceuticalsanddiagnostics changesinequityaredetailedinthefinance thepharmaceuticalsdivisioncomprisesthetwo reportnotestothefinancialstatementsof businesssegmentsrochepharmaceuticalsand rocheholdingltd chugaiwhereasgenentechastheformerthird thecompanyhasasharecapitalof segmenthasbeenintegratedintorochepharma swissfrancsdividedintofullypaid ceuticalsthediagnosticsdivisionconsistsof bearershareswithanominalvalueofswiss thefollowingfivebusinessareasappliedscience franceachtherearenorestrictionsontheexer diabetescaremoleculardiagnosticsprofes ciseofthevotingrightsofthesesharesupon sionaldiagnosticsandtissuediagnosticsbusi depositsharescanbevotedwithoutanyrestric nessactivitiesarecarriedoutthroughgroup tions subsidiariesandassociatedcompaniessignificant thereisnoauthorisedorconditionalcapital subsidiariesandassociatedcompaniesarelisted inadditionnonvotingequity inthefinancereportnotetotherochegroup securitiesneshavebeenissuedinbearerform consolidatedfinancialstatementssubsidiaries theydonotformpartofthesharecapitaland andassociates confernovotingrightseachnesconfersthe majorshareholdersarelistedinthefinance samerightsasonesharetoparticipateinavail reportnotesandtotherochegroup ableearningsandinanyliquidationproceeds consolidatedfinancialstatementsequity followingrepaymentofthesharecapitalroches attributabletorocheshareholdersandrelated nesandtherightspertainingtheretoincluding partiespagesandandinnoteto theprovisionsprotectingtheinterestsofnes thefinancialstatementsofrocheholdingltd holdersaredescribedinofthearticlesof significantshareholders incorporationofrocheholdingltd andrhoffmannvicechairmanoftheboardof informationondebtinstrumentswhichhavebeen directorsandandreasoerimemberoftheboard issuedandonoutstandingbondsisprovidedin ofdirectorsandchairmanoftheboardscorporate thefinancereportnotetotherochegroup governanceandsustainabilitycommitteeserve consolidatedfinancialstatementsdebt intheirrespectivecapacitiesontheboardandits committeesasrepresentativesoftheshareholders additionalinformationonemployeestockoptions groupwithpooledvotingrightsandreceivethe isprovidedinthefinancereportnotetothe remunerationsetforthintheremunerationreport rochegroupconsolidatedfinancialstatements onandinthefinancereportnote employeestockoptionsandotherequitycom totherochegroupconsolidatedfinancialstate pensationplans mentsrelatedpartiesandnote rochehasissuednooptionsapartfromemployee tothefinancialstatementsofrocheholdingltd stockoptionsstocksettledstockappreciation boardandexecutiveremuneration rightsssarsandoptionsissuedinconnection nootherrelationshipsexistwiththeshareholders withdebtinstruments withpooledvotingrights neithertheoptionsawardedtoemployeesnor therearenocrossshareholdings thedebtinstrumentswhichhavebeenissuedhave anyeffectonrochessharecapital httpwwwrochecomaboutrochecorporategovernance articleofincorporationhtm rochearengcorporate governanceindd corporate governance roche business report board directors corporate executive theboardofdirectorshasestablishedasystem committee ofcontrolswhichiscontinuouslymonitoredbythe informationoneachmemberoftheboardof auditcommitteeandbythecorporategover directorsincludingtheyearsinwhichtheywere nanceandsustainabilitycommitteeandconsists electedandtheyearsinwhichtheirtermsend ofthefollowingelements andoneachmemberofthecorporateexecutive reportonfinancialandoperatingrisks committeeislistedonpagestocurricula riskmanagementsystem vitaeandotherinformationincludinginformation systemofinternalcontrolsoverfinancial onboardmembershipsareavailableonthe reportingseepagesandinthe internet financereport theannualgeneralmeetingelectsthemembers internalaudits oftheboardofdirectorsinstaggeredelections groupcomplianceofficerandcompliance inwhicheachnomineeisvotedonseparatelysee officersinsubsidiaries ofthearticlesofincorporationofroche safetyhealthandenvironmentalprotection holdingltdandtheminutesofthendannual department generalmeetingofrocheholdingltdheld corporatesustainabilitycommittee march scienceandethicsadvisorygroupseag withtheexceptionoffranzbhumerwilliamm forissuesrelatingtogeneticsandgenetic burnsandarthurdlevinsonnoneofthemem engineeringestablishedin bersoftheboardofdirectorshasbeenamember eachyearseveralblackoutperiodsareimposed ofrochescorporateexecutivecommitteeor duringwhichsenioremployeesareprohibitedfrom servedinanexecutivecapacityatanygroupsub tradingincompanystockthefollowingblackout sidiaryduringthethreefinancialyearspreceding periodsareineffectfor thecurrentreportingperiod decembertofebruary theinternalorganisationoftheboardofdirectors apriltoapril andthedivisionofauthorityandresponsibilities junetojuly betweentheboardandmanagementtheremits octobertooctober oftheboardcommitteesandtheinformation blackoutperiodscanbechangedbythechair andcontrolmechanismsavailabletotheboard manoftheboardofdirectorsifcircumstances initsdealingswithcorporatemanagementare warrant governedbythebylaws intheboardofdirectorsmetforfive theboardofdirectorsofrocheholdingltdis meetingseachfromtohoursinlengthonce organisedsoastoensurethatthegroupsbusi forafulldaymeetingandonceforathreeday nessesareconductedresponsiblyandwitha focusonlongtermvaluecreationtothisendthe rocheboardhasdelegatedcertainresponsibili tiestoseveralcommitteestheircompositionand figures indicate actual length meetings chairpersonsasofjanuaryaredescribed include directors extensive premeeting preparations oneachcommitteesauthoritiesandre postmeeting followup activities sponsibilitiesaredefinedindetailinthebylaws httpwwwrochecomaboutrochemanagement boardofdirectorshtm oftheboardofdirectors httpwwwrochecomaboutrochemanagement allthecommitteesexceptthepresidiumare executivecommitteehtm chairedbyindependentdirectors httpwwwrochecomaboutrochecorporategovernance accordingtothebylawsoftheboardofdirectors articleofincorporationhtm httpwwwrochecomaboutrochecorporategovernance attherequestofanyofitsmembersaboard annualgeneralmeetingshtm meetingwithoutthechairmanpresentmaybe httpwwwrochecomaboutrochecorporategovernance convenedtherocheboardmeetsonceayear articleofincorporationhtm toassessthechairmansperformancethis httpwwwrochecomaboutrochecorporategovernance committeeshtm meetingwhichisnotattendedbythechairman httpwwwrochecomaboutrochecorporategovernance ischairedbyoneofthevicechairmen articleofincorporationhtm rochearengcorporate governanceindd roche business report corporate governance board board committees attendance corporate governance presidium nomination remuneration audit sustainability board committee committee committee committee number meetings f b humer b gehrig hoffmann p baschera j bell w burns l j r de vink w frey julius levinson oeri w ruttenstorfer b weder di mauro member committee board committee member since march visittoamajorsubsidiarywhichincludedaboard orthefullboardinternalauditregularlybriefs ofdirectorsmeetingtheboardcommitteesmet theauditcommitteewithreferencetoongoing asfollowsin auditreportsmembersofinternalauditattend presidiumoftheboardofdirectorsnomination auditcommitteemeetingsasdoexternalaudi committeefivemeetingsapproxhours torsforinformationontheexternalauditorssee remunerationcommitteefourmeetings membersofthecorporateexecutivecommittee approxtohourseach haveamaximumordinarynoticeperiodoftwelve auditcommitteefivemeetingsapproxto months hourseach therearenomanagementcontractswhichfall corporategovernanceandsustainabilitycom withinthescopeofsubsectionannexofthe mitteethreemeetingsapproxhourseach sixdirectiveoninformationrelatingtocorporate theboardofdirectorsregularlyconductsaself governance assessmentofitsperformance themembersofthecorporateexecutivecommit remuneration shareholdings loans teeareinvitedtoattendforandreportinperson alldetailsregardingremunerationshareholdings onthoseagendaitemsconcerningthemwhen andloansaresetforthintheseparateremunera thesituationwarrantsmembersoftheenlarged tionreportonpagestoandinthefinance corporateexecutivecommitteemayalsobe reportnotesandtotherochegroup invitedtoattendtheboardcommitteesinvitethe chairmanoftheboardandothercorporate figures indicate actual length meetings include directors extensive premeeting preparations executivecommitteememberstodeliverreports postmeeting followup activities atcommitteemeetingsandmayelecttocommis remuneration committee members permitted sionindependentexpertreportsandcallon contribute attend remuneration committee meetings theservicesofconsultantstheriskmanagement matters concerning deliberated decided additional information provided finance report note systemissubjecttocontinuousreviewwith roche group consolidated financial statements findingsbeingpresentedtotheauditcommittee risk management rochearengcorporate governanceindd corporate governance roche business report consolidatedfinancialstatementsequityattri theirauditstheauditcommitteeoversees butabletorocheshareholdersandrelated andassessestheauditorsandmakesrecommen partiespagesandandarelistedinthe dationstotheboardforinformationonthe notesandtothefinancialstatementsof responsibilitiesoftheauditcommitteeseearti rocheholdingltdboardandexecutiveremuner cleofthebylawsthestatutoryauditors ationandboardandexecutiveshareholdings participatedinfourmeetingsoftheauditcommit pagesand teein participatory rights shareholders thereportsofstatutoryauditorsontheconsoli theparticipatoryrightsofshareholdersare datedfinancialstatementsandonthefinancial definedinrochesarticlesofincorporationas statementscanbefoundonpagesand rochesharesareissuedtobearerthereare respectivelyofthisyearsfinancereport norestrictionsonadmissiontoannualgeneral meetingswiththeexceptionthatsharesmust kpmgreceivedthefollowingremunerationfor bedepositedwithinaspecifiedperiodbeforethe theirservicesasstatutoryauditorsofrochehold dateofameetingandanadmittancecardmust ingltdandotherrochecompanies beissuedintheshareholdersnameasprovided inofthearticlesofincorporationanyshare holdercanelecttoberepresentedbyanother millions chf shareholderatanannualgeneralmeetingthe auditing services articlesofincorporationcontainnorestrictions auditrelated services ontheexerciseofvotingrightsandtheonlyquo tax consultancy services rumrequirementsarethosestipulatedin total inconformitywiththeswisscodeofobligations underofthearticlesofincorporationshare thestatutoryauditorsareelectedeachyearby holdersrepresentingshareswithanominalvalue theannualgeneralmeeting ofatleastmillionswissfrancscanrequestthe placementofitemsontheagendaofanannual ernstyoungltdreceivedthefollowingremuner generalmeetingthismustbedonenolaterthan ationfortheirservicesastheauditorsofchugai daysbeforethedateofthemeeting change control defensive measures millions chf thearticlesofincorporationcontainnoprovisions chugai audits onthemandatorybidruleswisslawapplies consulting services therearenochangeofcontrolclausesthose provided chugai componentsofremunerationbasedonrochenes total wouldbeterminatedintheeventofanacquisi genentech chugai tionandvestingperiodrestrictionsonpreexist ingawardswouldberemovedsothatallsuch optionscouldbeexercisedimmediately information policy asprovidedbyofthearticlesofincorpora relationship statutory auditors tioncorporatenoticesarepublishedinthe attheannualgeneralmeetingofrocheholding swiss official gazette commerceandinother ltdonmarchtheshareholdersvotedto dailynewspapersdesignatedbytheboardof appointkpmgagkpmgasstatutoryauditors informationonhowlongtheauditorsandauditor httpwwwrochecomaboutrochecorporategovernance inchargehavebeenservinginthesecapacities articleofincorporationhtm isprovidedonthestatutoryauditors httpwwwrochecomaboutrochecorporategovernance articleofincorporationhtm participateinauditcommitteemeetingsthey httpwwwrochecomaboutrochecorporategovernance preparewrittenandoralreportsontheresultsof articleofincorporationhtm rochearengcorporate governanceindd roche business report corporate governance directorsbasler zeitung finanz und wirtschaft nonapplicabilitynegative disclosure lagefi le temps neue zrcher zeitung itisexpresslynotedthatanyinformationnot rochereportsitshalfyearandfullyearresultsin containedormentionedhereinisnonapplicable businessreportspublishedinprintandonline oritsomissionistobeconstruedasanegative formatsandatmediaeventsinadditiondetailed declarationasprovidedinthesixswissexchange firstandthirdquartersalesfiguresarepublished corporategovernancedirectiveandthecom eachyearinaprilandoctoberthemostcurrent mentarythereto listofpublicationdatesisavailableinenglishand germanontheinternet allrelevantinformationanddocumentsincluding allmediareleasesinvestorupdatesandpresen tationstoanalystandinvestorconferencesare availableontheinternetfurtherpublicationscan beorderedbyemailfaxortelephone baselwebmasterrochecom tel fax thecontactaddressforinvestorrelationsis f hoffmannlarocheltdinvestorrelations groupfinancebaselswitzerland tel fax additionalinformationincludingdetailson specificcontactpersonsisavailableonthe internet chief compliance officer thechiefcomplianceofficerwithhiscompliance officersnetworkiscommittedtoensuringthatthe rochegroupcodeofconductisconsistently compliedwiththroughouttherochegrouphe alsoservesasacontactpersonforshareholders employeescustomerssuppliersandthegeneral publiconissuesrelatingtotheimplementation ofandcompliancewiththiscodeemployeesand otherpartieswhobecomeawareofviolationsof therochegroupcodeofconductcanbringthem totheattentionoftheirmanagersorsupervisors orreportthemtothechiefcomplianceofficer ursjaislidirectphonenumber emailursjaislirochecom suchdisclosureswillbetreatedconfidentiallyin additionasoftheendofemployeesmay anonymouslyreportirregularitiesorcomplaints intheircorrespondingmotherlanguageviaa speakuphotlinethechiefcomplianceofficer httpwwwrochecommediahtm reportsregularlytothecorporategovernance httpwwwrochecominvestorshtm httpwwwrochecominvestorscontactshtm andsustainabilitycommittee httpwwwrochecomaboutrochecorporategovernance codeofconducthtm rochearengcorporate governanceindd remuneration report roche business report remuneration report summary abalancedmixoflongandshorttermremunera rochessuccessdependsontheabilitiesanddedica tioncomponents tionofitspeoplerecognitionofthisformsthebasis marketcompetitiveness ofourremunerationpolicyandsystem basepaybonusesblockednonvotingequitysecurities oneoftheprimaryaimsofourremunerationpolicyis nesawardsofstocksettledstockappreciation toencouragealongtermfocusandalignmanage rightsssarsandaperformanceshareplanpsp mentsinterestswiththeinterestsofrochesshare supporttheseprinciplestheseremunerationcom holdersandholdersofrochesnonvotingequity ponentsarelinkedtoourcompanysfinancialperfor securitiesnes manceandcommercialsuccessandthusalignthe interestsofrocheemployeeswiththoseoftheshare thisremunerationreportwillbesubmittedsepa holders ratelyforapprovalattheannualgeneral meeting theamountoftheseparatecomponentsofremunera theremunerationofcorporateexecutivecommittee tionforeachindividualmemberofthecorporate membersandotherseniorrocheexecutivesis executivecommitteeisshownintheindividualdescrip comprisedof tionoftheremunerationofthecorporateexecutive basesalaryfixed committeeinthisreport bonusvariable stocksettledstockappreciationrights base pay ssarsvariable basepaycashpaymentlevelsaredetermined performanceshareplanpspawardsvariable accordingtomarketdataoftheworldsbiggestphar underthepspnoneswillbeawarded maceuticalscompaniesforspecificpositionsand thessarsgrantedin individualemployeesabilitiesexperienceandperfor andhavestrikepricesabovethenesprice manceovertimepayincreasesarelinkedtoindividual asofdecemberandhavenovaluefor performanceandalsotakeintoaccountprevailing therecipientsthiscanchangeifrochesfuture marketconditionsandthecompanysoveralleconomic nespriceimproves situationbasepayandpayincreasesareconclusively therehasbeennochangeinthebaseremunera monitoredanddeterminedbytheremuneration tionoftheboardofdirectorssince committee pleaseseetherestofthisreportforfulldetails bonuses bonusescashpaymentareawardedinrecognition remuneration policy ofindividualcontributionstovaluecreationwhich rochefundamentallyreneweditsremunerationpolicy gobeyondnormaljobexpectationsandtheyare inandrevieweditinreconfirmingthe meanttobeanincentivetocreateorstrengthennew keyprinciplesitispartofaframeworkofemployee businessopportunitiesandstriveforoutstanding policiesaimedatmotivatingandretainingcurrent resultsbonusamountsarelinkedtogroupordivi employeesattractingtalentednewonesandhelping sionalbusinessperformanceconsideringprofit allrocheemployeestoperformatconsistently highlevelsourremunerationpolicyisdesignedto see stock optionsstocksettled stock appreciation rights fostervaluecreationandreinforceacultureof ssars performanceandinnovationanditappliestonon see also finance report note roche group managerialemployeesaswellastomanagers consolidated financial statements related parties notes financial statements roche thekeyprinciplesunderpinningthispolicyare holding ltd board executive remuneration board focusonvaluecreation executive shareholdings payforperformance peer set abbott laboratories amgen astellas enablingemployeestoshareinthecompanys astrazeneca bayer becton dickinson biogen idec bristolmyers squibb eli lilly gilead glaxosmithkline success johnson johnson merck co novartis pfizer fairnessandtransparencyinremunerationdecisions sanofiaventis takeda rochearengremuneration reportindd roche business report remuneration report variable remuneration elements bonuses ssars psp relation fixed base pay members corporate executive committee bonus ssars psp individual target value max relation value based annual base pay base pay measured january first year cycle minimum maximum relation value cash payment value development value development base pay determined determined performance nes performance nes grant grant performance criteria group objectives group individual contributions group performance divisional business upon remuneration tsr relation performance committees decision tsr performance individual objectives discretion peer set considering profit see sales growth opac operating profit capital charge split group objectives na b individual objectives na salesgrowthopacoperatingprofitaftercapital performance share plan chargeperformanceandtotheachievementof themembersofthecorporateexecutivecommittee individualandfunctionalmeasurableandqualitative andothermembersofseniormanagementcur performanceobjectivesforreasonsofcompeti rentlysomeindividualsworldwideparticipate tivenessrochedoesnotdisclosedetailsofindividual intheperformanceshareplanpspthepsp objectivesofthemembersofthecorporateexec wasestablishedinforperiodsofthreeyears utivecommitteetheremunerationcommitteeofthe eachandisbasedonathreeyearcomparison boardofdirectorshasdefinedthecorporateex ofthetotalshareholderreturntsrwithcom ecutivecommitteemembersbonusesindecember petingcompaniesintherewerethreeover basedonresultsachievedfor lappingperformancecyclespsp pspandpspofwhichpsp stocksettled stock appreciation rights ssars closedon december stocksettledstockappreciationrightswere introducedonjanuarythusestablishinga detailsforthepspcalculationandaddi uniformsystemofremunerationthroughoutroche tionalinformationaresetforthinremuneration ssarsentitleholderstobenefitfinanciallyfrom ofmembersofthecorporateexecutivecommittee anyincreaseinthevalueofrochesnonvotingequity performanceshareplanpsp securitiesbetweenthegrantdateandtheexer cisedateawardsareallocatedindividuallyuponthe remuneration board directors remunerationcommitteesdecisionatitsowndis corporate executive committee cretiondetailedinformationisavailableon eachyeartheremunerationcommitteewhichis andto entirelycomprisedofindependentexternalmembers oftheboardofdirectorssetsremunerationforthe rochearengremuneration reportindd remuneration report roche business report membersoftheboardofdirectorsandthecorporate nerationofthechairmanoftheboardofdirectors executivecommitteecashpaymentsbonuses themembersofthecorporateexecutivecommittee optionsstocksettledstockappreciationrightsand takingintoconsiderationpersonnelchanges policydecisionsaboutpensionbenefitstheterms oftheperformanceshareplanaredeterminedannually thefollowingpagesprovidedetailedinformationon bytheboardofdirectorsactinguponrecommen theremunerationearnedbyeachmemberofthe dationsfromtheremunerationcommitteetheremu boardofdirectorsandbyeachmemberofthecor nerationcommitteecontinuouslytrackssalarytrends porateexecutivecommitteefor inthemarketoftheworldsbiggestpharmaceuticals companiesandreportstotheboardofdirectorsin remuneration formationonthiscommitteesremitpowersandits remuneration members board proceduresformakingremunerationdecisionscanbe directors inthemembersoftheboardof foundinthebylawsoftherocheboardofdirectors directorsreceivedtheremunerationincashshown followingtherevisionoftheremunerationpolicy includingmarketcomparisonswiththeworldsmajor httpwwwrochecomaboutrochecorporategovernance articleofincorporationhtm pharmaceuticalcompaniestheremuneration list members positions committee committeehasdeterminedthebonusesandremu memberships chairmanship see remuneration members board directors additional compensation remuneration committee memberschairs chf chf additional special compensation f b humer see remuneration chairman board directors see b gehrig hoffmann p baschera j bell w burns l j r de vink w frey julius levinson oeri w ruttenstorfer b weder di mauro remuneration former members board directors additional compensation remuneration committee memberschairs chf chf additional special compensation p brabeckletmathe h teltschik see w ith exception members presidium vicechairmen board members receive chf year committee serve chf year committee chair see g highest total remuneration member board directors pages remuneration serving vicechairman board prorated remuneration period march december prorated remuneration period january march rochearengremuneration reportindd roche business report remuneration report inthetableremunerationofmembersoftheboard forhisconsultingworkandforhisboardmember ofdirectorsonfortheirboardactivities shipofgenentechamountingtousdollars remunerationofallmembersoftheboardofdirec swissfrancs torswillagainremainunchangedfor forthemembersoftheboardofdirectors besidethecashpaymentsthenonexecutivemem receivedremunerationtotallingswiss bersoftheboardofdirectorswerenotawardedany francsswissfrancs sharesnonvotingequitysecuritiesstocksettled stockappreciationrightsssarsstockoptions noadditionalremunerationwaspaidtomembersof orrestrictedstockunitsrsusin theboardofdirectors horstteltschikreceivedhonorariaamountingto remuneration members corporate eurosswissfrancsforservingon executive committee thegeneralprovisions theboardsofseveralrochesubsidiariesingermany assigningauthorityfordecisionsoncorporateexec utivecommitteeremunerationtotheremuneration williammburnsreceivedhonorariaamountingtoa committeeandtotheboardofdirectorsareoutlined totalofusdollarsswissfrancs onpagestoofthisremunerationreport forservingasamemberoftheboardofdirectorsof chugaipharamaceuticalcoltd see stock optionsstocksettled stock appreciation rights ssars sincehiselectiontotheboardofdirectorsofroche see remuneration members board directors holdingltdarthurdlevinsonreceivedpayments remuneration members corporate executive committee base pay chf annual salary annual salary annual salary schwan ayyoubi e hunziker g keller oday p soriot total member corporate executive committee duetoobligationsfromhisformerrocheassignment b bonus intheusdanielodayreceivedthefollowingpay allmembersofthecorporateexecutivecommittee mentsinmortgagesubsidyusdollars willreceivethebonusasacashpaymentdue swissfrancsforfinancialtaxservice forpaymentattheendofapril usdollarsswissfrancsdanieloday receivedinadditionswissfrancsforthe ondecemberthestocksettledstock schoolingofhischildren appreciationrightsgrantedin forthemembersofthecorporateexecutive committeereceivedremunerationtotalling see remuneration members corporate executive swissfrancsswiss committee af h excluding ahvivalv francs rochearengremuneration reportindd remuneration report roche business report bonus bonus bonus bonus total total total chf chf chf schwan ayyoubi e hunziker ga keller oday p soriot total member corporate executive committee including additional compensation successful integration genentech amounting swiss francs paid c stocksettled stock appreciation rights ssars ssars ssars ssars value chf value chf value chf schwan ayyoubi e hunziker g keller oday p soriot total member corporate executive committee ee stock optionsstocksettled stock appreciation rights ssars b lackscholes value described stock optionsstocksettled stock appreciation rights ssars values according annual report andmostofwhichcanbeexercisedfollow eachyearintherewerethusthreecyclesin ingtheendofthevestingperiodinfebruary progresspsppspandpsp hadnovaluefortherecipients asinthepreviousyearforthepsp thepspendedon decem membersofthecorporateexecutivecommittee berwithoutanyawardsoftargetednes additionallyreceiveannualexpenseallowancesof swissfrancstotallingswissfrancs undertheprovisionsofthisplananumberofnon votingequitysecuritieshavebeenreservedfor performance share plan psp theparticipantsineachcyclethenumberofse themembersofthecorporateexecutivecommittee curitiesactuallyawardedwilldependonwhether andothermembersofseniormanagementcurrently andtowhatextentaninvestmentinrochesecurities someindividualsworldwideparticipateinthe sharesandnesoutperformstheaveragereturn performanceshareplanpsp inthepspmovedtooverlappingthreeyear see strike prices table stock options ssars performancecycleswithanewcyclebeginning rochearengremuneration reportindd roche business report remuneration report onaninvestmentinsecuritiesissuedbyapeerset attheendofthepspcyclebasedona ofcomparatorcompaniescomparisonsarebased threemonthmovingaverageatconstantexchange onthesecuritiesmarketpricesanddividendyields rateswithdistributeddividendstotallingbil ieontotalshareholderreturntsrtoreducethe lionswissfrancsbillionswissfrancs effectofshorttermmarketfluctuationssecurity billionswissfrancsbillion pricesareaveragedoverthethreemonthsoctober swissfrancsthetsroftherochesecurities todecemberpriortothestartofaperformance nesandsharesrankedcomparedwithits cycleandoverthethreemonthsoctobertodecem peersetofcompaniesoperatinginthesamein berattheendofthecycleifrochesecurities dustrythereforeaccordingtothetermsoftheplan performaswellasorbetterthanthoseofofthe theparticipantsreceivednoneoftheoriginally peersetandinadditionrochestsrincreases targetednesseetablebelowfordetails atleastduringacycletheboardofdirectors canelecttoincreasethemaximumnesaward e indirect benefits byasmuchastwofoldintheeventthataninvest employercontributionsmadeintosocialsecu mentinrochesecuritiesunderperformsthe rityschemespensionplansandagroupwide averagereturndeliveredbythepeercompanies employeestockpurchaseplanrocheconnectin fewerornoneswillbeawarded respectofmembersofthecorporateexecutive committeeareshowninthetableindirectbenefits inneswerereservedundertheplanformem inon bersofthecorporateexecutivecommitteeas showninthetablebelowtheboardofdirectorswill rocheconnectisavoluntarystockpurchaseplan decideontheactuallevelofnesorcashequivalent offeringemployeestheopportunitytobuyroche awardsforthecyclesand nonvotingequitysecuritiesnesuptoanamount afterthecloseoftheandfinancialyears equaltooftheirannualsalaryatadis respectivelytheaimofthepspistoprovide anincentivetoparticipantstoachievesteadyvalue growth see footnote performance share plan psp total estimated value psp awards nes nes awards awarded awarded target number target number targeted number nes psp nes psp nes psp psp psp value chf value chf value chf schwan ayyoubi e hunziker g keller oday p soriot total member corporate executive committee total estimated value psp none originally targeted nes awarded psp estimated value calculated using yearend price december chf per nonvoting equity security nes based number nes originally targeted subject changes number value nes awardable plan december december respectively spread relevant period time ie year board directors vote actual allocation nes originally targeted december december respectively according tsr achieved rochearengremuneration reportindd remuneration report roche business report indirect benefits payments pension fundsmgb ahvivalv roche connect tax consulting services chf chf chf chf schwan ayyoubi e hunziker g keller oday p soriot total mgb stiftung der f hoffmannla roche ag fr mitarbeitergewinnbeteiligung employee profitsharing foundation supplementing occupational pension benefits ahvivalv swiss social security programmes providing retirement disability unemployment benefits countnespurchasedunderthisplanaresubjectto g highest total remuneration member aholdingperiodwhichisfouryearsinswitzerland board directors franzbhumerasthechairmanwasthememberof f remuneration emoluments loans theboardwiththehighesttotalremunerationfor inpensionsandtwopaymentsfortaxconsult seeremunerationofmembersoftheboardof ingservicestotallingswissfrancswere directorsthechairmansremuneration paidtofourformercorporateexecutivecommittee consistsofbasesalaryandbonusawardsaschair members manoftheboardafterthehandoverofhisexecu tivefunctionasceoattheannualgeneralmeeting membersofthecorporateexecutivecommitteehave onmarchhedidnotreceiveanyadditional amaximumnoticeperiodoftwelvemonthsincon ssarsornesfromnewpspcyclesandwas nectionwiththenewcompanyandpersonnelstruc nolongerenrolledinanyrochestockoptionplan turemembersofthecorporateexecutivecommittee orssars canreceivecompensationamountingtooneannual basepayincaseofterminationofthecontractbythe accordingtotheannouncementintheannual companyterminationthroughnofaultandnotbased reporttheboardofdirectorsreducedthe onlackofperformanceuntiltheageofsixty chairmansbasesalaryintomillionswiss highest total remuneration member board directors chf chf salary bonus total pension fundsmgb roche connect total value f detailed calculation remuneration chairman ceo see annual report gb stiftung der f hoffmannla roche ag fr mitarbeitergewinnbeteiligung employee profitsharing foundation supplementing occupational pension benefits ncludes additional compensation committee members chf payments tax consulting services chf chugai advisory mandate usd chf including employer contribution ahvivalv chf rochearengremuneration reportindd roche business report remuneration report highest total remuneration member corporate executive committee chf chf salary bonus total ssars blackscholes value grant minus pension fundsmgb roche connect estimated value targeted awarded nes according performance share plan awardsvalue nes total total value detailed information see annual report blackscholes value described stock optionsstocksettled stock appreciation rights ssars mgb stiftung der f hoffmannla roche ag fr mitarbeitergewinnbeteiligung employee profitsharing foundation supplementing occupational pension benefits basic rules detailed calculation see remuneration members corporate executive committee performance share plan footnote respectively includes annual expense allowance chf payments tax consulting services chf excluding employer contribution ahvivalv payments francsasof aprilanddeterminedatthe security holdings directorsandrhoffmann endofthathistotalremunerationincluding andandreasoeriandmembersofthefounders bonusescontributionstopensionfundsandad familieswhoarecloselyassociatedwiththembelong ditionalcompensationexpenseallowancewill toashareholdergroupwithpooledvotingrights dependingontheachievementofobjectivesnot attheendofthisgroupheldshares exceedthemaximumamountofmillionswiss ofissuedsharesdetailedinformation francstheshareholdersagreedtothismaximum aboutthisgroupcanbefoundinthefinancereport amountwiththeapprovaloftheremuneration notetotherochegroupconsolidatedfinancial reportattheannualgeneralmeetingon statementsrelatedpartiesandin marchtheeffectivetotalremuneration thenotetothefinancialstatementsofroche wasbelowofthedeterminedmaximumand holdingltdsignificantshareholdersin lowerthan additionasofdecemberthemembers oftheboardofdirectorsandpersonscloselyasso h highest total remuneration member ciatedwiththemandthemembersoftheexecutive corporate executive committee committeeandpersonscloselyassociatedwith severinschwanasceowasthememberofthecor themheldsharesandnesasshowninthetableon porateexecutivecommitteewiththehighesttotal remunerationforseeremunerationofmem bersofthecorporateexecutivecommitteeaf stock optionsstocksettled stock apprecia tion rights ssars atdecemberfranz bhumerandwilliammburnsbeingtheonly noadditionalremunerationwaspaidtocurrentor membersoftheboardofdirectorsholdingoptions formermembersofthecorporateexecutivecommit andasofjanuaryssarsduetotheir tee formerpositionsandthemembersofthecorporate executivecommitteeheldoptionsandstock settledstockappreciationrightsssarsfirst rochearengremuneration reportindd remuneration report roche business report introducedonjanuaryasshowninthetable thestrikepricesexpirydatesandgrantvalues stockoptionsandssarson foroptionsandssarsareshowninthetableon thenumbersofoptionsandssars alloftheoptionsshowninthetablewereissuedby ascalculatedatthetimeofissuehavebeenentered rocheasemployeestockoptionseachoption asvaluesinthetableremunerationofmembers entitlestheholdertopurchaseonerochenonvoting ofthecorporateexecutivecommitteecstockset equitysecuritynesataspecifiedstrikeprice tledstockappreciationrightsssarson atgrant underthetermsofthismultiyearoptionplan thestrikepriceforoptionsshownwastheclosing priceforrochenesonthelastdayoftrading priortotherocheannualmediaconferenceallof theoptionsshownarenontradableonethird oftheoptionsaresubjecttoavestingperiodofone yearonethirdhaveavestingperiodoftwoyears andonethirdavestingperiodofthreeyears unvestedoptionslapsewithoutcompensation ifemploymentisterminatedvoluntarilyforreasons otherthanretirementwhilevestedoptionsmust beexercisedwithinalimitedperiodoftimeifemploy mentisinvoluntarilylayofforredundancyjob eliminationorreductioninforceterminatedgranted butunvestedoptionsvestimmediatelyandmust beexercisedwithinsixmonthsortheyareforfeited thefairvalueoftheoptionsiscalculatedatthe dateofissueusingtheblackscholesformulaandas iftheoptionsweretradablewithandeduction fortheaveragetwoyearvestingperiod thessarsshowninthetableonwere introducedbyrocheonjanuaryinplaceof stockoptionsssarsentitleholderstobenefit financiallyfromanyincreaseinthevalueofroches nesbetweenthegrantdateandtheexercisedate thestrikepriceforssarsunderthetermsofthis multiyearplanwastheclosingpriceforrochenes onthefirstdayoftradingaftertherocheannual mediaconferenceallssarsvestwithinthreeyears ofthegrantdateieonethirdvestattheendof oneyearonethirdattheendoftwoyearsandone thirdattheendofthreeyearsvestedssars mustbeexercisedconvertedintoneswithinseven yearsofthegrantdateandunexercisedssars lapsewithoutcompensationthefairvalueofthe optionsiscalculatedatthedateofissueusingthe blackscholesformulaandasiftheoptionswere tradablewithandeductionfortheaveragetwo yearvestingperiod rochearengremuneration reportindd roche business report remuneration report security holdings december close relatives shares nes security holdings others number number numbertype number board directors f b humer ssars see rogtpk trackerplus cert zrcher kantonalbank roche genussschein rog underlying valor isin ch b gehrig hoffmann ubs longshort certificates linked roche bearer shares roche nonvoting equity securities valor isin ch p baschera j bell w burns stock options ssars see l j r de vink american depository receipts adr rhhby us isin us w frey julius nes levinson oeri ubs longshort certificate linked roche bearer shares roche nonvoting equity securities valor isin ch w ruttenstorfer b weder di mauro total nes corporate executive committee schwan nes stock options ssars see ayyoubi stock options ssars see e hunziker stock options ssars see g keller nes ssars see oday ssars see p soriot ssars see total nes shares held shareholders group pooled voting rights listed rochearengremuneration reportindd remuneration report roche business report stock options ssars number stock options ssars held current former members corporate executive committee december ssars first issued total corporate execu tive committee schwan ayyoubi e hunziker g keller oday p soriot total former corporate executive commit tee members f b humer none none none w burns none strike price chf market price per nes december chf expiry date grant value per option starting per ssar chf blackscholes value minus ssars stock options franz b humer receive additional ssars franz b humer received stock options ssars member corporate executive committee wiliam burns receive additional ssars william burns received stock options ssars member corporate executive committee rochearengremuneration reportindd corporate responsibility dow jones sustainability indexes named roche supersector leader healthcare second consecutive year sustainability core business practices positioning reflects commitment running business way ethical responsible creates longterm value stakeholders year made progress longterm diversity energy goals introduced new programmes increase access products rochearengcorporate responsibility partindd corporate responsibility roche business report corporate responsibility brief wefocusondevelopingnewmedicinesanddiag thesixthannualsustainabilityworkshopattended nosticsthataddressunmetmedicalneedandhelp bysustainabilityexpertsfromaroundthegroup patientsleadlongerbetterlivesdiscovering accesstomedicinesanddiagnosticsandthevalue anddevelopingtheseproductsremainsourgreatest ofourproductsandservicesremainedhighon responsibility theagendathisyearwhileaworkinggroupdis cussedournewkpis thenatureofourbusinessmeanswealwaysthink longtermittakeseighttotwelveyearstobringour web medicinestomarketsobeingsustainableiscritical sustainability principles foroursuccessaswellasforourcustomerssup wwwrochecomprinciples csc charter wwwrochecomcsrcommittees pliersandpartnersweaimtobalancetheneedsof kpis wwwrochecomsuskpipdf individualssocietyandtheenvironmentinourwork andtobearewardingemployerthatattractstalented peopleourvaluesofintegritycourageandpassion guideemployeestodotherightthingintheirwork approach roche management sustainability wefocusonthecorporateresponsibilityissuesthat aremostrelevanttoourstakeholdersandhavethe board directors greatestpotentialtoimpactourbusinesswemonitor ourprogressusingkeyperformanceindicatorskpis corporate foreachissueduringwerevisedourkpisto executive alignthemwithourstrategicframeworkensurethey committee supportourlongtermbusinessstrategyandgoals andfurtherintegrateresponsiblebehaviourthrough outthebusiness board committee corporate governance sustainability theupdatedkpismeasurethevaluewecreatefor fourmainstakeholdergroupsemployeespatients investorsandsocietywereportagainstseveralof corporate sustainability committee csc thesekpisplusadditionalperformancemeasures core team working team throughoutthisannualreportandonourwebsite inwewerenamedsupersectorleaderin healthcareforthesecondyearrunninginthedow key material sustainability topics jonessustainabilityindexesdjsiinrecognition ofourcommitmenttosustainablepracticesweuse thisindexandotheranalysestoevaluateourperfor manceandtoidentifyareaswherewecanimprove orlearnfromothers managing corporate responsibility network colleagues atrochecorporateresponsibilityisanintegralpart relevant corporate divisional functions ofeveryonesworkandiscoordinatedbyourcor poratesustainabilitycommitteecscasshownin thediagramthecscidentifiesandassessessig nificantsocialethicalandenvironmentalrisksand opportunitiesanddevelopsandrevisescorporate positionsandguidelinesonrelatedtopicsitmetfor mallyfourtimesinandinseptemberhosted rochearengcorporate responsibility partindd roche business report corporate responsibility stakeholder engagement weaimtocreatevalueforourstakeholdersthrough believeintwowaydialoguewherebothpartieslearn themedicalbenefitsourproductsprovideour fromeachotherthetableshowsexamplesfrom dailybusinessactivitiesandspecificactivitieswith andthereisfurtherinformationonourwebsite eachgroupweregularlyseekstakeholdersviews whenformulatingbusinessstrategysettingpriorities web includingthoserelatingtocorporateresponsibil stakeholder engagement itycrandthroughoutproductdevelopmentwe wwwrochecomstakeholderengagement stakeholder engagement stakeholder group examples engagement results engagement patients ran workshops patient groups several better understanding patients needs patient groups countries including france germany help manage disease reviewed informed consent forms consent forms easier patients read patient advocacy group egan understand healthcare market research needs assessment improved understanding customer needs professionals among hcps us top five eu countries hcps participated american hcps virtual conference services hcps society clinical oncology virtual conference governments participated industry initiatives topics development effective public health poli regulators biosimilars cies regulations shared learnings industry developed guidelines misuse com roche wada signed memorandum pounds world antidoping agency understanding healthcare payers worked payers develop methods development tools assess cost evaluate compare effectiveness effectiveness medicines improved understanding among payers developed pricing toolkit computer value products services models association payers employees groupwide programmes promote increased awareness understanding strategic framework strategic framework among global ran management town hall meetings work force major sites investors attended investor meetings improved investor understanding busi conferences ness model strategy latestage pipeline suppliers worked key suppliers commit minimised supply chain risks business partners new supplier code conduct extended supplier audits business critical began aligning supplier audit protocols service providers indirect spend psci members nongovernmental worked access medicines index ensure recognition access organisations ranking programmes engaged amnesty international launched project chinese ministry declaration bern others organ health establish organ donation donation china system communities donated time money expertise help reduce health inequalities causes aids orphans malawi maintain positive relationships clean water uganda communities contributed local communities support next generation scientists initiatives roche genetics education programme media corporate press releases trade maintain positive media image protect news updates reputation rochearengcorporate responsibility partindd corporate responsibility roche business report patients excellenceinscienceisfurtheringourunderstanding ourhealtheconomistsandreimbursementmanagers ofthemechanismsofdiseaseweareusingthis workwithnationalandlocalhealthauthoritiesto knowledgetodevelopmedicallydifferentiatednew demonstratetheeconomicandhealthbenefitsofour therapiesandhelpimprovepatientsqualityoflife productsandserviceswithineachhealthcaresys furthermorebyfittingtreatmentstopatientsand temweengagewithpayersandprovidersthrough achievingbetteroutcomespersonalisedhealthcare outaproductslifecycleandprovideguidanceon makesmoreefficientuseofhealthcarebudgets howtoassessthevalueofourproductsandservices throughevaluationssuchashtasinmarketssuch wecanincreasethiscontributiontosocietyby astheukwehavedevelopedmodelsthatassessthe demonstratingthemedicalandeconomicvalue costsandclinicalconsequencesofcertainthera ofourproducts piescomparedwithdifferenttreatmentoptionsto helpingtoimproveglobalaccesstohealthcare helppayersandhealthcareprovidersmakein runningsafeandethicalclinicaltrials formedchoices ensuringpatientsafety buildingrelationshipswithpatientsgroups weworkwithpayerstoagreepricingarrangements listeningandrespondingtocustomersviews thatsuittheirneedsourapproachconsidersa rangeofoptionsforreachingamutuallyagreeable value medicines diagnostics pricesuchasvolumebasedandotherdiscounts healthcarepayershavetobalancemedicalneedand pricecappingcostsharingandpaymentbyresults clinicalimpactwiththecostofnewmedicinesand thisworkwasparticularlyimportantformain theallocationofscarcebudgetsthishasledtothe tainingaccesstoourproductsinwhenmany developmentofavarietyofmethodsfordetermin governmentsfocusedonreducinghealthcare ingappropriatecoverageandreimbursementrates budgetsorrestrictingtheirgrowthtohelpmanage byexaminingtheclinicaleconomicsocialand publicfinances ethicalimplicationsofamedicaltechnologythese arebroadlytermedhealthtechnologyassess ourpositionsonpersonalisedhealthcareassessing mentshtasdifferentprovidersusedifferenthtas thevalueofourproductsandservicesandpricing resultinginvaryinghealthcareprioritiesdelivery describeourapproachinmoredetailandareavailable andaccesslevels onourwebsite itisessentialthatpayerscanassessourproducts global access healthcare usingobjectiveconsistentandopenprocesses theprovisionofhealthcareisasharedresponsibility whichconsiderthefullcycleofcareaswellasclini andlackofaccesstomedicinesanddiagnosticsis calandeconomicvalueforindividualpatientsand oneofmanysystemiccausesofhealthcareinequality forsocietyforthisreasonwehaveaglobaldepart otherbarriersincludelackofdiseaseawareness mentthatsetsandmaintainspricesforourportfolio lowlevelsofdiagnosisandlimitedhealthcareinfra throughouttheproductlifecycleitalsoensuresour structureandbudgets clinicaltrialsassessthecosteffectivenessaswell asefficacy wehaveanimportantroletoplayintacklingthe globalhealthcarechallengeweworkwithgovern whensettingthepriceforanewtestordrugwelook mentshealthcareprovidersthemediapatient atthemedicalbenefititprovidesandcompareits groupsandnongovernmentalorganisationsngos lifecyclevaluewiththeavailablealternativesmanyof toincreaseaccessandtacklethesewiderproblems ourproductshelpreducetreatmenttimesandthe needforsurgeryorpalliativecareminimisehospital healthneedsindevelopingcountriesandemerging stayspreventdiseasefromreturningandspeed marketsdifferfromthoseinthedevelopedworld patientsreturntoworktheassociatedsavingsare wecreatetailoredprogrammestoboostaccesstoour alsotakenintoaccountadditionallyweconsider productsplusresearchanddevelopmentrd localreimbursementmodelspopulationsizeand modelsforthediscoveryofnewproductsforthese prevalenceofthediseaseandlevelofunmetneed regionswearecommittedtofindingsustainable rochearengcorporate responsibility partindd roche business report corporate responsibility andimpactfulwaystomakealongtermdifferenceto healthcaretheillustrationshowssomeofourpro grammestoincreaseaccesstohealthcareandthere arefurtherdetailsonourwebsite new drug leads selected access need theworldhealth oneworld health investigate organizationwholistsmanyofourdrugsas potential new treatments childhood diarrhoea essentialmedicinestheseandourotherproducts areavailablethroughdoctorshospitalslaborato riesandpharmaciesinovercountriesmainly inthosewithestablishedhealthcaresystems howeveraroundathirdoftheworldspopulation doesnothaveadequateaccesstohealthcare patients received free medicines genentech access care foundation poorercountriessufferthehighestlevelsofdisease andhavetheweakesthealthcaresystemsmanyface acriticalshortageofhealthcareprofessionalsand facilitiesaswellaslowlevelsofunderstandingofthe causespreventionandtreatmentofdiseasewe aimtoprovidesustainableaccesstohealthcarein infants tested hiv thesecountriesbasedon amplicare initiative sustainablepatentandpricingpolicies partnershipswithgovernmentsngosandothers educationtrainingandknowledgetransfer rdintodiseaseswithunmetmedicalneeds wehavenotfiledorenforcedpatentsforanyofour medicinesintheleastdevelopedcountriesldcs definedbytheunitednationssincein employees participated annual childrens weexpandedthispolicytoincludethelowincome walk support care centres provide educational countrieslicsdefinedbytheworldbankcover opportunities aids orphans malawi well local community activities inganothersixcountriesinadditionwedonotfile orenforcepatentsforanyantiretroviralhivmedi cinesinsubsaharanafricanssacountries wesupplytwohivmedicinesatnoprofitpricesin theldcsandssaandweprovidethesemedicines developsnewmarketsforourproductsandservices atreducedpricesinlowermiddleincomecountries inthelongerterm valcyteourmedicineforaidsrelatedcytomegalo virusretinitisisavailableatreducedpricesforngo inwejoinedforceswiththeinternational ledaidstreatmentprogrammesintheldcslics atomicenergyagencyiaeatolauncheducare ssaandlowermiddleincomecountries amajornewprogrammetoimprovecancercare inafricacancerkillsmorepeopleeachyearindevel wefocusondevelopingpartnershipswithgovern opingcountriesthanaidsmalariaandtuberculo mentsandngosinthesecountriesouraimisto siscombinedyetthereisverylittleoncologyinvest establishprogrammesthatraiseawarenesstrain menttheprogrammeisestablishinganonline healthcareprovidersandimproveinfrastructurethis universityofferingcomprehensivetraininginseveral approachincreasesthecapabilitiesofhealthcare areasofcancermanagementandanetworkfor systemssotheycanstarttosustainablymeetpatient doctorstoshareknowledgeandexperiencewiththeir needsthisincreasesaccesstohealthcareand peersrocheisprovidingfinancialsupportcon rochearengcorporate responsibility partindd corporate responsibility roche business report treatment courses antiinfluenza medicine tamiflu donated countries need two sublicensing agreements reached tamiflu reserves programme established developing countries months employees go secondment contribute skills expertise help make difference health services ldcs countries roche file enforce patents hivinfected patients medicines eligible noprofit reducedprice roche medicines pilot countries selected online university courses oncology educare initiative ssa partnership iaea aids technology agreements reached companies ldcs ssa onsite technical help people reached year manufacture generic versions rural south africa roches hiv medicine saquinavir phelophepa healthcare train employees participated annual childrens children supported ssa monitoring orphaned children given primary healthcare walk support care centres provide educational diabetes partnership plus services assistance opportunities aids orphans malawi well novo nordisks changing diabetes act support unicef ecpp local community activities children programme aids orphan programmes sultationandexpertiseinweidentifiedsuitable patientsandtheirfamiliesinwetookpartin sitesforpilotprogrammesinghanazambiatan workshopsforhealthcareworkersincameroon zaniaandugandawherewewillbegintrainingpro andugandaandparticipatedinthediabetesleader grammesin shipforumafricamorethanparticipants fromsubsaharanafricancountriesattendedthis wealsohaveanumberofprogrammesforincreasing eventtodiscusstheappropriateresponsetothe accesstodiagnostictestsweareapartnerinnovo increasingburdenofdiabetesandothernoncommu nordiskschangingdiabetesinchildrenprogramme nicablediseasesinafrica alongwiththeworlddiabetesfoundationandsev eralafricangovernmentsmorethanchildrenin anumberofourpartnershipsimproveresearchinto africawereenrolledintheprogrammebytheend neglecteddiseasesofthedevelopingworldfor oftheyreceivededucationindiabetescareand exampleinwelaunchedaresearchfellowship accesstoinsulinanddiabetessuppliesprovided togetherwiththewhosprogrammeforresearch byrochewealsohelptotrainhealthcareworkers andtrainingintotropicaldiseasestdrthegates rochearengcorporate responsibility partindd roche business report corporate responsibility foundationandtheinternationalfederationofphar maceuticalmanufacturersandassociationsifpma boosting cancer care morocco thisfellowshipgivesresearchersfromdeveloping countriesfirsthandexperienceofstateoftheart morocco partnership lalla salma processesandtechniquestohelpimprovetheir association cancer alsc helped researchandclinicaldevelopmentexpertise increase cancer awareness access treat ment led launch first national rocherankedsixthintheaccesstomedicines cancer plan indexanindependentrankingofresearch plan includes construction new cancer focusedpharmaceuticalcompaniesbasedon centres expanded screening programmes indicatorswearepleasedwiththisscorepartic education awareness initiatives ularlyastheindexfocusedondiseasesoutsideour also partner alsc provide access areasofspecialtyandsodidnottakeintoaccount cancer treatments eight million moroccans oureducarecancerinitiativeordiagnosticsaccess living poverty line otherwise fall programmes outside healthcare system alsc buys drugs much reduced price roche donates access emerging markets improvinghealth money received help strengthen healthcare carestandardsinmiddleincomecountriespresent infrastructure country cancer asubstantialmarketopportunityforrochethe patients received free treatment result marketresearchagencyimsestimatesthatby partnership efforts paying dividends thevalueofemergingmarketswillequalroughly market cancer treatments ofusmarketvalueandexceedthatofwestern quadrupled last five years europeouremergingmarketsstrategyfocuses special ceremony november roche onspeedingupregulatoryapprovalsandsupporting accepted international award princess marketdevelopmentprimarilyinmajoremerging lalla salma efforts economiessuchasbrazilchinaindiaandrussia everycountryshealthcaresystemisatadifferent stageofdevelopmentandhasdifferentneedswe workwithgovernmentsineachcountrytohelp suchascancerhepatitiscandrheumatoidarthritis establishappropriatepoliciesprocessesandpro inwenegotiatedcommercialaccesspro grammessuchasdiseaseawarenesslocalclin grammesinmiddleincomecountriesforourhepatitis icaltrialsandtrainingforhealthcareprofessionals drugpegasysaswellasforourcancerdrugs avastinherceptinmabtheraandtarceva wealsodevelopspecificpricingprogrammesfor individualemergingmarketswheremanypatients forexampleindiahasahighhepatitiscinfection cannotaffordlongtermtreatmentfordiseases ratecoupledwithlowlevelsofdiagnosisandlimited impact hiv access programmes hivinfected patients hivinfected patients living living countries eligible countries eligible noprofit medicines reducedprice medicines rochearengcorporate responsibility partindd corporate responsibility roche business report accesstotreatmentcounterfeitmedicinespresent trialsincountrieswherewedonotplantomarketthe furtherchallengesourpharmaceuticalsanddiag medicinebeingtestedweincorporatetheinter nosticsdivisionshavesetupscreeningcampsblood nationalconferenceonharmonisationichgood banksanddialysisclinicstohelpovercomethese clinicalpracticegcpguidelinesintoourclinical problemswehavealsoengagedsupplychainsecu trialprogrammesandtrainmonitorandauditall rityexpertskezzlertoprovideencryptionsoftware thoseinvolvedtoensurecomplianceinwe thatenablesconsumerstoverifythattheirmedicine revisedtheinformationweprovidetopatientstaking isgenuinewhentheybuyitusingtheirmobilephone partinrochetrialswithhelpfromtheeuropean costassistanceprogrammesareavailableinindia geneticalliancesnetworkegantomakeit basedontherecommendationofthetreatingdoctor clearerandeasiertounderstand asaresultofthesecombinedeffortsthenumber ofpatientsreceivingpegasysandourcancerdrugs clinical trials hasdramaticallyincreased access developed world evenincountries number clinical trials withadvancedhealthcaresystemsmanypeople number healthcare cannotaffordtreatmentortheinsurancetopayfor centres involved itintheunitedstatesgenentechhelpspatients number patients toaccessourmedicinesregardlessoftheirability phase iiv clinical trials topay roche genentech genentechaccesssolutionshelpsinsuredpatients navigatethecomplexitiesofhealthinsurance peoplecansearchforclinicaltrialstotakepartin coveragebyexplainingwhattheirpolicycoversand orlearnfromtheresultsofcompletedtrialsat whattheyneedtopayforandbyhelpingthem wwwrochetrialscomasofdecember findpaymentsupportprogrammeswherepossible thewebsitecontaineddetailsofprotocols inweassistedmorethanpeople andtrialresultsthesestudiescovermorethan conditionsincludingalzheimersdisease thegenentechaccesstocarefoundationgatcf asthmaaroundcancerscardiovasculardisease providesfreemedicinestouninsuredandunderin depressiondiabeteshepatitishivaidsinfluenza suredpatientswhomeetcertainfinancialandmedi andobesitythewebsitehadvisitorsin calcriteriaingatcfprovidedfreemedicines detailsofourclinicaltrialsarealsoavailable tomorethanpatients throughtheinternationalfederationofpharma ceuticalmanufacturersandassociationsifpma safe ethical clinical trials clinicaltrialsportalandtheusnationalinstitutes clinicaltrialsareessentialtodemonstratethatnew ofhealthsglobalregistry medicinesaresafeandeffectiveandthatdiagnostic testsprovideusefuldatatheyalsoprovideimpor westorebiologicalmaterialusedinclinicaltrials tantinformationaboutthecosteffectivenessof suchastissueorgansbloodandotherbodilyfluids atreatmentandhowthisimprovesqualityoflifein inhumanspecimenrepositoriesorbiobanks additiontrialsprovideparticipatinghospitalswith thismaterialisinvaluableforlearningmoreabout educationalfinancialandmedicalsupportandgive diseasesandexploringpossibletreatments patientsaccesstothelatesttherapiespatients theyalsocontainsensitiveinformationaboutthe receivefreetreatmentduringthetrialanduntilthe personprovidingthesamplewearededicated drugisavailablethroughthehealthcaresystemif toprotectingdonorsprivacyandensuringtheyare noapprovedalternativeexists fullyinformedabouthowtheirsampleanddata willbeusedbeforetheyagreetotakepartinatrial wehavestrictpoliciesandprocessestoensurethe weapplyequallystrictmeasurestoallpersonaldata safetywellbeingandlegalrightsofpeopletaking aboutcustomerssuppliersandemployeesinline partinclinicaltrialsinadditionwedonotperform withourdirectiveontheprotectionofpersonaldata rochearengcorporate responsibility partindd handle disease area oncology indication firstline metastatic colorectal cancer trial avex avastin elderly xeloda mo patients fully recruited study sites countries daisy st michaels hospital oncology clinical research group toronto rochearengcorporate responsibility partindd jane senior international clinical trial manager roche basel rochearengcorporate responsibility partindd phase iv clinical trials avastin advanced colorectal cancer creating value patients means postapproval trials effective medicine benefit even wider population increasing number patients benefit avastin ml tml ml cairo ml aio duration treatment ml nordicact mo dream ml tribe new chemotherapy combinations avastin mo avex mo olivia special populations first results number expected patients trial nearly million patients treated avastin since first launched breakthrough cancer medicine developed extensive clinical trial programme cancer treatment constantly evolving oncologists try new drug combinations phase iv clinical trials conducted medicine entered market generate valuable new insights even drug thoroughly studied avastin phase iv trials provide important additional information safety efficacy reallife setting routine oncology practice use avastin special populations elderly many phase iv trials evalu ating avastin patients metastatic colorectal cancer designed determine optimal duration treatment others investigating new combinations avastin medicines rochearengcorporate responsibility partindd corporate responsibility roche business report organ transplantation inanngoraised weinvestigateallreportedsideeffectstofindout concernsthatorgansusedintworocheclinicaltrials whetherourproductcausedthemifthereisalink inchinamayhavebeenharvestedwithoutconsent wereevaluatewhetherthebenefitsofthemedicine andpossiblyfromexecutedprisonersthetrialsinto orteststilloutweightheriskswealsohaveproce theuseoftheimmunosuppressantcellceptin duresinplacetopromptlyinformpatientsphysicians organtransplantsinvolvepatientsataccred healthcareprovidersandregulatorsofanynewprod itedtransplantcentresandarebeingcarriedout uctsafetyinformationweupdateproductlabelling toestablishwhetherthestandardcellceptdosewill andinformationwithnewsafetyinformationas safelyandeffectivelypreventorganrejectionin requiredandwhennecessarywritetohealthcare peopleofchineseorigin providerswithupdatedadviceontheuseofour products forclinicaltrialsinchinawefollowthesamescien tificmedicalandethicalstandardsasinallother wehaveastrictproductrecallprocesstoensurewe countrieswesupportaworldwidebanonanyuseof canwithdrawproductsrapidlyontherareoccasions organsfromexecutedprisonersaswellasonthe thatqualityproblemsdoariseintherewereno deathpenaltyhoweverasinmanycountrieschi recallsinvolvingthepublic neselegislationpreventspharmaceuticalcompanies fromdeterminingtheoriginoftransplantorgans patient advocacy transparencyisessentialwhenpharmaceuticalcom wewillcompletethetwotrialsbuthavenoplansto paniespartnerwithpatientadvocateswedeclare carryoutfurthertransplantationtrialsinchinaat ourpatientgrouppartnershipsonourwebsitealong thisstageanyfuturetrialswillcontinuetoadhereto withashortdescriptionofthepartnershipsactivi thedeclarationofistanbulonorgantraffickingand tieswealsodeclaresignificantormeaningfulnon transplanttourismandthewhoguidingprinciples financialsupportasguidedbytheeuropeanfed onhumancelltissueandorgantransplantation erationofpharmaceuticalindustriesandassociations efpiaourpositionstatementandguidelinesfor wecontributedtochangesinchineselegislationin workingwithpatientgroupsdescribeourapproach asaresultofthesechangesthenumberof andareavailableonourwebsite transplantsfromlivingdonorshasincreasedefforts tointroduceasystemforpeopleinchinatosign theirconsenttodonateanorganarealsohavinga patient groups important positiveeffectwestronglybelievethatorgando nationbyfreelyconsentingdonorsisthemosteffec partners roche give us tivewaytocontributetoanethicalandsustainable solutioninthisareaofmedicalpracticewewelcome insight challenges facing allsupportinthisareatoimprovethesituationfor patientsinneedoforgans patients families patient safety share interest helping anymedicinemaycausesideeffectsinsome patientsourpriorityistomakesurethebenefits patients understand outweightheriskswehaverobustprocessesin allcountriestomonitorhowpatientsreacttoour manage condition medicinesweregularlyanalysemedicinesagainst variousreferencedatabasestohelpusspotpoten tialsafetyrisksallproductsinclinicaldevelopment haveasafetymanagementplanandallmarketed examplesofourpatientadvocacyininclude medicineshaveariskmanagementplanreviewed runningworkshopsinfrankfurtgermanyandbrus andapprovedbymajorhealthauthorities selsbelgiumtohelppatientgroupsimprovethe supporttheyprovidepeoplelivingwithdiseasein rochearengcorporate responsibility partindd roche business report corporate responsibility francetherochefoundationorganisedachronic chugaialsosupportseffortstoraisediseaseaware diseasemeetinginmaythiseventwhichwill nessinjunethecompanyheldaneventto nowbeheldannuallybroughttogetheralmost promotetheimportanceofearlydetectionandtreat patientspatientrepresentativesandhealthcare mentofrheumatoidarthritiswhichaffectsaround professionalstodiscusswaystoimprovequalityof peopleinjapanawarenessdaysineight lifeforpatientswithchronicdiseasethefoundation japanesecitiesbroughtattentiontotheimpor alsolaunchedanewpatienttestimonywebsite tanceofdetectingcoloncancerearlyforthesecond wwwlavoixdespatientsfrwhichpublishespatient yearrunningthecampaignusedagiantinflatable experiencesandsharesthemthroughlinksto colonwithinformationpostedonthewallsforvisitors socialnetworkssuchasfacebookandtwitter towalkthroughandlearnhowtohelpprevent coloncancerduringdailylifeindecemberchugai patient education awareness sponsoredaneventrunbythecancercharity ourresponsibilitiesdonotstoponcewehavesup medicineandhumourwhichhelpspatientsand pliedaproductwealsohelphealthcareprofessionals theirfamiliestomanagethedisease andpatientstofullyunderstandtheirdiseaseand treatmentoptionshowtouseourproductscorrectly web andanyotherservicesavailableforimprovingout personalised healthcare wwwrochecomphcinrd comes roche position statements phc access medicines diagnostics pricing neglected diseases working patient groups examplesincludetheaccuchekconnectwebsite wwwrochecompoliciesguidelinesandpositions andcoachingprogrammeswhichhelpdiabetic access medicines report wwwrochecom patientstolinktheirbehaviourtotheirconditionwe accesstohealthcare programmes ldcs wwwrochecom alsoprovidesupportservicesforourcancermedi programmesinleastdevelopedanddevelopedcountries cinesincludingcallsfromtrainedoncologynursesto programmes developed countries helppatientsmanagetheirtherapytreatmentdiaries wwwgenentechaccesssolutionscom roche trials patient safety wwwrochetrialscom torecordandlearnfromtheirexperiencespatient wwwrochecomclinicaltrials treatmentcalendarsandappointmentreminders wwwrochecommanagingmedicationsafety list patient groups supported ourbagofhopeprogrammepartnerswiththe wwwrochecompatientgroups accuchek connect wwwaccuchekconnectcom juvenilediabetesresearchfoundationjdrfto international federation pharmaceutical manufacturers distributebagscontaininginformationanddia associations ifpma clinical trials portal betessuppliestonewlydiagnosedtypediabetics wwwifpmaorgclinicaltrials todatethisprojecthashelpednearly us national institutes healths global registry wwwclinicaltrialsgov patientstoadjusttolifewiththeirconditionin rochereceivedjdrfschancellorsawardfor thiswork inadditionwehelphealthcareprofessionalsand patientgroupstoproducenewslettersandmagazines informationpacksguidesforfriendsfamilyand caregiverswealsosupplyneedleboxescounselling hotlinesandeducationprogrammesforexample wehavepartneredwiththeeuropeangeneticsalli ancesnetworktoproduceaseriesofsimpleleaflets inseverallanguageswhichanswerpatientsques tionsontopicssuchasclinicaltrialsandbiobanks theseareavailableatwwwbiomedinvoallcom inweaddedleafletsonpersonalisedhealth careandthesocialandpsychologicalaspects ofdiagnostictesting rochearengcorporate responsibility partindd corporate responsibility roche business report people ourpursuitofexcellenceinscienceprovidesdirec aschangingdemographicsandtalentshortagescon tionandpurposeduringchallengingeconomictimes tinuetoimpactthelabourmarketcompetitionfor morethaneverwerelyonourpeopletodevelop highlyskilledandexperiencedemployeesremainsan anddeliverinnovativeproductstopatientsandthere ongoingchallengeweareconstantlysteppingup bycontributetothefutureofhealthcare ourpracticestosourceandattractthebesttalentin thehealthcareindustry itisthecommitmentofouremployeesand theirdemonstrationofourvaluesofintegritycourage personalandprofessionaldevelopmentisveryimpor andpassionthatmakearealdifferenceinthelives tanttoouremployeesandapriorityinaninnovation ofpatients drivencompanylikeoursthisremainsthecasedur ingthesignificantorganisationalchangescurrently asacompanydedicatedtoinnovationandscience underwaywestriveforourpeopletoreachtheirfull ahighlyskilledpassionateandmotivatedworkforce potentialandsupportthemateverystage isatthecoreofwhoweareandwhatwedowe wanttobeatrulygreatplacetoworkfortodaysmost webelieveinrewardingachievementandcommit talentedpeoplebygivingthemthechancetomake mentwithfairandattractivecompensationthis theirmarkprovidinganenvironmentwheretheycan approachcontributessignificantlytoattractingreward growandrecognisingthemfortheirachievements ingrecognisingandretainingtherightpeople selected external awards recognitions top rankings rank award roche site science magazines top employer survey genentech universum swiss professional survey roche basel healthmedicine sector crf institute roche germany top employer engineers crf institute roche switzerland top employer switzerland san francisco business times genentech best places work bay area fast company magazines genentech worlds innovative companies san diegos best places work genentech great places work denmark roche denmark best pharma companybest multinational company best medical company science magazine top employers survey roche basel fortunes best companies work genentech large companies great places work austria roche vienna best employers employees great places work spain roche madrid best workplaces jra best workplaces new zealand roche auckland small medium sized business category great places work urugay roche urugay st place amongst pharmaceutical companies rochearengcorporate responsibility partindd roche business report corporate responsibility peoplefromdiversebackgroundsbringarange hasbeennamedbestemployerinthehealthcare ofperspectivestotheirworkhelpingtodriveinno industrybysciencemagazineforeightofthelastnine vationthisiswhywevaluetheexperienceofall yearsandinrocherosefromthtothplace employeesandfosteraninclusiveworkingenviron inthesamesurveysurveyparticipantsgaveboth mentinwhicheveryonefeelsrespectedregardless companieshighratingsforbeinginnovativeleaders ofagebackgroundorgenderwheretheycan inthehealthcareindustryandfordoingimportant developtheircareersandseethepositiveimpact highqualityresearchactivitiesinthefieldofsocial oftheirwork responsibilitywerealsoratedhighlyandcontrib utedtothepositiveresultsrochewasalsorecog thewayweimplementtheorganisationalchanges nisedinrankingsbyuniversumtopemployerand takingplaceaspartofourrecentlyannounced thegreatplacetoworkinstitute operationalexcellenceprogrammewilltestourcom mitmenttoremainingagreatplacetowork championing diversity inrochesexecutivecommitteecommittedto great place work increasingthepercentageoffemaleleadersinkey rochewasrecognisedasanattractiveemployerby positionsbybykeypositionsaredefined anumberofawardsinforexamplegenentech asthoserolesthatarecriticaltobusinessdelivery drivesignificantvalueandhavethegreatestbreadth anddepthofresponsibilitykeypositionsareclosely programmes ensure diversity workforce linkedtoorganisationalstructurewewilltherefore reviseourcurrentlistofaroundpositionsto reflecttherecentchangesthathavetakenplace global local leadership programmes todevelopinclusive giventhecommitmenttoincreasefemaleleaders leadershipbehavioursandfostera cultureofdiversity inkeypositionswehavereplacedourpreviously reportedwomeninseniorleadershipmetricbased onapproximatelypositionswiththeper sponsored employee affinity centageofwomeninkeypositionsthebaselinefor groups associations net thisnewmetricwaswomeninkeypositions works toprovidesupportexchange ofideasandsharelearnings indecemberwearealreadyseeingapositive impactfromthevariousactionstakentosupport womeninleadershipwithanincreaseofwomenin programmes improve keypositionstoindecember standing oftheneedsofemployees withdisabilitiesandtoincrease numberofhires gender diversity mobility programmes topromote women total internationaltransferofemployees acrosstheglobe workforce women management women top executives attraction sourcing pro cesses standards toensure women diversityofcandidatepools key positions na genderisonlyoneelementofourcommitmentto diversityandwedonottoleratediscriminationofany programmes focusing older employees whichvaluetheir formasstatedinourglobalemploymentpolicy expierienceandretainknowledge ourapproachistoembeddiversityinallourmain processesandobjectivesourhumanresources rochearengcorporate responsibility partindd corporate responsibility roche business report functionhasmeasuresandgoalsinallkeyprocesses applicationsforspecificjobsandregistered relatingtorecruitingdevelopingpromotingand newcandidatestotherochegrouptalent recognisingemployeestosupportadiversework pooladatabaseofjobseekersinterestedin forceandinclusiveenvironmentinthecontextof becomingrocheemployees ourdiversitygoalwehaveextendedourrangeof programmesandinitiativestoencourageandsafe advertisingrolesinternallyalsooffersgreaterop guardemployeediversityandsupportanumberof portunitiesforrocheemployeesasbyjoiningthe employeeassociationsandnetworkstheseinclude rochetalentpooltheyarenotifiedbyemailas rochebaselsfamilyandcareersandwomenin soonaswepostapositionmatchingtheirprefer leadershipgroupsgenentechwomenprofession encesandskills alsgwpandgenentechoutequalgoe strengtheningtiesacrossgenerationsseniors weregularlyconductaglobalsurveytogaugethe stagesandafricanamericansinbiotechnology effectivenessofourrecruitmentservicesandtrain aaib ourrecruitersworldwideonthelatestmethodsand strategiesthroughouttheyearasmallgroupof fostering innovation ourrecruitmentspecialistsattendedbusinesscon innovationisthecoreofourbusinessandisdriven ferencesandeventsattopinternationalbusiness bydiverseapproachesideasandexperiencesour schoolstogiveprospectiveemployeesthechanceto talentmanagementprocessesarealldesignedto learnmoreaboutourcompanyandforustoadd recogniseanddriveinnovationinadditionwecon targetedtalenttoourpipelineforthefuturethese ductabroadarrayofspecificandlocalisedactivi andmanyotherinitiativescombinedwiththework tiesourpharmaresearchandearlydevelopment ofourprofessionalrecruitmentteamsaroundthe researchorganisationintroducedascientificcareer globeensureourpoolofdiverseandtalentedcandi ladderinandsponsoredamajorrecognition datescontinuestogrow programmetheleosternbachawardsforinnovation inchemistrythisyeartheawardrecognised inrochescoredamongstthetopcompanies dr bradgravesandhisteamfornewclassesofcom ontalentattractionandretentioninthedowjones poundsintheareaofcancertreatmentresearch sustainabilityindexes organisationsatbothrocheandgenentechpartici pateininternalandexternalscienceconferences thetalentselectionsurveyshowsapointin andwritepublicationsinprestigejournalsin creaseinthepercentageofrocherecruitment rochepublishedmorethansientificarticles managerswhobelievetheirnewhireperformswell ofwhichnearlywereinhighimpactjournalssuch comparedwiththeirpeersthisplacesusabove asnaturecellscienceandthenew england jour thebenchmarkinthisexternalsurveyofovermul nal medicineourpostdocfellowshipprogramme tinationalcorporationsandsuggeststhatweare awardsgrantstoourbestscientistsenablingthem successfullyattractingtoptalent toconductexploratoryresearchandstrengthening ourrdtalentpipelineseveralgenentechscien developing employees inweenhancedour tistsreceivedprestigiousexternalscienceawardsin supportforemployeestodevelopfunctionalprofes amongthemdrrichardschellerwhoreceived sionalandleadershipskillsthisyearofour thekavliprizeinneuroscienceanddrnapoleone employeestookpartincareerdevelopmentplanning ferrarawhowonthelaskerdebakeyclinicalmedi discussionsinadditionweworkwithemployees calresearchaward individuallytoguidetheirdevelopmentaccordingto theirneedsinterestsandspecialitiesconsistent attracting employees toattracttalentwe globaltrainingmaterialsnowreflectourdevelopment continuetoleverageourstronganddifferentiating philosophywhichisbasedonemployeeengage employerbrandthroughcareerswebsitesin mentindividualgrowthandorganisationalsuccess countriesthesesiteshadapproximatelymillion visitorsininadditionthegenentechcareer websitehadmillionvisitswereceived excluding genentech ventana chugai rochearengcorporate responsibility partindd roche business report corporate responsibility ourleadershipdevelopmentprogrammesinstilwhat leadership pipeline itmeanstobealeaderatrocheandequipmanagers toliveuptotheseexpectationstoincreasethecon sistencyoftheseprogrammesworldwideinwe number highpotential leaders createdaglobalframeworkforleadershipdevelop percentage women menttobeimplementedinphasesbythiseffort highpotential leaders willbesupportedbythecontinuingrolloutofaglob percentage women allearningmanagementsystemandwillprovide leadership programmes easieraccesstolearninganddevelopmentsupport internal staffing rate key positions top ourbusinessisbecomingincreasinglyglobaland thisyearweintroducedapartnershipwithglobal wecompletedoursuiteofgloballeadershippro englishaservicethatprovidesonlinebusinesseng grammeswiththeintroductionofamoduleforglobal lishtrainingtheondemandservicegivesemployees employeeswithhighpotentialinthelongerterm accesstofastcosteffectiveandintensivelanguage globalprogrammesarenowavailableforhighpoten coursestodateoveremployeesfromcoun tialleadersatallcareerstageswehavealso trieshaveusedtheservice enhancedoursuiteofprogrammesbyupdatingcon tenttofocusoninclusivebehaviourandcultural ourdiagnosticsandeuropeanpharmaceuticalsaffili awarenessaswellastobuildgreatercollaboration atesofferednearlycoursesinthrough andunderstandingacrossdivisionsregionsand ourcommontrainingmodelwhetheronlineorclass functionsfinallywehaveimprovedthewaywe roombasedtrainingsessionswithalmost selectparticipantssetlearninggoalsandmeasure employeestakingpart theeffectivenessoftheprogrammes learning development ourleadershipdevelopmentprogrammeprovedsuc cessfulwhenseveraloutstandinginternalleaders steppedintocriticalrolesduringtheorganisational total training changesthattookplacethisyeartheinternalfill investment rateforallpositionsisandforthetop million chf executivepositions training spend per employee chf inthedowjonessustainabilityindexesrated total number rocheasthebestcompanyinthehealthcaresector training hours million forhumancapitaldevelopmentcontributingtoour average training hours positionashealthcaresupersectorleader per employee number postdocs international mobility weconsiderinternational students interns experiencetobeanimportantaspectinthepro fessionaldevelopmentoffutureleadersinwe excluding chugai sawamarkedincreaseinthenumberofnewinter nationalassignmentsfromintoin developing tomorrows leaders inwecon thiswaspartlyduetothegenentechintegra tinuedourprogressinidentifyinganddeveloping tionandresultingexchangeoftalentedemployees highpotentialleaderscapableoftakingoncritical betweencaliforniaandotherpartsoftheworldour seniorrolesintheshortmediumandlongterm expatriatesandcrossboundaryemployeesrep resentdifferentnationalitiesandarewomen movingabroadcanbestressfulsowetrytomake theexperienceassmoothaspossibleinapril welaunchedrevisedinternationalassignment rochearengcorporate responsibility partindd corporate responsibility roche business report policiesofferingadditionalflexibilitytoassignees duringandourgoalistorolloutourglob wenowalsoofferachildcareallowanceandin allyalignedcompensationstrategysupportedby creasedspousalsupportinadditionweintroduced thenewglobalperformancemanagementprinciples astandardhealthcareprogrammeforglobalassign thenewcommonapproachwillensureourcompany eeswhichhascomeintoeffectonjanuary remainscompetitiveandsustainableandcontinues thisprogrammeofferscompetitivehealthinsurance tocreatevalueforallstakeholdersbymaintaininga toassigneesandtheirfamiliesthroughaleading stronglinkbetweenperformanceandcompensation specialistprovider wewillpreserveemployeesopportunitytosharein oursuccess rewarding recognising employees performance management inofour benefits benefitsareanimportantpartofthe employeestookpartinperformancemanagement totalrewardpackageweofferouremployeesmost discussionswiththeirmanagerstoreachashared programmesaretailoredtolocalmarketsandregu understandingoftheirperformanceobjectivesand lationsbuttypicalexamplesincludefinancialsupport achievementsthroughtheyearanddeterminecom foremployeesandtheirdependentsuponretirement pensation andincaseofillnessdisabilityordeaththesebene fitsusuallysupplementlocalstatesystemswealso asthemobilityofouremployeesincreasesandmany offerwellnessprogrammesthatencourageahealthy leadersmanageorganisationsacrosscountrybor lifestyleandbenefitsthatsupportemployeeswork dersweareworkingtoalignourperformanceman lifebalanceoverofaffiliatesofferextensiveben agementprinciplesgloballyinandthe efitsplansmostgobeyondstateschemesand newcommonapproachwillputgreateremphasison includefreeaccesstoawiderangeofmedicalser anongoingdialoguebetweenemployeesandman vices agerswebelievethiscontinuoustwowayfeedback processwillcontributetotimelyinputaboutideas inweworkedtomakeaffiliatesbenefitpro forimprovementbetteremployeedevelopmentand grammesconsistentwithincountriesthiswillensure ultimatelymaximisescientificinnovationandbusi employeesaretreatedequallyandimproveefficien nessresults cybyconsolidatingvendorsintheunitedstates ourcombinedworkforceofemployeeswillall compensation ourtotalremunerationinvestment enjoythesameattractiveandcompetitivebenefit inamountedtoapproximatelybillionswiss programmesfromjanuaryintheunitedking francs domwehaveextendedourflexiblebenefitspro grammetocoverallpharmaceuticalsanddiagnostics ourbasepaypackagesrewardperformanceand employeesfromapril commitmentwhileourbonusschemesincentivise employeesforinnovationandoutstandingresults inadditionwehaveintroducedaglobalassistance thatsupportourstrategicobjectivesbonusesreflect programmetosupportemployeesandtheirfamilies bothindividualandteamachievementsaswellas whiletravellingabroadthiswillprovideaccess overallbusinessperformance tomedicalandsecurityinformationandemergency assistancefromjanuary wewantemployeestoshareinoursuccessthrough rocheconnectemployeesinmostcountriescan duringwecontinuedtocloselymonitorthe purchasenonvotingequitysecuritiesatadiscount statusofourmajorpensionfundsalongsidesome ofuptoinemployeesincoun cashinjectionsweinitiatedchangesinseveral triestookpartinthisprogrammethisrepresents localpensionplanssomeofourmajorpensionfunds approximatelyofeligibleemployeesandsecuri removedearlyretirementincentivesandhaveintro tiesworthmillionswissfrancswerepurchased ducedmoreflexibleretirementmodelsinanticipation inadditionallymanagersandemployees ofanageingworkforce receivednonvotingequitysecuritiesthroughthe rochelongtermplan rochearengcorporate responsibility partindd roche business report corporate responsibility aligning human resources processes web overthecourseofgenentechandournorth employees wwwrochecomemployees americanpharmaceuticaloperationswillbeincorpo group policies positions guidelines wwwrochecompoliciesguidelinesandpositions ratedintoourcommonhrinformationsolution global careers portal httpcareersrochecom chrischrisenablesgloballyalignedprocesses employment policy wwwrochecomemploymentpolicypdf thathavebeenadjustedtoreflectthebestprac core standards wwwrochecomcommitments ticesofbothgenentechandtherestoftheroche groupcurrentlychriscoversaffiliatesand representativeofficesandofrocheemployees human rights labour relations therocheemploymentpolicygovernshumanrights andlabourrelationsthechiefcomplianceofficer monitorsimplementationandcompliancewiththis policyandservesasacontactforallemployees werespecttherightofemployeestofreedomofas sociationandcollectivebargainingmorethan ofouremployeesaretradeunionmembersand overaremembersoforganisationsthatfreely representthemincountrieswherethisislegal therocheeuropeforumrepresentstheinterestsof almostemployeesincountries ourdirectiveontheprotectionofpersonaldata ensuresthatwesafeguardemployeeinformationand complywithrelevantlocallegislation adedicatedemployeerelationsofficermonitorsthe levelofemployeeengagementandensuresthat appropriateprogrammesandpoliciesareinplaceto ensurefairtransparentandrespectfultreatment ofemployeesincludingduringtheimplementation ofouroperationalexcellenceprogrammewe willmanagethisprogrammecarefullykeepingem ployeeswellinformedthroughoutsupporting themthroughthechangesandensuringthoseleav ingthecompanyaretreatedwithfairnessdignity andinasociallyresponsiblewayourlocallydefined severancepackagestypicallyincludearangeof measurestoreflectthedifferentneedsofthoseaf fectedmeasuresincludeseverancepaywith optionstoconverttotimeoutplacementservices counsellingcareersfairsandcentresretraining andredeploymentoptionsaswellasanincreased focusoninternalrecruitmentandopportunities rochearengcorporate responsibility partindd corporate responsibility roche business report key figures employees fte function employees rocheemployspeopleincountries servicing clusteredinfivemainregionsourworkforce manufacturing representsmorethannationalitieswith logistics ofemployeesworkinginrd marketing distribution research roche employees worldwide development fulltime equivalentsfte general administration total europe north america asia staffing rates latin america australia africa new hires total internal staffing rate external staffing rate employees fte operating divisions retaining employees instaffturnoverincreasedfromto pharma driveroftheincreaseisthefirstwaveofemployer chugai relatedterminationsaspartofoperationalexcel diagnostics lenceinaustralialatinamericaandnorthamerica total turnover including genentech restated reflect consolidation finance total employees contract types europe north america asia regular fte latin america fixed term fte australia full time headcount africa part time headcount regular temporary employees roche contract reasons leaving employeeinitiated employerinitiated neutral rochearengcorporate responsibility partindd roche business report corporate responsibility society ourresponsibilityextendsbeyondthehealthcare breakdown giving area productsweprovidetopatientsandthewellbeingof ouremployeeswearealsocommittedtosupporting thewelfareofcommunitiesinwhichweoperate humanitarian social projects ourdonationprogrammesseektogivebacktocom science munitiesinfourstrategicareashumanitarianand education socialprojectsscienceandeducationartsandcul arts culture tureandcommunityandenvironmentineach community areawesupportprogrammesthatmeetthecriteria environment definedbyourpolicyonphilanthropicdonations andnoncommercialsponsorshipaswellaspro grammesthatwebelievewillmakealasting launchingaprogrammeorcontributingtoacauseis tangibledifference onlythefirststepinrochessocialengagementwe carefullyconsiderwhatwewantourphilanthropyto rigorous approach achieveandcontinuallymonitorprogresstowards tocreaterealchangewehavedeveloped thedesiredimpactthereforewetracktheoutcomes atargetedstrategywhichhingesonfourcriteria ofourprojectsnotjusttheinitialinvestment innovativeappliescreativeandeffective solutionstosocietyschallenges sample philanthropic impacts sustainabledeliversenduringeffectsin patient orphaned children given adynamicresourceconstrainedworld community health primary healthcare malawi collaborativedrawsonthestrengthsand outreach courses community capacitiesofrespectivepartners health workers held south outcomedrivenprovidestangiblelongterm african villages benefitstothepeopleinvolved community rebuilding bore holes rehabilitated strengthening uganda wemakemostofourcontributionslocallysothat primary school classrooms eachbusinessunitcanbestaddresstheneedsofits built furnished malawi owncommunityourbusinessesconceiveand education students receive implementtheircommunityactivitiestoprovidethe enhancement secondary scholarships greatestpossibleimpactgiventhespecificchal opportunity receive postsecondary lengeandavailablecapabilities assistance malawi students enrolled week someissuescallforglobalinterventioninsuch international research casesweworkwithourinternationalnetwork exchange germany ofpartnerstosupportprojectsthatwillmeetsocie united states tysmostcriticalneedstheseprojectsdonotoften makeheadlinesbutneverthelesshelptoresolve humanitarian social projects fundamentalobstaclestogoodhealthsuchasalack improvingwellbeingisatthecoreofrochesphilos ofbasicmedicalsuppliesortrainedhealthcare ophyhumanitarianandsocialprojectsaccountfor professionalsbymobilisingourresourcesandexpe thelargestportionofourgivingandfocusonsup rienceacrossourfourstrategicareasweaimto portingthemostvulnerablemembersofsociety makeanotabledifference oftenchildren managing impact employeeparticipationinourprogrammesamplifies developingandmanagingourphilanthropicactivities theirimpactforexampleemployeesfrom requirescarefulcoordinationprinciplesandpriori morethanaffiliatesparticipatedinthe tiesaresetatthegrouplevelandimplementedlo annualchildrenswalktheygeneratedovermil callybybusinessunitsandpartners lionswissfrancsincludingmatchingfundsfrom rochearengcorporate responsibility partindd corporate responsibility roche business report thecompanythisyearofthismoneywillgoto rilythroughtheteachersrochehelpedtrain supportdaycarecentresinmalawithatprovide thisyearwealsoexpandedourroche genetics foodsheltereducationandskillstrainingtoaids educationprogrammeprovidingteachingmaterials orphanstheremainingwillsupportlocal forsecondaryteachersinthebaselregionwith charitiesthatsupportvulnerablechildrenselected fourlaboratoryworkshopsandtwotalkingscience byaffiliates workshopstheschoolbasedtrainingmodelraises understandingandinterestingenetics itisimportantthatemployeesseetheimpactoftheir effortseachyearnineofthemostsuccessfullocal arts culture childrenswalkfundraisersvisittheprogrammeswe innovationcomesinmanyformsweseeastrong supporttoreaffirmourcommitmentandwitness creativeconnectionbetweenscienceandtheartsin thedifferencewemakeinmalawitheythenreturn partnershipwiththelucernefestivalthecleveland homeandactasambassadorsforthewalkandits orchestraandcarnegiehallweregularlycommission objectives newworksfromcontemporarycomposersthis augustwewelcomedtheworldpremiereoftoshio accesstohealthcareshouldbeuniversalbutinmany hosokawasorchestralpiecewovendreamsand countriesthisisnotthecasewehaveanumber announcedoursixthcommissiontocomposersofia ofprogrammesthathelptobuildinfrastructurepro gubaidulinaweprovidefurthersupportforcrea videbasichealthcareortransferknowledgeand tivityandexpressionthroughmonthlyrochenjazz expertise eventswherewebringtogetherthelocalcommuni tywithworldclassmusicianstoexploremodern forexampletherochesponsoredphelophepa inventivemusicnowinitsfifthyearrochenjazz healthtraindelivershealthsuppliesandservicesto hasentertainedmorethanpeoplewithper poorandremotesouthafricancommunitiesin formancesbyensembles thetrainsthyearrocherefurbishedthe primaryhealthcoachimprovingventilationprivacy community environment anddisabledaccess webelievethatindividualwellbeingiscloselytied tohealthycommunitiesforexampleinkualalumpur science education rochehasestablishedacommunitybasedreha excellenceinscienceiscriticalforrocheweaimto bilitationprojectwithmalaysiasdepartmentofsocial inspirefuturegenerationsofscientistswhowill welfaretheprojectprovidesoccupationaltherapy drivethediscoveryofnewtreatmentsanddiagnostics forchildrenwithmentalphysicaldevelopmentalor fortodaysunmetmedicalneeds emotionalconditionsinruralcommunitiesthis helpsthechildrenimprovebasicmotorfunctionsand weprovideyoungscientistswithopportunitiesto reasoningabilitiesandthereforetoleadindepen expandtheirexperienceinthefieldthroughour dentandproductivelives internationalrochepostdocfellowshipprogramin webuiltuptheprogrammetopositions web withtwoyeargrantsexpandableuptofouryears roche social programmes wwwrochecomsociety basedonscientificmerittheseareforjointrd roche n jazz wwwrochenjazznet roche act wwwreactrochecom projectswithpartneruniversitiesincludingthefirst postdocsapprovedinchinaandjapanin additionalprogrammesareplanned scienceandhealthmattersofteninvolveethicalcon siderationsrochenutleysupportsthenewchoices newresponsibilitiesprogrammewhichintroduces middleandhighschoolstudentstobioethicsthe curriculumsupplementhasreachedapproximately studentssinceitsintroductioninprima rochearengcorporate responsibility partindd roche business report corporate responsibility responsible practices ourreputationisoneofourmostvaluableassets rocheweaskedlocalmanagerstoimplementa itisvitalthatallemployeescomplywithlawsregula comprehensiveanticorruptioncompliancepro tionsandinternalstandardstofulfilourcommit grammeandlaunchedaglobalrochemarketing menttoactwithintegritythisistheminimumour andsalescompliancequestionnairetofurther stakeholdersexpectforthesereasonswejudge promotetheimportanceofgoodbusinessconduct ourselvesnotonlyonourresultsbutalsoonhow wewillcontinuethesemeetingsthroughout weachievethem risk crisis management integrity compliance ourriskmanagementcharterdefinesourriskman therochegroupcodeofconductsetsclearex agementapproachandresponsibilitiesitisavailable pectationsforourpeopleitguidesemployeeson onourwebsitealongwithalistofriskstoourbusi correctbusinessbehaviourhowtoactwithintegrity nessweusestakeholderfeedbacktohelpidentify andhowtospeakupincaseofcompliancecon andassesssocialenvironmentalandethicalrisks cerns andopportunitiesandincludethemostsignificantin thegroupriskmanagementprocesswehavein weencourageemployeestospeaktotheirlineman troducedanewsystemtodetermineexposurefrom agerthelocalcomplianceofficerorthechief salesandmarketingrisksthatarenotyetfullymiti complianceofficertheycanalsoreportcompliance gated concernsanonymouslyusingthespeakuptelephone lineandwebservicelaunchedindecember thegroupandallsubsidiarieshaveestablishedcrisis speakupoperatesinlanguagesandcountries managementteamstoensureweactquicklyinan makingitavailabletoalmostemployees emergencytheseteamsregularlyrehearsedifferent betweendecemberanddecember crisisscenariosalertsandescalationprocedures reportsweremadeviathesystemroughly weareusingourexperienceofourpandemicpre halfweregeneralcommentsaboutrochesbusiness parednessplaninresponsetothehninfluenza whicharenotclassedasnoncompliancesthe pandemicintostrengthenourbusinessconti otherhalfrelatedtoallegedviolationsofthecodeof nuityproceduresglobally conductanalysisoftheissuesreportedshowsthat employeesareusingthespeakuplineresponsibly sustainable supply chain wespentaroundbillionswissfrancsinwith inmaterialbusinessethicsincidentswere rdpartiesonrawmaterialsactivepharmaceuti reportedintotalincludingsevencasesreported calingredientsandotherdirectspendplusindirect throughthespeakuplineafterinvestigatingeach spendlikecontractrdlicenceslaboratorysup incidentandtakingcorrectiveactionwherenec pliesequipmentconsultancymarketingservices essaryweterminatedemploymentcontractsas andothersensuringthatthecompaniessupply aresultofunethicalbehaviour ingtheseproductsandservicesactresponsiblyis anessentialpartofsustainableprocurement wecarriedoutvariousactivitiestostrengthen complianceinweupdatedouronlinetraining rocheisamemberofthepharmaceuticalsupply programmesonourcodeofconductandonanti chaininitiativepsciandendorsesthepsciprinci trustissuesbyclearlylistingtheoptionsavailablefor pleswhichsetstandardsforsuppliersintheareas reportingconcernsinwebeganrollingout ofethicslabourhealthandsafetytheenvironment amoreuserfriendlyonlinetrainingprogrammecalled andrelatedmanagementsystemsoursuppliercode rochebehaviourinbusinessrobibandseta ofconductintroducedinincorporatesthese targetforofemployeestocompleteitin principlesaswellasotherimportanttopicssuch asinnovationfinancialsecurityandsupplierdiversity weheldseveralmeetingsforlocalcomplianceoffi attheendofthemajorityofkeysuppliers cerstosharebestpracticeinwenowusethe hadprovidedtheirwrittencommitmenttothesupplier genentechstaglinecomplianceisgoodbusiness codewhichisnowincludedinnewsuppliercon tocommunicateaconsistentmessagethroughout tracts rochearengcorporate responsibility partindd corporate responsibility roche business report roche supplier assessment prioritisation direct spend indirect spend priority auditing contract manufacturers cros r laboratories improvement api manufacturers rd party waste management hazardouschemical manufacturers animals temp labour logistics services chemicalsbiotech raw materials construction marketing services primary packaging fleet services travel facility management informatics general admin services secondary packaging consulting services engineering services equipment inmayweintroducedonlinetrainingtoteach contractresearchcompaniestemporarylabour procurementstaffhowtoencouragesustainability agenciesmarketingagencieslogisticsproviders amongoursuppliersthetrainingisavailableonour andotherserviceprovidersthemajorityofsup intranetinchineseenglishgermanandspanish pliersmetourstandardswhilefindingsrequiring morethanemployeeshavetakenthecourseto actionrelatedmainlytolabourconditionshealth datesomeclassroomtrainingsessionswerealso andsafetywewillworkwithsupplierstocorrect heldourpharmaceuticaldivisionintroducedanew problemsfoundandprovidetrainingtoprevent procurementcodeofconducttoguideprocure futureissues mentmanagersinresponsiblesourcing aspartofourworkwiththepsciwehavebegunto wewillcontinuetoimplementboththesupplierand alignoursuppliersustainabilityauditprotocolwith procurementcodesofconductduringwealso thoseofothermembercompaniesthiswillpromote plantoworkwithselectedhighimpactsuppliersto transparencyandenableustoshareauditfindings measureandreducetheirenvironmentalfootprints reducingbureaucracyandduplicationofeffortwe followingapilotprojectwithalogisticssupplier havesuccessfullypilotedthealignedauditproto colwithtwosupplierssofar wemonitorcompliancewithoursustainabilityre quirementsatcriticalsuppliersusinginternaland responsible research externalauditswetakeariskbasedapproach ourbusinessmodelreliesonscientificexcellenceand toprioritisethecompaniestoauditwhichfactors adetailedunderstandingofthemechanismsof inrisklevelsbyindustryaswellasprevioussus diseasesowecantranslatescientificbreakthroughs tainabilityperformance intoinnovativemedicinesanddiagnosticsthatmake adifferencehoweverethicalquestionsinevitably inweconductedauditsinthedirectspend ariseasweexplorethepotentialofcuttingedgetech areaegapichemicalsandbiologicalssuppliers nologieswecarefullyconsiderandmanageany contractmanufacturersforthefirsttimewebegan concernstomakesurewemaintainourintegritywhile auditsofcriticalserviceprovidersweaudited makingsurethatnoopportunitiesarelost ksir roche supplier code conduct demands high ethical standards suppliers demands high standards social responsibility safety health environment management systems also demands cooperation suppliers additional important topics innovation economic sustainability supplier diversity rochearengcorporate responsibility partindd roche business report corporate responsibility ethics r wehaveclearpoliciesandpro weprovideregularonlineethicstrainingforem ceduresinplacetopreservehighethicalstandards ployeesandinaprillaunchedanewonline inourresearchanddevelopmentr dactivities modulebasedoncasestudies ourpositiononclinicalresearchdefinesthesestan dardsandclarifiesourviewsonspecificareasof animal welfare wetakepublicconcernaboutani concern malresearchveryseriouslywepromotetheuseof alternativemethodsandworkhardtoidentifyoptions employeeswhoencounteranethicaldilemmain otherthantheuseofanimalshoweveranimaltest theirworkandcannotresolvethiswiththeirimmedi ingremainsindispensabletobiomedicalresearchfor atecolleaguescancontactourglobalethicsliai scientificandlegalreasonsregulatoryauthorities sonofficeinthisofficereceivedandresolved requireallhealthcarecompaniestotestthesafetyand querieswithouttheneedforescalationthe efficacyofnewdrugsinanimalsbeforetheycanbe vastmajorityrelatedtoinformedconsentandtheuse usedinhumans ofsamplesfrombiobankstheglobalethicsliaison officeconsultsexpertswithinandoutsidethecom inweusedanimalsinourresearch panytobrokerasolutionasneeded aslightincreaseonforthefirsttimewealso reportthenumberofanimalsusedbycontractors inwemergedourexternalscienceandethics carryingoutresearchonourbehalfaround advisorygroupseagwiththeclinicalresearch ofallanimalsweremiceandrats ethicsadvisorygroupcreagtoformoneindepen dentbodythatadvisesusonethicalissuesinour wefollowandpromotethersapproachtoanimal rdactivitiesthenewseagcomprisesexternal researchthismeanswereplaceanimaltestswhere expertsinethicslawandsocialscienceaswellas possiblereducethenumberofanimalsusedand patientadvocatesitwillcontinuetoprovideadvice refinetestsandanimalwelfarestandardsallem asrequiredandmeetformallyonceayear ployeesandcontractorswhoperformanimalresearch forusarerequiredtomeetorexceedapplicablelaws andindustrystandards key activities access employee diversity philanthropy suppliers healthcare engagement increasepercentage systematicallycollect continueimplementation expandsuccessful achievepositiveratings ofwomeninkeypositions andreportoutcomesof ofboththeprocurement accessprogrammesin inemployeeengagement increasefrom affiliatephilanthropic andsuppliercodeof developingcountries surveyspositive activitiesandcorporate conduct toothercountries ratingsbyend signatureprogrammes rochearengcorporate responsibility partindd corporate responsibility roche business report weuseincentivestrainingandcommunicationsto withanimalsthecommitteecoversrocheresearch promotetherstheseincludetherochers facilitiesineuropeandtheusaandwillincludeour awardforemployeesgloballywhichnexttakesplace shanghaisiteandchugaifrom inthisyearwebeganworkonarsdatabase forsharinggoodpracticesthroughoutthegroup innovation new technologies breakthroughs whichwillbelaunchedin insciencecreateopportunitiesfornewdrugdis coverydevelopmentanddeliveryforexamplestem rochewasoneofthefoundersofthenewswiss cellsandtheirapplicationsoffertremendouspoten charteronanimalwelfareadoptedinbyinter tialforrelievingchronicpainandevencuringserious pharmatheassociationofresearchbasedphar conditionssuchasarthritisdiabetesandparkinsons maceuticalcompaniesinswitzerlandthecharter diseaseinparticularthediscoveryofinducedplurip commitsustoconsistentlyhighstandardsofani otentstemcellsderivedfromadultcellsprovidesan malwelfarethroughaprogrammeofauditingem alternativetoembryonicstemcellsopeningupaddi ployeetrainingstakeholderdialoguepromotion tionalopportunitiesinthispromisingfield ofthersandmanagementofexternalcontractors wewillreportourprogressinimplementingthe weareinvolvedinstemcellresearchpartnerships charter includingtheinstituteforstemcelltherapyandex plorationofmonogenicdiseasesisteminfrance ouranimalwelfareethicscommitteebecamefully andthemassachusettsgeneralhospitalandharvard operationalandmetfourtimesinthecommit universityintheunitedstatesinweestab teehasdevelopedrecommendationsfortheuse lishedstemcellsforresearchscrinbaseland ofcontractorsforanimalresearchandwillexamine nutleytodevelopourexpertiseinthisareathis allnewstudiesusingnonhumanprimatesnhps groupfocusesondrugdiscoverypreclinicalsafety particularlythosecarriedoutbycontractorsthe testinganddiseasemodelling committeehascreatedaquestionnairetohelpre searcherssubmitnhpstudiesforexaminationitalso wearecommittedtoresponsibleandtransparent advisesemployeesonbestpracticeswhenworking stemcellresearchwehavethereforeestablished customer relation responsible cr reporting green energy efficiency ship management marketing evaluateandimplement promotebestpracticesof reduceenergycon provideaddedvalue applythenewsales improveditsystems useofvirtualittoreduce sumptionandimprove throughcustomersatis marketingcompliance forreportingonkeycon energyconsumptionand energyefficiency factionassessments questionnairegroupwide tributionstohealthcare solutionstoreducetravel reductionfrom tomeetorexceed institutionspatientorgani andenableexpanded customerexpectations sationsandindividual communication hcps rochearengcorporate responsibility partindd roche business report corporate responsibility animals used research roche contract responsible marketing research organisations strictregulationsandindustryguidelinesgovern thesaleandmarketingofmedicinesanddiagnostics tomakesuretheyareprescribedadministered mice rats andusedcorrectlyandthatpatientsunderstandthe rodents benefitsandrisksoftakingthem rabbits dogs howeverregulationsvaryfromcountrytocountry primates evenwithineuropeinrocheandothercorpo fish frogs ratemembersoftheeuropeanfederationofphar maceuticalindustryassociationsefpiadeveloped aleadershipstatementwhichprovidesguidance infivesensitiveareastheserelatetopatientinfor bindingprinciplesforstemcellresearchinconsul mationtrainingformedicalsalesrepresentatives tationwithinternalandexternalstakeholderswhich theprovisionofmedicalsamplestohealthcarepro wewillpublishin fessionalsorganisingmeetingsforhealthcare professionalsandrelationshipswithpatientorgani inpartnershipwithbiopharmaceuticalcompany sationsrochehasfullycommittedtofollowing halozymeweareexploringanewmethodofdrug thisguidanceinadditionourchiefcomplianceoffi deliverythatcouldmakeitpossibletogivebiological cerjoinedefpiasnewtrustreputationandcom medicinessuchasherceptinandmabthera pliancepolicycommittee rituxanbysubcutaneousinjectionratherthanintra venouslyhalozymesenhanzetechnologyallows rochemanagersareresponsibleforensuringall subcutaneousinjectionoflargevolumesofmedicine marketingactivityundertheircontrolcomplies injustthreetofiveminutesmakingitmorecon withourcodeofconductandindustrymarketing venientandcosteffectivethanintravenousdelivery codesinwelaunchedtherochemarketing working stakeholders make best product regulators policy makers physicians healthcare providers input regulatory filings clinical trial design participation clinical trial design results publication product shape treatment guidelines feedback product performance profile input training education material shape treatment guidelines patients patient groups payers reimbursers market research patients needs health outcome studies focus groups product profile eg ease use determination medical value codevelop support awareness reimbursement programmes educational material training patient groups rochearengcorporate responsibility partindd corporate responsibility roche business report andsalescompliancequestionnairermscqto tionsandpoliciesforpublichealthaswellasfor helpmanagersassesshowwelltheiroperations moregeneralareassuchastheassessmentofthe performonsensitivecompliancetopicsallgeneral valueofhealthcareandourworkwithpublic managershavetosignadeclarationthatconfirms healthorganisationsthinktanksandacademics theircompliancewealsoranrefreshertrainingon responsiblemarketingforglobalproductstrategy oneexampleisourcontributiontotheeuropean teamsinthepharmaceuticalbusinesswewill commissionprocessoncorporateresponsibilityin carryoutrefreshercoursesonantitrustissuesand thefieldofpharmaceuticalsthisprocesswas anticorruption launchedintoimprovetransparencyandbusi nessethicsaccesstomedicinesindeveloping customer relationship management countriesandpricingandreimbursementsystems ourcustomersrangefrompatientshealthcarepro ineuropewearealsoparticipatinginaproject fessionalshospitalsandreferencelaboratoriesto todevelopmarketaccessforbiosimilardrugs publicandprivatehealthcarepayersitisimportant tomanagetheserelationshipsinaprofessional inwedevelopedguidelinesforsharinginfor andtransparentwayweconsidertheirneedsand mationonthepotentialofmisuseofdrugsinsports viewswhendevelopingourproductsandservices inassociationwiththeworldantidopingagency wadarocheandwadasignedamemorandum wefocusonbuildingstrategiclongtermpartner ofunderstandingdescribingtheprocesstofollow shipswithhealthcareadministratorsaswellasspe whensuspicionariseswadapresentedrochewith cialistsinindividualdiseaseareasthishelpsus anawardinrecognitionofourroleinthisarea gainabroaderoverviewofpatientneedsacrossall areasofhealthcareandenablesustoofferafull wealsocontributetopolicydevelopmentthrough rangeofappropriatepharmaceuticalanddiagnostic ourmembershipofindustrybodiessuchasthe productsthisapproachalignsmorecloselywith europeandiagnosticsmanufacturersassociation ourvisionforpersonalisedhealthcareandwillim edmatheeuropeanbiopharmaceuticalenter provecustomerserviceidentifyadditionaloppor prisesebetheinternationalfederationofpharma tunitiesandcreateefficienciesandcostsavings ceuticalmanufacturersandassociationsifpma andtheeuropeanfederationofpharmaceuticalin forexamplegenentechemploysthoughtleader dustryassociationsefpiainefpiaapproved liaisonswhoworkwithexternalmedicalexpertsto fourpriorityareasforthenexttwoyearsthesere ensureweunderstandtheiropinionsandestablish latetoimprovingtheeffectivenessofhealthtechnol lastingmutuallybeneficialpartnerships ogyassessmentsstrengtheningintellectualproper tyframeworksenhancingethicstrustandreputation wecarryoutcomprehensivemarketresearchand andattractingmorerdtotheeuropeanunion analysistobetterunderstandtheneedsofspecific throughefpiawecontributedtoupdatestoeuro customergroupsandmarketsinindepen peanunioneulegislationaimedatstrength dentresearchamongcancerspecialistsinthe eningsystemsformonitoringthesafetyofmedicines unitedstatesandfiveeuropeancountriesshowed inparticulartoprotectagainstcounterfeitmedi thatrochescustomerretentioninthesemarkets cinesandensurepatientsreceivereliableinformation iscomparedwithanaveragerateof onprescriptionmedicinesthisworkwillcontinue amongourpeersinadditiontoproductefficacy themaindriversofcustomerretentionwasfoundto bethesalesrepresentativesconductknowledge wehavecontributedtotherevisionoftheeudirec andexpertiseandtheinformationandsupportpro tiveontheprotectionofanimalsusedforscientific videdforpatientsandclinicians purposessincetheprocessbeganinthedirec tiveaimstobalancetheneedsofresearchandpa public policy tientswithanimalwelfaresignificantnewprovisions weshareourviewsandexpertisewithgovernments includeamandatoryethicalreviewprocessand andregulatorstohelpdevelopeffectivelawsregula thedevelopmentandimplementationofalternative rochearengcorporate responsibility partindd roche business report corporate responsibility methodsthattangiblyimproveanimalwelfarethe cessesthataredifficulttoreproducecopiesofabio directivewillapplyinalleumemberstatesfrom logicalproductarethereforesimilarbutnotidenti november caltotheoriginalthesebiosimilarproductscannot beconsideredgenericmedicinesorapproved wecontributedtoresponsesfromedmaandebe basedonthelimiteddatasetmostregulatorybodies toaeuropeancommissionconsultationonin vitrodi acceptforgenerics agnosticsivdsinwesupportthecommis sionsproposedriskbasedclassificationsystemfor wesupportthedevelopmentofaclearregulatory ivdsaslongasmanufacturersaregivenenough frameworkfortheapprovalofbiosimilarproducts timetoadjusttotheincreaseindevelopmentcosts whichcomparesthemwiththeoriginaldrugthe itwillincurmoreclarityisneededonproposed europeanmedicinesagencyhasestablishedsucha requirementsforprovidingclinicalevidenceforhigh systemandpublishedadditionaldraftguidelineson riskivdsalsothroughedmawecontributedto similarbiologicalmedicinalproductscontainingmon theeuropeancommissionsreviewofthemedicalde oclonalantibodiesforreviewtheuscongressintro vicessectorwhichidentifiedmajorchallengesrelat ducedalegislativeprocessforapprovingbiosimilars ingtocompetitivenessinnovationandpatientaccess aspartofthehealthcarereformsinmarchfor countrieswherethereisnospecificframeworkfor combating counterfeits counterfeitmedicalprod approvingbiosimilarswebelievethatregulatory uctsareillegalandaseriousglobalpublichealth authoritiesshouldfollowtheworldhealthorgani problemtheyendangerpatientsundermineconfi zationwhoguidelinesonevaluationofsimilar denceinthehealthcareindustrybreachintellectual biotherapeuticproductswhereacomparisonwithan propertyrightsandwastehealthcarebudgetswe originalbiologicalproductisrequiredtoestablish workwithrelevantstakeholderstoimproveproduct similarityinweengagedwithregulatoryauthor securitystrengthenandenforceexistinglawstrain itiesandbiosimilarmanufacturersaroundtheworld localofficialsandeducatethepublicthroughefpia topromotethewhoguidelinesastheminimumstan wehavecontributedtotheproposedeuropeancom dardwewillcontinuetodosotoensuresimilar missiondirectiveoncounterfeiting versionsofourbiotherapeuticproductsbroughtto marketaresafeandeffectiveanupdatedposition eliminatingcounterfeitsrequiresacomprehensive onbiosimilarsisavailableonourwebsite universalapproachacrossthepharmaceuticalindus trythisshouldincludestandardisedproductseriali political contributions rochedoesnotfundin sationanduniversalsafetyfeaturessawthe dividualpoliticiansemployeesintheusacanmake conclusionofanefpiapilotprojectofonepotential personalcontributionsthroughrochesgoodgov approachasystemforverifyingthatmedicinesdis ernmentcommitteeggcandgenentechsgenen pensedinpharmaciesaregenuineoneachpacka pacbotharevoluntarypoliticalactioncommittees uniquebarcodesmallerthanafingernailholdsa pacinemployeesdonatedusdol randomserialnumberandtheproductcodebatch larstopoliticalcampaignsthroughthesepacs numberandexpirydatebeforedispensingamedi cinepharmacistsscanthebarcodetocheckitis web authenticpharmacistsinstoresscannedandver position papers wwwrochecom policiesguidelinesandpositions ifiedalmostpacksfrommanufacturers responsible marketing risk management compliance includingrochetheresultsshowthatthetechnol wwwrochecombusinessintegrityandresponsible marketing ogyisafeasiblecosteffectiveandsecuremeans wwwrochecomriskmanagementandcompliance ofenhancingpatientsafetyandsupplychainsecurity pharmaceutical industry principles responsible supply chain management httppharmaceuticalsupplychainorg patents counterfeiting biosimilars biosimilar products unliketraditionalmedicines wwwrochecommedicalvaluepatentsandpricing whichcontainsmallmoleculesproducedbychemical wwwrochecompatents new products technologies synthesisbiologicalmedicalproductshavecomplex wwwrochecomcsrresearchanddevelopment molecularstructurestheyareproducedfromliving wwwrochecominnovationandtechnologies systemsusingsophisticatedmanufacturingpro rochearengcorporate responsibility partindd corporate responsibility roche business report safety security health environmental protection rocheisdedicatedtogoodhealthweareascom supplementthesecoursesinweexpanded mittedtopreservingthesafetyandwellbeingof thenumberoflanguagesouronlineshetrainingis ouremployeesandtheenvironmentaswearetoim availableinbringingthetotaltoandensuring provinghealthandqualityoflifeforpatients allrocheemployeescanunderstandthematerials thisenabledemployeestoaccessthepro managing grammeandofthesehaveparticipatedin goodsafetysecurityhealthandenvironmentalshe wewillexpandthisprogrammetogenentech managementisessentialtoourbusinessweem employees ployateamofdedicatedpeopleatourheadquar tersinbaselwhichiscomplementedbyateamof security intheunitedstateswhileoverfulltimeem thevisionofsecurityatrocheistoprotectourem ployeessupportoursheprogrammeacrossour ployeesandvisitorsphysicalassetsintellectual sitesmaintaininggoodperformanceiseveryem propertyandproductsfromharmorlossourglobal ployeesresponsibility networkofsitesecurityofficersworkedwithroches chiefsecurityofficerinonsupplychainsecuri eachsiteidentifiesitsspecificsherisksandoppor tytravelsecurityincidentmanagementandtraining tunitiesandcommunicatestheseaccordingtolocal preferencesthisensuresthatcolleaguesunder wehavelaunchedapilotprojectinlatinamericato standandadheretoourshepolicyandguidelines systematicallyassesstransportsecurityrisksinour supplychainsuchastrucksbeinginterceptedand ourpolicyistointernallyauditcriticalsitessuchas implementadditionalsecuritymeasuresasneces chemicalandpharmaceuticalmanufacturingfacilities sarywehavealsoimprovedthehelpavailablefor everythreeyearsandallotherrelevantsitesperiod employeesshouldemergencysituationsariseduring icallyaccordingtorisktheseauditsratesheper businesstravelthisincludessecurityanalysisbefore formanceaccordingtointernalstandardsandstipu travellingtodangerouscountriesandasecurityand latefutureimprovementswehaveincorporated medicaladviceserviceforuseduringtravel genentechsitesintothecorporatesheauditpro grammeandthesearenowassessedagainstthe regionalsecurityrisksneedtailoredsolutionsin samestandardsasotherrocheoperations thegroupsecurityteamchairedaseriesofre gionalsecurityworkshopstoreinforcethisapproach audits forexampleaworkshopinindianapolisunited statesenabledparticipantstoexchangeinsightsand experiencesintheareasofintellectualpropertypro worldwide audits tectionworkforceviolenceandsupplychainsecurity firsttime audits health safety inwevisitedsitesfourforthefirsttimeof thesitespreviouslyauditedalmostallhadim provedtheirperformancerecommendedimprove roche accident rate mentsinincludeincreasedtrainingontopics occupational accidents suchasemergencymanagementbusinesscontinu occupational illnesses ityandsafedrivingasweexpectsimilarlyhigh workrelated fatalities shestandardsfromoursuppliersourprocurement workrelated accidents departmentconductssheauditsatthirdparty per million working locationsandissuesfollowuprecommendations hours trainingisatthecoreofourshestrategylocal employeehealthandsafetyisoneofourforemost managersprovidetailoredtrainingthroughlectures prioritieswehaverigorouspoliciestosafeguard andcoursescustomisedtositespecificsherisks theirwellbeingandexpectthesamestandardsfrom regularregionalsheconferencesandworkshops ourcontractors rochearengcorporate responsibility partindd roche business report corporate responsibility investmentsinshetrainingappeartobepaying total environmenttal impact ecobalance offwehavereducedworkrelatedaccidentspermil lionworkinghoursbysinceemployees use resources energy tj reportedoccupationalaccidentsina raw materials increaseinfrequencycomparedwithlastyearhow water evertheaverageseveritytheresultingnumberof emissions air lostdaysdecreasedoveralltherocheacci voc dentrateameasurethatcombinesfrequencywith severityimprovedbyapproximatelyoccupa x tionalillnessimprovedinbothincidenceandseverity co withcasesreported halogenated hydrocarbons ouroccupationalaccidentandillnessprofileremains particles consistentwithslipsfallsandrepetitivestrains water representingthemajorityofworkrelatedcomplaints toc intherewerenomajoraccidentsthisyear heavy metals forthethirdconsecutiveyear phosphorus nitrogen thoughwearepleasedwiththispositivetrendwe landfilled waste inert waste recognisetheneedtoremainvigilantwehave construction waste installeddefibrillatorsincentrallocationsatalmost reactor waste allsitesandcontinuetosupportouremployees mio impact points wellbeingbothduringandoutsideofworkhours ecobalance per employee manyrochesitesorganisecampaignstoreduce accidentsoutsidetheworkplacesuchassellingpro tectivesportsequipmentandrunningmotorcycle ecoefficiency rate eer safetycourses environmental footprint sales million chf ourtotalenvironmentalfootprintiscomprisedof environmental manyindividualimpactsincludingenergyusewater expenditure andwastewemeasureourtotalimpactusingthe million chf ecobalancemetricdevelopedbytheswissagency environmental damage fortheenvironmentbafuthisweightstheim environmental pactsofairandwateremissionslandfillwastepri damage units maryenergyandrawmaterialusagetocalculatea eer totalfootprintwealsocalculateimpactperemployee sowecanmeasureourprogressasthebusiness weassesstheefficiencyofourenvironmentalin growswesetourselvesatargettoimproveoureco vestmentsandrunningcostsbycomparingsalesfig balancebyfromlevelsby ureswithourtotalenvironmentalexpendituresand impactascalculatedaccordingtothebafumethod wearepleasedtohavereachedthisgoalearlyand ologyourresultingecoefficiencyrateeerhas nowplantoimproveourecobalanceafurther decreasedtoachangefrom fromlevelsbythisyearinkeeping thereisadetaileddefinitionatwwwrochecom withanupdatedbafuecobalancemethodology factsheetecoefficiencypdf wehaveincludedadditionalparameterssuchas wateruseresultinginanecobalanceof rochearengcorporate responsibility partindd corporate responsibility roche business report energy climate change greenhouse gas emissions co equivalent asrochesgreenhousegasemissionsresultmainly fromenergyuseourclimateandenergystrategies areinextricablylinked total emissions million tonnes ourpriorityistoreduceemissionswhileremaininga total emissions viableprofitablecompanyweplantodothisby per million chf sales increasingenergyefficiencyandswitchingtosustain tonnes ableenergythroughagroupdirectivewehave developedasystematicapproachforconservingen ergythisincludesmeasuressuchasdesigning energy use terajoules newplantsandbuildingstobemoreenergyefficient andoptimisingandretrofittingexistingassetsthe directivecoversallaspectsofourbusinessfrompur total energy use chasingandoperationstoresearchmarketing total energy use administrationandtransport per million chf sales total energy use per inwesetagoaltoimproveenergyefficiency employee measuredasconsumptionperemployeeby bywithanimprovementofinfiveyears employeeawarenessandmotivationwillalsobecriti wemissedthisgoalthisshortcomingislargelydue caltoachievingourgoalswearefortunatetohave torecentacquisitionsandcorrespondingincreases innovativeanddedicatedemployeesourannualre inbusinesstravelwhichhaveraisedouroverall sponsiblecareawardrecognisesthisbyencour energyconsumptiontheenergyefficiencyofbuild agingemployeestocollaborateonideasforenergy ingsplantsandmachineryhasimprovedbymore savingprojectsthisyearwerewardedsitesthat thanduringthisperiod includedremarkableprojectsintheirenergyreduc tionplanswerecognisedelevensitesforonsite wearefirmlycommittedtoimprovingourperfor energyconservationprojectsandfivereceived mancethisyearwedefinedplansforafurther awardsforprojectsinvolvingtheirfleetsandflights efficiencyimprovementbyfromlevels inthelongertermweaimtoreduceusageby whilewearereducingtheamountoffuelweuse peremployeebyfromlevelsachieving toheatcoolandrunourbuildingsandmanufacturing thesegoalswillrequiresignificantlearningandin sitesbusinesstravelisprovingmoreofachallenge vestmentweareimprovingourenergymeasurement businessairtravelisincreasingandnowrepresents andmanagementprocessesdefiningaccountabili almostofoverallenergyuseintroducedin tiesanddevelopingframeworksforcommunication ourpolicyofusingonlycarsthatemitamaxi andknowledgesharing mumgrammesofco perkilometreinour europeanpharmafleetbyisbearingfruitand eachbusinessunitandsitewillneedtocontributeif hasimprovedfuelconsumptionefficiencyby wearetoreachourenergyefficiencygoalsthisyear inoneyear weaskedthelargestenergyconsumingsites acrossthebusinesstocreateenergyreductionaction whileefficiencymeasureswillplayalargerolein planstheresponsehasbeenverypositiveresulting reachingourenergytargetwemustalsoconsiderthe intotalpotentialsavingsofterajoulesperyear typesoffuelweuseourlongtermstrategyisto asignificantproportionofthesesavingscomefrom continuetoreplacefossilfuelswithsustainableener retrofittingrefrigerationheatingventilationandair gysourceswhereverpracticalandfeasibleasa conditioningsystemsweareconfidentthatsuccess groupourgoalistoincreasetheproportionofsus fullyimplementingthesubmittedplanswillachieve tainableenergyweusetoby ourgoalandwillcloselymonitorimplementa tionoftheplanstomakesuretheystayontrack rochearengcorporate responsibility partindd roche business report corporate responsibility energy use type acquiredsiteswillworktowardsseparatetimelines togivethemthesametimeframeasoperations fuel used involvedintheoriginalprocessforgenentechthus company vehicles thetargettobemetis oil achievingthesetargetswillrequiresignificant investmentthoughwearesearchingforalternatives fuel due business therearecurrentlynoviablesubstitutesinsomecir air travel cumstanceswewillcontinuetoexaminealternatives andworkwithrefrigerationsupplierstomakefurther grid electricity reductionsinthefuture district heating emissions air tonnes waste renewable energy vocs particulates natural gas nitrogen oxides sulphur dioxide halogenated hydrocarbons tonnes ourmanufacturingoperationsemitvolatileorganic compoundsvocsparticulatesnitrogenoxides xandsulphurdioxideso thesecontributeto variousformsofpollutionincludingairpollution smogandacidrainweminimiseemissionstoair holdings whereverpossiblethroughavarietyoftechnologies andpracticesfluegasscrubbersreducenoand x vocsarereducedthroughvariousincineration emissions andfreezingprocessesthoughstillunderinvesti gationinswitzerlandandtheusthelattermay ithasbeenchallengingtoreduceemissionsof alsoreduceenergyusethetableshowsouremis chemicalrefrigerantsthatareeitherozonedepleting sionstoairinparticulatesno andso x suchascfcsandhcfcsorhaveahighglobal fluctuatefromyeartoyearbutalwaysatverylow warmingpotentialsuchashfcsthevolumeof levels refrigerantholdingsreportedsignificantlyincreased inasgenentechsfiguresincluderented waste tonnes orleasedbuildingsandequipmentforthefirsttime wecommittedtophaseoutallcfcsandhcfcsfrom general waste ouroperationsbyandallhalogenatedhydro produced carbonrefrigerantsbythoughwehavemade general waste per significantprogressareductionofhalons million chf sales andanreductionoffullyhalogenatedcom chemical waste poundsinsevenyearsexcludinggenentechsites produced ourrecentacquisitionsandlackoftechnicalsolu chemical waste per tionsforsomeapplicationshavemadethisgoalun million chf sales realisticinconsultationwithourengineerssites andbusinessrepresentativeswedecidedtorevise rochesincreasedwasteproductionthisyear ourgoalwenowplantoreducehalogenated reflectsanumberofoperationalchangesthe refrigerantsatrochesitesbybynewly increaseingeneralwasteincludeslargeamounts rochearengcorporate responsibility partindd corporate responsibility roche business report ofconstructionwastefromdemolishedbuildings ouroperationsdischargedkilogrammesofheavy inmannheimgermanyandbellevilleusachem metalsintowatercoursesprimarilyflushedout icalwasteincreasedslightlyinlinewithhigher frommetalpipeswedischargethesepollutantsonly productionvolumes ifthisfullycomplieswithallrelevantregulations includingpretreatmentrequirementswearestriving water toreducetotalwastewatertoxicitybybetween andandarecurrentlydevelopinganalyti calmethodsandperformancemeasurestohelpus water withdrawn achievethis million cubic metres water used biodiversity million cubic metres pharmaceuticalsandthenaturalworldhavebeen wastewater discharged closelylinkedforcenturiesnatureholdsmuch treatment plant inspirationandpotentialfortreatingillnessandwe million cubic metres mustguardagainstspecieslosswesupportthe organic matter principlesofresourcestewardshipasdefinedinthe discharged water conventiononbiologicaldiversitycbd courses treatment tonnes thewinnersofrochesecompetitionaward heavy metals havefoundasurprisinglysimpleyeteffectivewayto discharged water countertheprevalenceofinvasiveplantspecies courses treatment ourcoloradositerecentlywelcomedaherdofmoun kilogrammes taingoatswithanappetitefortheweedsthreat eningthelocalecosystemcomparedwithharsh wateravailabilityisincreasinglycriticalforroche chemicalsorlabourintensivealternativesthegoats andforsocietyandvariesgeographicallywhile providealowimpactandcosteffectivemeansto rochecurrentlyhasnohighusageoperationsin solvingasignificantenvironmentalchallenge areasofwaterscarcityweadaptconservationand reductionprogrammesaccordingtolocalconditions pharmaceuticals environment pie andneedsforexampleourcaliforniansitesuse tracesofpharmaceuticalproductsmaketheirway droughtresistantlandscapingatothersiteswecol intotheenvironmentprimarilythroughnatural lectandrecyclewaterfromourcoolingtowers processesfollowingnormalpatientusemanufactur creatingaclosedloopsystemthatreduceswateruse ingandimproperdisposalbypatientsalsocon tributeasmallproportioncurrentevidencesuggests wecarefullymanagebothwateruseandwastewater thatexposuretotheselowlevelconcentrationsin dischargesourwithdrawalandconsumptionin surfacegroundanddrinkingwaterdoesnotposeany creasedinduelargelytotheinclusionoftwo harmtohumanhealthbutwerecognisetheneed newsitesthisyearouroperationswithdrew forfurtherresearchintotheeffectsandsupportsci millioncubicmetresofwaterreducingtotalwith entificworkinthisfield drawalisanimportantpartofouroverallenviron mentaltargetandourrevisedmethodforcalculating theriskstoaquaticlifearethoughttobegreater environmentalimpactecobalancenowincludes studiestodatedonotsuggestanyshortterm waterusagetoreflectthis effectsfromexposuretolowlevelconcentrationsof pharmaceuticalsbutmoreresearchisbeingcon wecarefullycontrolthequalityofwateremissions ductedtoevaluatethepotentialimpactoflongterm inwedischargedmillioncubicmetresto exposure treatmentplantsaftertreatmentwedischarged tonnesoforganicmatteranincreaseprimarily weconsidertheentirelifecycleofourdrugsand causedbytheacquisitionofasubstantialsingapore takestepstominimisereleasesintotheenvironment biotechoperationinlinewithlowlevelfluctuations atallstageswedesignourmanufacturingsitesto rochearengcorporate responsibility partindd roche business report corporate responsibility reducetheriskofactiveingredientsenteringwaste waterandusefinancialincentivestoencourage customerstoreturnunusedproductforproperdis posal compliance incidents wemeetalllocallawsorregulationsasamini mumbutsetoursightshigherourgrouppolicies areoftenmorerigorousthanexternalstandards wereceivednosignificantshefinesinforthe eighthconsecutiveyear howeverwepaidthreesmallfinesthisyearforminor infractionstheserelatedtoawaterqualityviola tionaphysicaldefectinastoragetankandexces siveuseofaboilerwhilenoneoftheseincidents presentedasignificantrisktoouremployeesorthe localcommunitywetakeallincidentsseriously wehavetakenstepstocorrecteachproblemand preventsimilarincidentsfromoccurringinfuture web performance goals wwwrochecomsheperformance environmental protection wwwrochecomenvironment policy wwwrochecomsafetyhealthandenvironmental protectionpdf group fact sheets positions policies guidelines wwwrochecompoliciesguidelinesandpositions genentech sustainability report wwwgenecomgeneaboutenvironmental rochearengcorporate responsibility partindd independent assurance report roche business report independent assurance report tothecorporategovernanceandsustainabilitycommitteeof therochecorporategovernanceandsustainabilitycommittee rocheholdingltdbaselroche isresponsibleforboththesubjectmatterandthecriteria ourresponsibilityistoprovideaconclusiononthesubjectmat wehaveperformedassuranceprocedurestoprovideassurance terbasedonourassuranceproceduresinaccordancewith onthefollowingaspectsofthecorporateresponsibility theinternationalstandardonassuranceengagementsisae reportingofroche subject matter main assurance procedures dataandinformationdisclosedinthecorporateresponsibility ourassuranceproceduresincludedthefollowingwork reportingofrocheanditsconsolidatedsubsidiariesexcluding evaluation application group guidelines chugaipharmaceuticalcoltdforthebusinessyearended reviewingtheapplicationoftherocheinternalcorporate decemberonthefollowingaspects responsibilityreportingguidelines themanagementandreportingprocesseswithrespectto site visits visitingselectedsitesofrochespharmaceuti thecorporateresponsibilityreportingandtothepreparation calsanddiagnosticsdivisionsingermanyhungary ofsheandpeoplekeyfiguresaswellasthecontrol russiaandtheustheselectionwasbasedonquantitative environmentinrelationtothedataaggregationofthese andqualitativecriteria keyfigures interviewingpersonnelresponsibleforinternalcorporate theshekeyfiguresinthetablesonpagesto responsibilityreportinganddatacollectionatthesites andsomeselectedpeoplekeyfiguresdisclosedonpages wevisitedandatthegroupleveltodeterminetheunder tooftherochebusinessreport standingandapplicationofrocheinternalcorporate responsibilityguidelines criteria assessment key figures performingtestson therochegroupinternalcorporateresponsibilityreporting asamplebasisofevidencesupportingselectedsheand guidelinesbasedontheresponsiblecareprogramme peoplekeyfiguresrocheaccidentrateenergycon healthsafetyandenvironmentalprotectionreportingguide sumptioncoemissionsrelatedtoenergyconsumption linespublishedbytheeuropeanchemicalindustrycouncil releaseofhalogenatedhydrocarbonsuseofwater ceficandthesustainabilityreportingguidelinesgpub finesinrelationtosafetyandenvironmentalprotection lishedonoctoberbytheglobalreportinginitiative headcountftedatastaffturnoverandseniormanage griand mentpositionsconcerningcompletenessaccuracy thedefinedproceduresbywhichsheandpeoplekey adequacyandconsistency figuresaregatheredcollatedandaggregatedinternally review documentation analysis relevant policies basic principles reviewingtherelevant responsibility methodology documentationonasamplebasisincludinggroupsustain theaccuracyandcompletenessofcorporateresponsibilityindi abilitypoliciesmanagementandreportingstructures catorsaresubjecttoinherentlimitationsgiventheirnature anddocumentation andmethodsfordeterminingcalculatingandestimatingsuch assessment processes data con solidation dataourassurancereportshouldthereforebereadincon reviewingtheappropriatenessofthemanagementand nectionwithrochesinternalguidelinesdefinitionsandproce reportingprocessesforcorporateresponsibilityreporting duresonthereportingofitscorporateresponsibilityperfor andassessingtheconsolidationprocessofdataatthe mance grouplevel rochearengcorporate responsibility partindd roche business report independent assurance report conclusions global reporting inouropinion initiative sustainability theinternalcorporateresponsibilityreportingguidelines arebeingappliedproperly reporting guidelines theinternalreportingsystemtocollectandaggregate sheandpeoplekeyfiguresisfunctioningasdesignedand withthisyearsannualreportwecontinueourapproach providesanappropriatebasisforitsdisclosure ofaligningoursustainabilityreportingtotheguidelinesofthe globalreportinginitiativegri basedonourworkdescribedinthisreportandtheassess mentofcriterianothinghascometoourattentionthatcauses asforthelastthreeannualreportsrocheisoftheopinion ustobelievethatthecorporateresponsibilityinformation thatthealevelofthegrigguidelinesappliestoitsannual mentionedinthesubjectmatteranddisclosedwiththecorpo reportthiswascheckedwithandconfirmedbythe rateresponsibilityreportingintherochebusinessreport gri doesnotgiveafairpictureofrochesperformance detailsofhowwereportagainsteachindicatorcanbefound zurichjanuary atwwwrochecomreportingandindices pricewaterhousecoopersag drthomasscheiwiller stephanhirschi severinschwan rochearengcorporate responsibility partindd published cautionary statement regarding forwardlooking f hoffmannla roche ltd statements basel switzerland annual report contains certain forwardlooking state tel ments forwardlooking statements may identified fax words believes expects anticipates projects intends seeks estimates future similar expressions discussion among things strategy media office goals plans intentions various factors may cause actual group communications results differ materially future reflected basel switzerland forwardlooking statements contained annual report tel among others pricing product initiatives competi fax tors legislative regulatory developments eco nomic conditions delay inability obtaining regulatory investor relations approvals bringing products market fluctuations currency exchange rates general financial market condi basel switzerland tions uncertainties discovery development tel marketing new products new uses existing products fax including without limitation negative results clinical trials research projects unexpected side effects pipeline world wide web marketed products increased government pricing pres wwwrochecom sures interruptions production loss inability obtain adequate protection intellectual property rights corporate sustainability committee litigation loss key executives employees adverse publicity news coverage tel email corporatesustainabilityrochecom statement regarding earnings per share growth profit forecast interpreted mean order publications roches earnings earnings per share tel subsequent period necessarily match exceed fax historical published earnings earnings per share roche email baselwebmasterrochecom trademarks mentioned enjoy legal protection next annual general meeting links third party pages provided convenience march express opinion content third party pages expressly disclaim liability third party information use roche annual report published german english printed nonchlorine bleached fsccertified paper roche annual report issued f hoffmannla roche ltd basel group communications cover jone f usa participant phase iii emilia trial receiving treat ment tdm advanced herpositive breast cancer rochearengimprintindd rochearengimprintindd key figures roche group index sales mchf free cash flow mchf research development mchf total dividend mchf f hoffmannla roche ltd basel switzerland operating profit mchf number employees trademarks legally protected wwwrochecom income taxes mchf total employee remuneration mchf net income mchf patients clinical trials core earnings per share chf ecoefficiency rate price development nonvoting equity security genussschein chf roche nonvoting equity security swiss market index rebased key figures indexed figures annual report core results full index global reporting initiative gri proposed board directors indicators used report see development phase iv wwwrochecomreportingandindices calculation ecoefficiency rate see e wwwrochecomenvironment rochearengkey figuresindd roche annual report x roche annual report creating value patients rochearugengindd rochearengfront coverindd